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ABSTRACT

Precision Medicine (PM) seeks to customize medical treatments for patients based
on measurable and identifiable characteristics. Unlike personalized medicine, this effort
is not intended to result in tailored care for each patient. Instead, this effort seeks to
improve overall care within the medical domain by shifting the focus from one-size-fitsall care to optimized care for specified subgroups. In order for the benefits of PM to be
expeditiously realized, the diverse skills sets of the scientific community must be brought
to bear on the problem. This research effort explores the intersection of quality
engineering (QE) and healthcare to outline how existing methodologies within the QE
field could support existing PM research goals. Specifically this work examines how to
determine the value of patient characteristics for use in disease prediction models with
select machine learning algorithms, proposes a method to incorporate patient risk into
treatment decisions through the development of performance functions, and investigates
the potential impact of incorrect assumptions on estimation methods used in optimization
models.
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CHAPTER ONE
INTRODUCTION TO RESEARCH
1.1 Introduction
1.1.1 Research Motivation and Scope
In 2008, the National Academy of Sciences outlined the top 14 priorities for
research in the “Grand Challenges for Engineering.” Of the research priorities highlighted
in the document, three challenges are directly related to healthcare: advanced health
informatics, engineering better medicines, and reverse-engineer the brain (National
Academy of Engineering, 2018). The inclusion of healthcare challenges reflects the
importance of medical advancements in comparison to other national and global issues.
In spite of the research progress in this area, there remains a significant need for
continued refinement in the understanding of how the human body operates and
development of improved treatment techniques for identified ailments. Finding solutions
to the identified healthcare research challenges necessitates a multidisciplinary effort that
spans partners in government, industry and academia.
The primary aim of this dissertation is to outline the potential role of quality
engineers in addressing healthcare challenges. Chapter 1 will briefly outline the
motivation for this research endeavor by touching on the financial implications to society
of the current healthcare system. In the following section, a brief explanation of prevision
medicine, a relatively-new initiative aimed at improving medical care through by
providing tailored care for groups of people with matching characteristic profiles. If
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successful, this research effort will spur current innovators in the field of quality
engineering to consider future healthcare centric research projects.
1.1.2 Drivers for Systematic Improvement within Healthcare
The cost of healthcare in the United States consumes a larger percentage of available
wealth with each fiscal year. In 2015, United States’ healthcare spending reached $3.2
trillion and accounted for 17.8% of the gross domestic product (Martin et al., 2016).
While the rising healthcare costs are attributable to a wide range of causes, the three
primary contributing factors were the rising percentage of the population using available
healthcare resources, increased utilization of services by the individual, and growing cost
for specific medical services (Martin et al., 2016). The increased cost for specific medical
procedures most likely reflects changes to healthcare policy, adjustment to patient
treatment protocols, or attempts by the medical establishment to more accurately
distribute overhead costs to the individual consumer. One example of a procedure whose
total cost increased over the past decade is pediatric spinal fusion. From 2000 to 2013 the
price of the procedure grew from $29,930 to $56,920 (National Center for Health
Statistics, 2016).
The relentless growth of healthcare costs has fueled concerns regarding long-term
affordability of national healthcare programs at the national level and affordability of care
by individuals. By addressing inefficiencies within the domain of healthcare delivery,
research teams may potentially stabilize or decrease the total cost of healthcare to the
nation and for individuals.
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1.1.3 Precision Medicine: Emerging Approach for Transforming Healthcare
As identified by Berwick et al.(2008), addressing the cost of healthcare will
necessitate improving quality of patient treatment and developing additional preventative
measures for disease. The accomplishment of these two objectives results in a reduction
of per-capita care costs. In order to reach these goals, research teams must first focus
improving understanding of the complex system that is the human body and how the
system reacts to both disease and treatment.
Medical professionals have a limited number of diagnostic tools and treatment
options at their disposal with which to assess and treat patients. In the healthcare system
that exists today, misdiagnosis, missed diagnoses, and poor response to treatment still
occur. The reasons for each of these issues vary. However, at the heart of the matter is the
need to be able to measure patient’s health characteristics, the ability to relate the
characteristics to a set health complication, and to be able to provide the patient a
treatment protocol that will have a positive effective.
In 2015, the federal government launched the Precision Medicine Initiative (PMI), a
research effort aimed at changing the treatment of patients from a one-size-fits-all
approach to a treatment approach that takes into account individual differences between
patients. Precision medicine (PM) is defined as “an approach to disease treatment and
prevention that seeks to maximize effectiveness by taking into account individual
variability in genes, environment, and lifestyle” (Hudson et al., 2015). The research
initiative has been touted for its potential to revolutionize the treatment of disease. In his
2015 State of the Union address, President Obama ignited interest in PM by stating
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“Doctors have always recognized that every patient is unique, and doctors have always
tried to tailor their treatments as best they can to individuals. You can match a blood
transfusion to a blood type – that was an important discovery. What if matching a cancer
cure to our genetic code was just as easy, just as standard? What if figuring out the right
dose of medicine was as simple as taking our temperature?”(Obama, 2015). His words
provided a compelling vision of how the advancement of PM could revolutionize the care
of patients and improve medical outcomes.
As the underlying knowledge needed to support the application of PM grows and as
the application of PM becomes more common place within the healthcare system, more
medical professionals will able to use patient features to select the best treatment protocol
based on likelihoods of positive treatment response for populations with similar features.
To that end, research is needed to illuminate which patient factors are the best indicators
of health for each disease and additional research needs to assess treatment protocol
response for groups identified by common patient characteristics. It is in this area of
healthcare research that quality engineers will find a problem set that matches their skill
set. The combination of the statistics, decision analysis, optimization, and process
development are all critical components of increasing the probability of applying the best
treatment for each individual at the right price within the shortest window of time
possible.
PM is poised for greater gains in the coming years due to the increase of existing
biologic repositories, improved analytic methods to identify subpopulations, and the
refinement of computational tools used to find optimal solutions (Collins & Varmus,
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2015). Unique patient groups routinely examined in medical research are defined by
common patient features which may include genetic differences, environmental factors,
or lifestyle choices. The study of response differences between patient groups allows
researchers to identify patients groups who are more susceptible to a disease or respond
differently to specific treatment plans. One significant advancement in the medical field
that greatly affected the future of precision medicine was the ability to map an
individual’s deoxyribonucleic acid (DNA). Since DNA is unique to the individual and
dictates how that particular body functions, this knowledge may explain why treatments
are effective in some patients, but not in others. By determining which genes affect drug
metabolism, an individual’s genes can be used to screen out treatments which will not be
effective. This course of action will increase the likelihood of a patient receiving
immediate relief instead from the prescription medication and decrease the likelihood of a
repeat office visit. There remains a need to find additional differences between
individuals which affect treatment response so that patient profiles may be used to inform
treatment selection to predict an individual patient’s response to a specific drug treatment.
1.1.4 Overlap of Precision Medicine and Quality Engineering
Precision medicine will transform medical care in two ways. First, it will improve
prevention and diagnosis by improving the ability to identifying differences between
individuals that are healthy, at risk for a future complication, or have a health
complication. Secondly, it will improve the likelihood of assigning the patient an optimal
treatment strategy with the least number of remedial visits for the same ailment. In order
for PM to be effectively applied in practice, medical professionals must have the ability
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to compare the likelihood of effectiveness of different treatment regimens for different
patient profiles. Quality engineers have the requisite skills to make significant
contributions to in both of these areas.
Quality engineers have knowledge to explore possible causes for variance within
treatment response and assess patient risk when undergoing treatment. In the past, quality
engineers have focused primarily on applications within the manufacturing sector but
their knowledge is frequently applied in other applications areas. The quality engineering
field is well known for the design of processes, a tool which enables production at
consistent high quality outputs with few defects. Quality engineers analyze processes to
determine how to produce predictable and accurate results. In the advancement of
precision medicine, quality engineers can help the medical community to determine the
optimal level of a measurable characteristic for a specific subpopulation, investigate
optimal treatment strategies that take into account multiple ailments and combinations of
drugs, and predict the impact of treatment strategies were based on incorrect assumptions.
A literature review of major quality engineering journals revealed that most of the
previously published research which combined these domains are editorials or offer an
analysis at the macro scale. While the author cannot definitively provide a rationale for
the lack of overlap, one reason might be the qualitative nature of medicine in the past
century. At the start of the twentieth century, doctors were reliant on a limited number of
sources to obtain information about s patient’s health when making a diagnosis. Medical
providers would gain data from a visual inspection of the patient, measurements from a
limited number of medical tests, and qualitative information from the patient’s
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perspective regarding ailment and treatment response. The scope and sensitivity of
measurement tools available to medical professionals continue to improve as technology
continues to advance. As a result, practicing medical professionals now have more “data”
at their fingertips than medical professionals had fifty years ago. In order to optimize
patient care, doctors are in need of improved methods of analyzing data and advisement
on how best to integrate the results into the decision making cycle. Quality engineers
have both the technical acumen and comfort of operating in uncertainty to provide
support to the medical community as it moves forward. Another reason for the lack of
involvement of quality engineers within the medical domain could also be due the nature
of the problem. In manufacturing endeavors, engineers seek to improve the output of a
process. The variability between products is limited and the changes to the assembly line
are assumed to impact items on the line in similar fashion. Unlike manufacturing, the
product examined in the medical system, an individual’s health, is measurable in a vast
number of ways. In addition, the target value for a measured characteristic cannot be
precisely determined. Instead, healthcare providers have utilized a range of values to
assess an individual’s health. The turn to precision medicine could reduce the measured
differences between individuals as smaller subgroups are identified. The advancements to
reducing variability in treatment response based on newly-measured characteristics could
be as impactful as the improvement to transplant success once blood type differences are
recognized.
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1.2 Research Outline and Objectives
This dissertation explores how best to use quality engineering tools within the
healthcare domain. Three separate, viable pathways for pursuing improvements in
healthcare are examined with an eye toward evaluating patient risk. To start, chapter 2
summarizes literature published within the past five years which used machine learning
for research on T2DM. The two most important outcomes are a consolidated list of the
research goals and a summary of research limitations from the point of view the
researchers. Next, in chapter 3, a new method for risk quantification using an adaptation
of quality loss functions is described. Whereas quality loss functions were developed for
point targets, a new performance loss function could be used for risk assessment when
measure characteristics are evaluated within a target range. Performance functions would
allow medical professionals to assess the potential impact of a treatment on a patient
across multiple characteristics of interest. The last chapter explores the impact of
incorrect assumptions during parameter estimation on optimization outcomes. In total, the
dissertation provides insights into the potential impact and the challenges of medical
research. Each of the chapters is summarized in more detail in the following paragraphs.
Chapter 2 is a systematic review of the use of machine learning efforts that
support the advancement of precision medicine for a selected disease. This chapter
outlines a basic methodology for assessing the state of medical research for an analytic
tool as applied on a specific disease. Type 2 diabetes mellitus (T2DM) was selected as a
focus area because of its high prevalence within the population. As of 2017, an estimated
9.4% of the United States’ adult population is afflicted with diabetes mellitus (DM), a
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group of chronic diseases which affect insulin production within the human body (Center
for Disease Control and Prevention, 2017). In the most recent published assessment of
the financial impact of DM by the American Diabetes Association, the organization
estimated that DM cost United States at least $245 billion annually (American Diabetes
Association, 2013). The tally includes both the cost of medical treatment for DM and cost
of lost workforce productivity. To mitigate the future impact of DM, researchers must
develop more effective means of preventing the development of the disease in more
patients and improve treatment methodologies to improve patient outcomes. To achieve
those goals, researchers are exploring the potential of PM, an emerging approach to
patient care that seeks to customize medical treatments based on measurable and
identifiable characteristics. If the promise of PM is realized, the shift of medical care
from the one-size-fits-all convention to optimized care for specified subgroups will
improve medical outcomes. This literature review examines the use of machine learning
to achieve PM aims for T2DM. The paper outlines major T2DM research areas, the most
common algorithms utilized for research, and the measures of effectiveness used to
assess their performance. This work also provides insights into the limitations that
decrease the potential of the current research efforts.
Chapter 3 lays out the motivation for continued research at the convergence of
healthcare and quality engineering. It examines the state of healthcare, the needs which
have motivated new research, and past efforts of quality engineers to influence medical
research. At the end of the chapter, areas for potential research are identified.
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In Chapter 4 the potential of robust design is examined when it is paired with
conditions based selection of regression estimators. At the start of the chapter, alternative
methods of estimating parameters when the underlying distribution is unknown are
compared and contrasted. If the researcher’s assumptions regarding the underlying
distribution are correct, results found using optimization models developed using the
estimated parameter will not be impacted. However, if the researcher’s assumptions
regarding the parameter are proven incorrect, the results of optimization efforts using the
parameters will be impacted. This chapter explores the potential impact of inaccurate
assumptions made during parameter development phase of research. For illustrative
purposes, the hypothetical research team assumes that the underlying distribution is
normal when, in actuality, the underlying distribution is skew normal. This chapter also
provides insight into the impact of incorrect assumptions during made during early
phases of research on final recommendations. The analysis is particularly important for
parameter estimation supporting medical applications since researchers may not know the
underlying distribution. While medical researchers work to better describe physical
phenomena, a parallel effort within the engineering community should focus on the
development of improved methodologies for parameter estimation when the distribution
may be non-normal.
Each chapter practically describes how quality engineers could apply their skills
to support the development of precision medicine. Chapter 2 explores how machine
learning is being applied to bridge identified research gaps for one prevalent disease. The
three most important products from this chapter are a list of research needs, an
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assessment of the types of quality characteristics being used to gauge health, and
assessment of the limitations of current research due to limited data availability. Chapter
3 illustrates how informed adaptation of current QE methodologies could improve the
assessment of patient risk when undergoing treatment with known, measurable side
effects. Chapter 4 critically considers the impact of incorrect assumptions early in the
analysis. The dissertation provides a foundation from which other quality engineers will
be able to craft innovative research efforts for the continued development of tools needed
for PM.

11

CHAPTER TWO
TYPE 2 DIABETES MELLITUS: OBTAINMENT OF THE PROMISE OF
PRECISION MEDICINE WITH MACHINE LEARNING METHODS
2.1 Precision Medicine Applied to Diabetes Mellitus
The term diabetes mellitus (DM) refers to a group of chronic diseases
distinguished by hyperglycemia, abnormally high blood glucose. The rise of glucose
within an individual’s blood stream can be either attributed to the insufficient production
of insulin within the body, a physical resistance to insulin, or a combination thereof
(American Diabetes Association, 2017). The increased blood sugar negatively affects the
function of important organs to include the heart, eyes, vessels and kidneys among others
(Pippitt & Li, 2016).
The importance of the disease may be attributed to the prevalence of the disease
worldwide and the resultant costs. From 1980 to 2014, the number of individuals with
DM has risen from approximately 108 to 422 million (World Health Organization, 2016).
As of 2017, 7.2% of the United States’ adult population was diagnosed with DM (Centers
for Disease Control and Prevention, 2018). An additional estimated 7.2 million adults
have the disease, but have not been diagnosed. In 2012, the American Diabetes
Association funded research to quantify the total cost of DM for the United States. The
final report estimated that within the United States over $176 billion was annually spent
for direct medical costs of DM and another $69 billion was lost due to decreased
productivity (American Diabetes Association, 2013). The DM related medical costs to
the individual is estimated to be significant as well. The average annual medical
expenditure for a patient diagnosed with diabetes in 2012 was on average $13,700 with
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$7,900 of that cost directly relating to diabetes. Past research efforts have shown that
early diagnosis and proper management of the disease can improve an individual’s health
and reduce risk for further complications.
Current medical research continues to focus on early diagnosis and treatment of
DM. Within the field of medicine, one particular area, PM has shown promise for
advancements in patient treatment. PM focuses on finding the best treatment for a patient
based on the individual’s characteristics which may include “genetic, biomarker,
phenotypic, or psychosocial traits” (Jameson & Longo, 2015). The success of PM hinges
on the ability to classify individuals into groups of susceptibility and treatability for a
particular disease or a combination of diseases using measurable characteristics. Two
challenges to PM include resolving competing healthcare system stakeholder interests
and the challenge of dealing with a vast, continuously growing, and complex data set
(Jameson & Longo, 2015). The first challenge will require changes to government policy
to realign stakeholder interests into a more mutually beneficial system. To overcome the
second challenge, efficiently and quickly, the involvement of other parts of the scientific
community will be required. This challenge involves wrestling large medical data
repositories in an attempt to find new medical knowledge through the identification of
subpopulations and unpredicted responses to treatment plans. As such, the size of the data
and the complexity of the problem should make working on medical problems a desirable
application area. The complexity of medical care provides an interesting area for
application of other skill sets. Hence, the classification of a disease within a patient will
depend on more exact definitions requiring adjustment to decision algorithms.
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Machine learning (ML) is a branch of artificial intelligence that gives machines
the ability to learn and automate analytical models for classification and predictions with
big data. PM research efforts focused on DM are making significant progress in
identifying the portion of the population most at risk for developing DM and in
improving treatment methodologies. This chapter seeks to document the state of current
ML research efforts using published literature. It will outline the general research goals
for type 2 diabetes mellitus (T2DM), the types of approaches, sources for data, and
limitations of recent work. It is the hope of the author that this work will provide a
foundation for future research efforts involving T2DM and ML, the study of algorithms
to uncover insights within a dataset and to develop models for prediction.
In the following sections, an overview of DM and basics of ML will be discussed.
Section 2.1.1 provides a brief overview of the disease and outlines the reasons for
narrowing the scope of this research effort on T2DM, a single variant. Section 2.1.2
examines the broad categories of ML and briefly discusses the most common types of
ML algorithms. The section is concluded with research considerations when attempting
to use ML. Section 2.2 provides a methodology for the literature review. Specifically this
section covers the search criteria, inclusion and exclusion criteria. Section 2.3
summarizes the results of this research effort. Section 2.4 provides a way ahead for
T2DM research involving ML and suggestions for how to improve medical data
repositories.
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2.1.1 Diabetes Mellitus Overview
As stated earlier, the disease DM is caused by malfunctions affecting the amount
of insulin within the human body. Insulin is a hormone produced by beta cells in the
pancreas. The hormone regulates the amount of glucose within the blood stream. Too
little insulin within the body results in high levels of glucose which is known as
hyperglycemia. The impact of DM on the patient’s health is affected by a variety of
factors including the severity of type of DM, the speed with which DM is diagnosed and
treated after initial onset, the effectiveness of the treatment protocol, and the patient’s
adherence to the prescribed treatment protocol. If a glucose level with the patient’s blood
stream remains above the recommended threshold for an extended period of time, the
patient is at greater risk for serious health complications to important organs. The disease
is linked to damage to eyes, kidneys, nerves, and the heart.
The most prevalent types of DM are defined by their etiopathogenesis and are
referred to as type 1, type 2, and gestational diabetes. Classification is important since the
disease progression for each variant of DM is different. Type 1 diabetes mellitus (T1DM)
occurs when the immune system produces antibodies which attack beta cells in the
pancreas. The presence of antibodies within the blood stream is an indicator of T1DM
(American Diabetes Association, 2017). The disease progression for T1DM depends on
the how early antibodies are detected and the number of antibodies detected. Once a
patient has type 1 diabetes, the patient requires treatment with exogenous insulin to
facilitate metabolic survival (Atkinson, 2014). T1DM affects approximately five percent
of the population diagnosed with DM (Centers for Disease Control and Prevention,
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2017). In comparison, T2DM occurs when either the body does not produce enough
insulin or the body is resistant to the effects of insulin. This variant of DM accounts for
approximately 90-95% of the DM cases (Centers for Disease Control and Prevention,
2017). The disease most often appears in individuals once they reach adulthood with only
132,000 people under the age of 18 in the United States diagnosed with any form of DM
(American Diabetes Association, 2017). Like T1DM, this form of the disease creates an
increase in glucose within the patient’s blood stream. Unlike T1DM, insulin is typically
only required for disease management, but not necessarily survival. The third most
common form of DM is referred to as gestational diabetes (GD). GD occurs during
pregnancies and is considered a temporary condition. Most often, the clinical signs of
gestational diabetes will disappear after the birth of a child. Some patients, however, do
progress from diagnosis of GD to T2DM after the birth of a child.
While the impact of all three forms of DM is significant, this chapter will focus
specifically on T2DM because it affects a greater portion of the population. Of the 23.1
million people in the United States diagnosed with DM, 90-95% of those patients have
T2DM (Centers for Disease Control and Prevention, 2017). This form of the disease is
considered progressive with symptoms becoming more intense over time. The initial
onset of the disease is not always recognized by the patient because the short-term
symptoms may not be distinguishable. T2DM symptoms may include increased thirst,
weight loss, or increased need to urinate more frequently. The impact of the
hyperglycemia, the presence excess glucose in the bloodstream, on the patient, may
progressively get worse over time as either the individual’s resistance to insulin grows or
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as the gap between the insulin needed by the body to regulate glucose and the amount of
insulin produced increases. Long-term complications of having hyperglycemia may result
in additional complications including blindness, loss of limbs due to poor blood flow, or
kidney failure. However, unlike T1DM, T2DM may be partially preventable through
behavior changes and the disease may go into remission given a reduced severity of the
form of DM and patient response to treatment protocol. Accordingly, early detection of
the disease and proper management is critical for the health of the patient. The continued
investment in PM research for T2DM is made with the goal of improving detection of the
disease and determining of the best treatment protocols for specific patient profiles.
Given the prevalence of the disease, the medical community has collected a vast
amount of data concerning T2DM. As stated earlier, one of the primarily challenges of
PM is how to effectively use the data to develop insights that illuminate patient
characteristics which best align with increased incidence of the disease. Within recent
literature, one prevalent method for investigating T2DM has been the use of ML. The
following section provides a brief overview of the topic.
2.1.2 Machine Learning: The Basics
The field of ML exists at the intersection of computer science and data science.
ML was built on the premise that computer systems have the ability to improve the
specified task completion without the necessity of successive improvements to the initial
implementation being programmed by the user. Computer systems use algorithms to
develop knowledge about a dataset. Feedback on performance enables the computer to
make adjustments to calculated predictions or decision recommendations. The increased
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computational power realized over the past thirty years has added increased capability to
the field. As a result, feedback on performance enables the computer to make adjustments
to calculated predictions or decision recommendations.
Today ML is used to develop a greater understanding in research areas with a vast
amount of data. The tool also helps researchers identify patterns within the dataset that
are not obvious. In fact, ML has been applied to a broad spectrum of areas. It has been
used for identification, speech recognition, and statistical arbitrage (Pazzani et al,
1998)(Graves et al., 2013)(Galindo & Aamayo, 2000) . ML also provides a means of
quickly detecting oil spills from radar images of the ocean’s surface (Kubat et al, 1998).
Moreover, ML has helped to close the gap between automatic speech recognition systems
in comparison to human performance (Deng & Li, 2013). In addition, ML has also been
heavily relied upon to develop quantitative training strategies for financial assets to
include hedge funds, the field referred to as statistical arbitrage (Krauss et al, 2017). The
investment strategy looks for patterns within financial data streams to identify patterns
for exploitation. The field of ML is growing quickly due to high interest from both the
government and industrial sectors. In 2016, McKinsey Global Institute estimated that
machine learning received between $5 and $7 billion dollars in investment funding
(Bughin et al, 2017).
The term “machine learning” encompasses a broad field of work which uses
multiple techniques for a wide range of applications. Within the field, learning is
classified as one of three major tasks: supervised, unsupervised, or reinforcement. A
supervised learning task infers a relationship between inputs and outputs. Algorithms
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classified as “supervised” require feedback during the training stage. The training dataset
includes both the input data and associated outputs, also termed “supervisory data.” The
algorithm uses the training data to develop an inferred function that relates inputs to
outputs. Once a base model is formed, the model is tested using a validation dataset, a
portion of the training dataset held in reserve. Performance is then judged on the ability
of the algorithm to correctly link inputs to outputs. The parameters of the model are then
adjusted to improve the accuracy of the model, and the model is used for prediction or
classification purposes. Common metrics used to compare supervised ML performance
between algorithms are accuracy, sensitivity, and specificity. Robust functions will have
the capability of correctly analyzing samples that were not specifically included within
the training data set. Unlike supervised ML, unsupervised learning algorithms only use
input data to develop knowledge about the data set. The algorithms deduce relationships
between the predictor variables. Since this type of learning does not have known
outcomes, there is no means of evaluating the accuracy of the final model. The third type,
reinforcement learning examines the trade space between exploration and exploitation.
When discussing ML, the three most important aspects are the purpose of the
algorithm, the type of learning, and the data set used to train the algorithm. Typically
supervised ML algorithms are used to perform two types of tasks: classification or
prediction. For classification, a model is developed that assigns inputs into the system
into a predefined class in the system. For diabetes research, classification algorithms can
be used to determine if a patient is at risk for developing diabetes. Whereas classification
algorithms are used to predict the correct group, regression modeling is used to

19

strengthen the ability of predictive analytics. For diabetic research, machine learning can
be helpful in determining the proper dosage of insulin for patients based on individual
characteristics. In this way, ML has the potential to provide power to the application of
PM within healthcare. This tool has proven effective for the use of both continuous,
discrete, and mixed data sets.
2.1.2.1 Supervised Learning Algorithms
There are a wide variety of algorithms in use today within the field of ML. It is
commonly acknowledged that there is no single algorithm that works better across the
wide variety of supervised learning problems. This type of ML is used for both
classification and regression purposes. For classification methods, the output value is a
category. One example of classification for T2DM research is that based on input data a
patient could either be classified as either having diabetic retinopathy or not having
diabetic retinopathy. For the purposes of regression, however, the output value from the
model would be a real number. If considering the application within PM, this type of
model could be used to determine the optimal dose of insulin for a patient. When
applying supervised ML techniques, researchers must be aware of two typical issues that
commonly occur. First, the researcher finds a balance between over-fitting and underfitting the data. This is often referred to as the bias-variance trade-off. Under-fitting
occurs when bias exists causing the algorithm to not identify a relationship between the
independent variables and their associated dependent variables. Contrarily, over-fitting
occurs when the developed model fits the training data too closely. When the model is
subsequently used with other data, these exists high sensitivity to small changes in the
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input variables. Analysis of the bias-variance may be captured in a discussion of the
algorithm’s expected generalization error. Secondly, the final outcome is dependent on
the quality of the training dataset used to develop the ML algorithm. The algorithm is
used to develop a function to be used for predictions or classification by relating known
input and output values. Training datasets that are too small may not provide enough
instances for which the resultant model may not be robust to a variety of input
combinations. If the training dataset has a large number of input variables, the chosen ML
methodology must be able to effectively judge which features are critical to optimal
model development. In addition, the dataset may have missing entries, infeasible values
or outliers. Researchers must determine how to best process the data to ensure that it is
adequate for the intended purpose.
For supervised learning, the comprehensive analysis of a dataset is extremely
important in the development of the inferred solution because the training dataset
connects the input data to output values. The supervised learning process is iterative.
After the algorithm develops a solution based on the training input, the algorithm learns
by comparing its generated output, the prediction for a given set of input values, against
the true output value. The algorithm is “correct” if the function’s output matches the
training set output. Training stops when the algorithm reaches an acceptable level of
performance based on output values. The algorithm’s performance is then validated with
the portion of the available data held in reserve. Development of a training methodology
for model development and development of a validation strategy to assess model
performance are critical steps in supervised learning. Probably the most important factor
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to take into consideration when conducting supervised learning is the size of the training
dataset. If the set is large, the researcher may choose to just divide the available data into
two subsections: a training dataset and a validation dataset. The parameters for the model
will be developed using the training set and the model will then be verified with the
validation dataset. While an established standard for the division of the dataset does not
exist, common convention dictates that the data be divided proportionally 2/3 to 1/3
(training to validation). The other method, known as cross-validation, divides the dataset
into mutually exclusive sections of equal size. Iteratively, one of the sections will be held
for testing performance of the algorithm trained by the other subsets. The final model will
be formed by combining the results of each iterations. The following paragraphs provide
a brief overview of the most prevalent ML algorithms.
a. Naive Bayes Algorithm
The naïve Bayes (NB) algorithm uses training data to develop frequencies for
each possible outcome which provides the class prior probability (Rish, 2001). The
algorithm can then determine the posterior probability for each of the possible outcomes.
The outcome with the highest posterior probability then becomes the prediction. NB
needs less training data in comparison to other types of algorithms. Three considerations
when utilizing the NB algorithm are the necessity for independence of predictors, the
reliance on all outcomes being observed in the training data, and the known performance
of NB in producing estimators. If a variable is not observed in the training dataset, the
probability for that outcome will be zero and the ability to make a prediction is
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eliminated. The algorithm has proven to be valuable for both real time predictions and for
instances where there are multiple classes.
b. Decision Tree Algorithm
The decision tree (DT) algorithm is one of the most prevalent ML algorithms and
as such it has been extensively studied in literature. DT is non-parametric, simple to use,
and can effectively be implemented with large datasets. The algorithm has been put to
use for purposes of classification and regression. A decision tree is sequentially formed
by segmenting the dataset into smaller groups based on the values of successive features
of the data. The end result is a hierarchy of features with each node representing where in
the decision process a specific features affects the final process outcome. The branches
departing a node represents the split of the dataset based on the outcome of the test.
The use of DT algorithms is not constrained by the data type as it can be used
with categorical and continuous variables. The methodology of how to split the data is
dependent on the associated probability of a set outcome. For regression decision trees,
sum squared error for the training samples is used to select the order of the predictor
variables within the tree. For classification trees, the Gini function is used to determine
the best choice of splits. It is a measure of difference between values of a frequency
distribution.
Implementation considerations when using this type of algorithm are the size of
the final tree (number of nodes) and the level of accuracy expected from the algorithm. If
too few nodes are included in the model, the accuracy of the model decreases. If too
many nodes are included, the model’s accuracy is higher, but the researchers run the risk
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overfitting the dataset. Two possible methods for coping with the risk of overfitting are
either artificially limiting the number of levels within the tree or pruning the tree once the
algorithm has been run. While there are many alternative methods for how to best
determine the split attribute, three highly effective methods include the greedy, gain ratio,
or the distance-based measure. Finally, another option is to use the gain ratio which
considers how broadly and uniformly the features splits the data. One drawback of using
this algorithm is that DTs can have problems with high variance or increased bias.
c. Support Vector Machines
Support Vector Machines (SVM) are supervised learning models that examine
data for classification or regression. SVM adds a dimension to the dataset as a way to
make classes linearly separable (for linear applications). Simply put, a class is a subset of
data identified by a common feature, or input variable. Given a classification context,
SVM inserts a hyperplane between two classes. The selection of the best hyperplane to
divide the dataset into classes is the difficult part of this method. In theory, the
hyperplane is able to separate the two classes without error and the greatest margin.
However, an error often occurs when a member of one class appears on the same side of
the hyperplane as the second class. The margin is the distance between the closest point
of each class and the hyperplane. When the data is non-linear, the SVM uses a kernel to
convert a low dimensional feature space to a higher dimensional feature space,
transforming the data, and enabling separation of classes by a hyperplane. In addition,
SVM is known for being robust for outliers.
d. k-Nearest Neighbors Algorithm
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The k-nearest neighbors (k-NN) algorithm is a non-parametric method used for
classification and regression. The value or class of a point of interest is approximated
“locally” within a defined feature space. The feature space is comprised of a set number
of training points, denoted by k, closest to the point being examined that will be used to
classify the test point. Small values of k can create many small regions which could lead
to non-smoot decision boundaries or overfitting of the data. However, large values of k
will leave larger regions and possible under-fitting of the data. For use in classification,
the k-NN input is the k training examples that are closest to the point of interest and the
output is a class membership. The class of the point of interest is determined using a
similarity measure. The similarity measure for continuous variables is the distance
between the test point and the point of interest. The similarity measure for categorical
variables is the Hamming distance. If there is a mix of variable types, one solution is to
use standardized distance on the same training set. For use in regression, the output value
is the average of the selected feature of the k closest points. One method to validate the
choice of k is to use cross-validation. A variant of the k-NN algorithm is the use of
weights to weigh the values of the surround k points based on the distance from the
selected point.
e. Random Forest Algorithm
The random forest (RF) algorithm is a form of ensemble learning. It is used to
rank the importance of variables for either regression or classification problems. Initially
developed by Breiman and Cultler (2007), the algorithm incorporates the results of
several runs of the DT algorithm, each constructed with a unique subset of the initial

25

dataset, into a single result in order to decrease variance, decrease bias, or improve
predictive power. The RF algorithm produces a final tree which combines the most
common nodes. For the construction of trees using the DT algorithm, the dataset is
sampled with replacement. When choosing the attribute from which to create the node,
only a small, random subset of the available attributes is considered. Each tree within the
forest is restricted to a subset of characteristics, thus reducing the dimensionality of the
problem. This method is considered an improvement over decision trees because it
reduces the tendency for overfitting that is often seen with decision trees. RF is
considered robust to inclusion of irrelevant features and it is known to be capable of
classifying a large quantity of data accurately.
Researchers typically find a balance between the performance, processing time
and memory. The number of trees is related to the number of variables. The greater the
number of variables, the greater the number of trees that may be developed for the
dataset. However, it has been noted that increasing the number of trees does not
necessarily improve performance. Research by Amit and German (1997) illustrated that
the accuracy of RF algorithms is dependent on the individuals trees and the dependence
between the trees. One advantage of using RF is that the method is capable of
maintaining accuracy even with missing data. Common variants to this method include
kernel RF, centered RF, and uniform RF.
f. Artificial Neural Network Algorithms
Artificial neural network (ANN) algorithms can be constructed for both
supervised and unsupervised learning. The concept behind the algorithm was to create a
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learning process modeled after the human brain. For example, if an artificial neural
network is used to classify patients as diabetic using electronic health records, it develops
its own set of relevant characteristics from iterations with the training dataset. This
algorithm is best defined as a combination of optimization theory and statistical
optimization. It seeks to find the best model from the set of models that minimizes the
cost to traverse the network.
2.1.2.2 Unsupervised Learning Algorithms
Unsupervised learning assumes that there is a hidden structure within the data. As
opposed to supervised learning in which input data is paired with supervisory data,
unsupervised learning depends only on the input data. The goal of unsupervised learning
is to learn more about the dataset. It is primarily used for clustering and association
efforts. The method of clustering looks to discover groupings within the data. The
method of association attempts to determine a rule (or rules) that can be used to describe
a large portion of the data.
a. K-means
The k-means clustering (k-means) algorithm, or Lloyd’s algorithm, divides the
data space into k cells. To initialize the algorithm, k initial “means” are chosen. Once
initialized, k-means consists of two iterative steps. In the assignment step, each point is
assigned the cell that has the least squared Euclidean distance between the point and the
mean. Once all the points have been assigned, the new means, called centroids, are
updated. The observations are then sorted again and placed in the cell with the closest
mean. The algorithm stops when observations are no longer being assigned to new cells.
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b. Apriori Algorithm

The apriori algorithm is an example of association rule learning. It is used to find
frequent “item sets.” Since it was initially developed for datasets that contain a large
number of transactions, it has been used within the field of healthcare for the detection of
adverse drug reactions by creating association rules for the combinations of drugs on a
specific subpopulation of patients (Harpaz et al., 2010).
2.1.2.3 Reinforcement Learning Algorithms
Reinforcement learning makes use of a small labeled dataset which includes
supervisory data, and a larger unlabeled dataset with only input variables. This type of
learning is based on the concept that the use of unlabeled data after training with labeled
data can still provide incremental improvement in the results. This learning method is
particularly valuable when the cost of labeling datasets makes labeling a full dataset
prohibitive. This would be true in the development of algorithms to help review images
for significant features or automatic image processing. Given a large number of images
available, it would be costly to have a subject matter expert on the images review all
available images. Instead, it is more likely that the subject matter expert would review a
smaller sample of images examples to provide appropriate labels.
This section included summaries of common algorithms used for supervised,
unsupervised, and reinforcement ML. As the field is still developing, the total number
will continue to grow through both the addition of completely new algorithms and
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development of variants of existing methods. Table 2.2, below, summarizes both the
methods, available algorithms, and the purposes for which they are typically utilized. If
an algorithm has been used for more than one type of learning, it was entered in the
section for which its use is most prevalent.
Table 2.1. Common Machine Learning Algorithms

Machine
Learning
Learning
Purpose

Type

Supervised Learning

Classification

Regression

Unsupervised Learning

Reinforcement Learning

Clustering

Association

Prediction

Control

▪ Logistic
Regression
(LR)

▪ Linear
Regression
(LR)

▪ Hidden
Markov
Models
(HMN)

▪ DCA

▪
Temporal
Difference

▪ Criterion
of
Optimality

▪ Support
Vector
Machines
(SVM)

▪ Non-linear
Regression
(NLR)

▪ Neural
Networks
(NN)

▪ Single
Value
Decompositi
on (SVD)

▪ Tabular
Temporal
Difference

▪ Brute
Force

▪ Discriminant
Analysis (DA)

▪ Ensemble
Learning

▪Gaussian
Mixture

▪ K-Means

▪ Value
Function

▪ Naïve Bayes
(NB)

▪ Neural
Networks
(NN)

▪ Principal
Component
Analysis
(PCA)

▪ Apriori

▪Direct
Policy
Search

▪ Nearest
Neighbors
(kNN)

▪ Nonlinear
regression

▪ Single
Value
Decom
-position
(SVD)

▪ Decision
Trees (DT)

▪ Decision
Trees (DT)

▪
Hierarchical
▪ Selforganizing
maps

29

2.1.3 Open Software for Machine Learning
There is a wide variety of open source software platforms readily available to
assist researchers harness the power of machine learning algorithms. Open source
software is accessible to the general public for use as is or maybe adapted for greater
performance or a different application. Typically developed in a group, the software is
free which makes the software attractive to individuals or teams without extensive
financial assistance.
With the growth of open source ML platforms readily available and the decision
on which software to utilize becomes harder. Considerations should include the
availability of a specific algorithm within a library or framework and the researchers
comfort with coding in general or a specific program. Table 2.2 contains a brief list of
popular ML libraries and their associated platforms or frameworks. A library contains a
set of objects for a particular use. A framework, on the other hand, is a collection of
libraries designed to support a methodology. Software is defined as containing support
programs, the existence of a code library, and reliance on a scripting language.
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Table 2.2. Available open Source Machine Learning Software
ML Library

Accord.NET

Language

C#

Amazon ML

Apache
Mahout

Java,
Scala

Apache Singa

C++,
Python,
Java
Java,
Python,
R
Java,
Scala,
Apache
Hadoop
Python

H20

Oryx 2

Scikit-learn,
TensorFlow,
Theno*
Caret,
R
randomForest,
rpart*
Shogun
C++,
Java,
Python,
C#,
Ruby, R,
Lua,
Octave,
Matlab

Description

Creator

Established

.NET ML framework with audio and
image processing libraries (.NET, 2018)
Guided platform built on proven,
scalable ML technology which serves
the parent company (free only with
AWS) (AWS 2018)
Project which produces free
implementations of ML algorithms for
filtering, clustering, and classification
(Mahout, 2017)
Flexible architecture for distributed
training (Apache Incubator, n.d.)

Cesar
Souza
Amazon

2009

Apache
Software
System

2014

DB
Systems
Group
H2O.ai

2015

Open-source ML Platform focused on
enterprise service (H2O.ai, 2018)
Real-time large scale ML; packages for
filtering, classification, regression, and
clustering (Onyx 2, n.d.)

2015

2011

2014

3 “most popular” ML libraries for use
within python (Raschka, 2015)

Various

2016

Open source platform for statistical
programming and applied ML (R Core
Team, 2012)
Open source ML library with range of
ML methods (Shogun, n.d.)

University
of
Auckland
Soeren
Sonnenburg
and Gunnar
Raetsch

1993
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1999

2.2 Overview of Survey Methodology
This paper is the synthesis of a formal, systematic literature review of published
research concerning machine learning and diabetes mellitus within the past several years.
The basis for the research was a protocol developed to explore the breadth and depth of
current research on T2DM using the techniques of machine learning. The protocol is
explained in detail in the following sub-sections.
2.2.1 Research Focus
In order to understand the focus and research completed on T2DM using machine
learning techniques, this work investigates the following research questions.
Question 1: What are the major T2DM research areas that are being
actively pursued by the scientific community?
Question 2: What ML techniques are commonly being implemented?
Question 3: How is the effectiveness of machine learning research being
assessed?
In the course of the literature review, it was noted that one of the greatest
limitations on the research involved the data used as a foundation for the work. Therefore
one additional research question was added which focused on the suitability of current
data and the limitations on researchers and results due to datasets.
Question 4: What limitations exist that hamper the productivity of the
current research efforts?
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2.2.2 Repository Search Strategy
The purpose of this research effort was to explore the current research for the T2DM
using ML technology. The search was limited to articles as part of the PubMed database.
This online archive contains 28 million citations for biomedical literature from a variety
of sources to include MEDLNE, journals, and books (National Center for Biotechnology
Information, n.d.). The strategy used to identify search terms for an automated search
within PubMed consisted of identifying major search terms from the research questions,
identifying alternative spellings and synonyms for major terms, and then determining the
best search phase to use within the selected database.
During a preliminary literature investigation, the author noted that T2DM is
annotated with a variety of alternative phrases in published literature to include type II
diabetes, type II diabetes mellitus, type 2 diabetes, type 2 diabetes mellitus, T2, and DM
type 2. The inconsistent use of a reference term had the potential to remove relevant
articles for a key search. The final search string selected for used in PubMed for this
literature review was:
“machine learning” AND (“diabetes” AND (“type II” OR “type 2” OR
“T2DM” OR “T2” OR “T2D” OR “DM2”))
This search string resulted with 76 citations for review. Figure 2.1 provides an
overview of the research methodology utilized for this paper. An initial search utilizing
the aforementioned string was conducted to create the initial literature repository.
Inclusion criteria were applied against abstracts of papers included in the initial
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repository to form the base repository. The full papers were then examined with
exclusion criteria to form the refined repository. The refined repository contained all
relevant articles to the literature review.

Figure 2.1. Research Methodology for Literature Review
2.2.2.1 Search Documentation
The title, author(s), journal title, year published, and title for the documents
identified in PubMed using the chosen search string were stored in an Excel table
designed as an initial repository for the remainder of the literature review. The list of
articles was then evaluated using the inclusion criteria detailed in Section 2.2.2.2 against
the information included in the published abstract. All papers that met this criteria were
downloaded and the full papers were then reviewed using the exclusion criteria. Those
papers were then examined for key pieces of information chosen for analysis using Table
2.2.
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Table 2.3. Literature Review Checklist
Article Authors

All authors listed on the publication

Year

Year published

APA Reference

APA reference

Journal Title

Journal Title

Article Title

Article Title

Key Issue

Concern or gap that prompted research

Research Purpose

Goal of research paper

Model Dependent Variable

Dependent variable for analysis

Type of Learning

Supervised, unsupervised, semi-supervised

Machine Learning Purpose

Various

Machine Learning Algorithm(s)

Various

Dataset Methodology

Traditional or Train/Validation

Traditional Data Allocation

Percentage for training/percentage for validation or N/A

Cross Validation

Various

Model Performance Metrics

Various

ML Software

Software used for ML

Country of Dataset Origin

Various

Dataset Name

Various

Data Time Frame

Start Year - End Year

Dataset Time (Years)

Number of Years

Data Issues

Researcher recognized issues with data collection or format.

Instances
Instances Used in Model
Development
Instances (Dependent Variable)

Number of subjects or cases included within the dataset.

# of Features
# of Features used in Model
Development
# of Features in Model

Number of variables/features in the dataset

Types of features

Types of variables/features included in the dataset

Study Limitations

Study limitations acknowledged by the author

Benefits of Analysis
Recommendations for Future
Work
Sources of Funding

Stated benefit of the analysis

Number of subjects/cases used in analysis
Number of subjects/cases used in analysis with T2DM

Number of variables used in the modeling portion of the analysis
Number of variables included in the final model

Recommendations for future work by the author
Various
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2.2.2.2 Inclusion Criteria
When reviewing abstracts, the author focused on the following considerations:
Inclusion Criteria 1: Publications that describe research in which ML
techniques are used to investigate a research
question focused on the prevention, diagnosis, or
management of T2DM.
Inclusion Criteria 2: Documents published after 2012.
2.2.2.3 Exclusion Criteria
When reviewing published papers, the author focused on the following
considerations:
Exclusion Criteria 1: Identified article was published as a conference
proceedings.
Exclusion Criteria 2: Identified article was a literature review.
Exclusion Criteria 3: Identified article was qualitative.
Exclusion Criteria 4: Publications/reports for which only an abstract is
available.
Exclusion Criteria 5: Research that was not primarily focused on T2DM.
Exclusion Criteria 6: Dataset must include data from human subjects
Exclusion Criteria 7: Research methods did not include ML.
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Exclusion Criteria 8: Method of medical diagnosis is not recognized by
the American Medical Association
2.3 Literature Survey Outcomes
2.3.1 Summary of Articles Included
This literature review limited the scope of the search of articles included within
PubMed through March 22nd, 2018. Of the 76 documents included in the initial
repository, only a total of 39 articles were included in the refined repository on which the
rest of this paper is based. 36 articles were excluded from the refined repository, and 14
articles were rejected for failure to meet the established inclusion criteria. Of these
articles, 11 were published prior to 2013. Another 22 articles did not meet the exclusion
criteria. The most prevalent reasons for exclusion of an article from the literature review
was that the research did not focus of T2DM.
Table 2.4. Impact Table of Inclusion and Exclusion Criteria
Criteria
Inclusion 1
Inclusion 2
Exclusion 1
Exclusion 2
Exclusion 3
Exclusion 4
Exclusion 5
Exclusion 6
Exclusion 7
Exclusion 8

Explanation
Publications that describe research in which ML techniques
are used to investigate a research question focused on the
prevention, diagnosis, or management of T2DM.
Documents published after 2012.
Identified article was published as a conference proceeding.
Identified article was a literature review
Identified article was purely qualitative.
Publications/reports for which only an abstract was available
online.
Research not primarily focused on T2DM.
Dataset must include data from human subjects.
Research methods did not include ML.
Method of medical diagnosis not recognized by the American
Medical Association.
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Articles
Impacted
3
11
3
0
1
0
13
3
1
1

Figure 2.2 shows the growth within the research conducted over the given year
period. In 2013, only four articles were published, but by 2017, 16 articles were
published for the T2DM research using machine learning techniques.

Figure 2.2. Annual Comparison of Published Articles on Type 2 Diabetes Mellitus and
Machine Learning
Of 39 published articles that met this review’s inclusion and exclusion criteria
were published in 31 different journals. Table 2.4 lists all of the journals in which the
papers were published. The journals with more than one paper published on the topic
included Big Data, IEEE Journal of Biomedical and Health Informatics, Journal of
Diabetes Science and Technology, and Medical Care. In looking at the authors, the 29
papers had over 244 contributors. On average six authors were listed as contributors in
each paper. What was surprising in looking at the authors was that only eight authors had
published research papers on the intersection of T2DM and ML. Of those the highest
number of published contributions within that window was three. Only two authors had
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successive publications which were published in the same journal that was IEEE Journal
of Biomedical and Health Informatics.
Table 2.5. Summary of Journals with Publications on Type 2 Diabetes Mellitus and
Machine Learning Between 2012 and 2018
Journal
Artificial Intelligence in Medicine
Big Data
BMC Nephrology
BMJ Open
Briefings in Bioinformatics
Computational Biology and Chemistry
Diabetes
Diabetes Care
Diabetes, Obesity and Metabolism
Diabetologia
Diabetology & Metabolic Syndrome
Health Informatics Journal
Health Informatics Research
IEEE Journal of Biomedical and Health Informatics
IEEE Transactions on Biomedical Engineering
Information Sciences
International Journal of Biostatistics
International Journal of Medical Informatics
Journal of American Medical Informatics Association
Journal of Biomedical Informatics
Journal of Clinical Epidemiology
Journal of Diabetes Science and Technology
Journal of Translational Medicine
Medical Care
Medical Decision Making: An International Journal of
the Society for Medical Decision Making
Medical Physics
NPJ Genomic Medicine
Plos One
Sao Paulo Medical Journal
The Lancet: Diabetes & Endocrinology
Translational Psychiatry
Total

39

Number of Articles
1
2
1
1
1
1
1
1
1
1
1
1
1
3
1
1
1
1
1
1
1
5
1
2
1
1
1
1
1
1
1
39

2.3.2 Major Topics Covered
A key component of this research effort was determining areas of interest for
medical research and narrowing down the most frequently used analytic approaches to
tackle those issues. Before delving into the articles themselves, a simple keyword
analysis was performed. While eight articles chose not to list key words, the other 31
articles cited 112 key terms. After removing repeated and similar terms, the words were
placed into one of two primary categories consisting of healthcare or analytics. Once
placed into the categories, the words were again sorted by general topic areas. For
healthcare, the important topics, outlined in Table 2.5, covered medical measurements,
medical concerns, healthcare systems, and T2DM related issues. Determining the correct
features in which to measure physical health and disease progression is a challenging and
complex issue. First and foremost, choosing the best measurements comes from
understanding the disease at the heart of the study. The medical measurement terms
included within this bin were either general terms (phenotype and genotype) which
indicated whether the research was focused on physical or genetic characteristics or was a
unique or non-traditional indicator of T2DM.
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Table 2.6. Healthcare words cited in published literature focused on Type 2 Diabetes
Mellitus and Machine Learning
Medical Measurements

Medical Concerns

Healthcare

T2DM Related Issues

anthropometric
measurements

disease progression

healthcare

diabetes mellitus type 2

anthropometry

early disease prediction

high throughput

diabetic kidney disease

arterial markers

high throughput

primary care

diabetic retinopathy

biomarkers

medication adherence

privacy

disease complex

body mass index

missing heritability

disease progression

continuous glucose
monitoring

noisy labels

glycemic variability

fats

noninvasive treatment

healthcare

genotype

patient centered medicine

hypoglycemia prediction

glomerular filtration rate

patient similarity

impaired glucose tolerance

glycemic control

population screening

kidney failure

glycemic variability

privacy

metabolic syndrome

hypertriglyceridemic waist
phenotype

risk assessment

microvascular complications

optical coherence
tomography

risk classification

pre-diabetic state

phenotyping

risk predictions

renal insufficiency

photoplethysmorgaphy

screening

prognostic tool
protein
protein-protein interaction
serum creatinine
SNPs
triglycerides
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Table 2.7. Analytic key words cited in published literature focused on Type 2 Diabetes
Mellitus and Machine Learning
Analytical Purpose

Available Tools

Machine Learning

Methods of Analysis

Analytical Concerns

risk assessment

big data analytics

artificial neural
networks

big data analytics

positive predictive value

evidence based medicine

cohort study

boosting

comparative
effectiveness research

selection bias

medical informatics

comparative
effectiveness research

classification

contextual anomaly
detection

sensitivity

predictive analytics

data mining

classification and
regression tree

data mining

size constraints

predictive models

database research

ensemble learning

interaction network

time dependent
confounding

predictive models

electronic health records

FDSP

inverse probability
weighting

predictor

feature engineering

feature learning

joint image-region-map
model

propensity score

machine learning

Gini importance

Kallikrein-Kinin system

risk classification

medical informatics

predictive models

marginal structural
model

risk predictions

modeling

random forest

Markov-Gibbs random
field

regulatory feature data

random forest feature
contribution method

metric learning

Semi-supervised
clustering

mixture of generalized
linear effects

super learning

multivariate model

supervised decision
techniques

non-negativityconstrained
autoendcoder

supervised machine
learning

prediction

support vector machine

predictive models

survival tree

signal processing
statistical learning
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2.3.1.3 Insights on Current Type 2 Diabetes Mellitus Research
The articles in this literature review focused on finding solutions on gaps between
today’s medical capabilities and identified medical needs in the diagnosis and treatment
of T2DM. As part of the introduction for published articles, the authors outlined the
purpose of the research. Each cited a critical gap, explained implications of leaving this
aspect of medical care at the status quo, and then proceeded to explain their research
methodology. For the most part, the issues addressed by the researchers are not unique to
T2DM, but if the gaps could be bridged for patients with T2DM the payoff would be
more impactful due to the prevalence of the disease. While the solutions proposed by the
researchers are important, the documentation of the gaps themselves provides valuable
insight into the research areas that are seen significant enough to attract funding support,
areas and for which current technological capabilities may potentially be able to solve. As
a majority of the research was funded, the gaps identified were seen as significant to
wider audiences than just the authors. The gaps generally fell into three categories.
The first gap category included papers that looked at potential applications or uses
for new medical knowledge. For example, Acciaroli et al. (2018) focused their research
on how to best use glycemic variability indices to classify patients. An individual’s
glucose levels fluctuate throughout the day based off food consumption and exercise. The
glucose level increases after meals and decreases after cardiovascular events. Glycemic
variability is the measure of change in glucose swings. Researchers discovered that some
patients have greater glycemic variability than other patients. Another region of growth is
the advancement of molecular technology. As aptly summarized by Leung et al. (2013) a
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major challenge is synthesizing new knowledge so that it can impact clinical practice.
The increased ability to measure patient characteristics at the molecular level provides
more detailed information, but increased knowledge has not fully been translated into
better medical practice. Continued research needs to be done to link more refined
measurements to more precise care.
The next bin includes research that attempts to address how best to decrease the
time that a provider must spend on a single patient to identify the ailment and recommend
treatment. Doctors must analyze a patient’s medical history and current laboratory results
to narrow down possible ailments and associated treatment plans. Researchers are
examining the medical diagnosis process to determine if they are possible efficiencies
within the system. Efficiencies exist where technology can replace the human in the loop
in assessing routine data collected to look for abnormalities. While the doctor’s opinion
will remain central to the decision of the final treatment plan, automatic review of
portions of a patient’s record potentially improves the speed of the decision making, or
call a doctor’s attention to a critical component of the record. One area of growing
interest is the application of machine learning technology as part of the medical image
review process. Available medical imaging includes x-ray, computed tomography,
magnetic resonance imaging, and ultrasound imaging. To assess a patient’s current
physical health, a medical professional will need to review each image to look for signs
of disease. If the initial image review is automated, doctors would only need to review
files for which the images indicated risk of a particular disease. The change to the process
would reduce the time an individual needs to spend reviewing multiple images.
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EITanboly et al. (2017) focused research efforts to develop a computer-aided diagnostic
system for optical coherence tomography images. By detecting retinal changes in T2DM
diagnosed patients earlier in the development of the disease, the improved prediction
model would provide patients additional time and awareness to make appropriate
decisions that could either delay or prevent the onset of diabetic retinopathy, a
complication associated with hyperglycemia. One common concern with articles that
addressed automating medical tasks was ensuring that the process would perform better
than a human’s performance on the same task. Automated processes that do not perform
as effectively medical professionals could negatively affect patients and should not be
implemented.
Another gap between current medical capabilities and medical needs is the ability
to assess a risk for individuals with regard to developing a disease because once having
the disease an additional risk of developing specific complications associated with the
disease. Current prediction methods do not capture all patients who will develop T2DM.
However, given the advancements of analytics and medical measurements, there exists
the possibility of refining prediction models to better identify individuals at risk. Also,
technological advancements have broadened the available characteristics for medical
professionals to better assess patient health by increasing the number of characteristics
measured. Measurements that may be used as indicators are broken down into two
distinct groups: genotypes and phenotypes. Genotypes are an individual’s heritable
genetic identity. Phenotypes are observable characteristics that include physical
appearance, development, and behavior. Researchers are working to link specific
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genotypes and phenotypes to individual diseases. Allalou et al. (2016) noted that 20-50%
of patients with gestational diabetes progress into T2DM within 5 years. The
characteristics that make gestational diabetic patients more likely to become T2DM are
not well documented. By finding the characteristics common to patients who progress
from gestational diabetes to T2DM, clinics would be able to better treat mothers during
and immediately following pregnancy. Li et al. (2016) noted that using anthropometric
measurements, human body measurements, to predict T2DM remains controversial. Their
work was unique in that it offered to reexamine the use of non-invasive measurements as
indicators. The benefit of noninvasive measurements is that they are less expensive to
obtain and could potentially be used to screen portions of the populations that are not
routinely able to access healthcare.
Anderson et al. (2016) explored how to best use existing EHR data to gain new
knowledge about the progression of T2DM. Li et al. (2016) attempted to use limited EHR
data to evaluate patient risk for T2DM in order to better protect patient privacy. Farran et
al. (2013) noted that the medical community needed an effective way to stratify patients
by classifying potential risks of developing complications over time. Advances in the
development of better methods for assessing the patient risk allow for the medical system
to focus prevention and treatment efforts on patients with the greatest level of risk. It also
creates the potential for patients to be aware earlier of their risk so that if properly
motivated they can make alterations to their behaviors to lower their risks.

46

2.3.2 Insights on Medical Data for Research
The medical datasets used as a basis for the research came from a variety of
sources. Each dataset had its own limitations due to the structure and completeness of the
available information. The following section provides a review of the data sources used,
the types of variables used within the research, and the associated limitations. Analysis of
existing data resources provides a foundation which can be leveraged to recommend
changes to how data is current collected and stored within the medical system.
2.3.2.1 Data Sources
The articles in this literature review utilized data from four primary sources:
electronic health records, national health studies, completed research efforts, or data
collected for the purposes of the specific research paper. The first three sources of
information provide data at potentially reduced cost to researchers, but research utilizing
this type of data may be limited in that researchers may have to adjust the scope of their
research effort to conform to the data at hand.
Ethical and security concerns have informed the construction of a detailed
approval process for the use of medical data. A critical detail in the construction and use
of medical data is ensuring that the data is used in a manner consistent with the way the
data was initially collected or approved secondary uses. Most medical data is collected
with the intent to assess a patient’s health and inform treatment decisions. The data
collected for this type of use, also termed as the original use, may contain a patient’s
family history, laboratory test results, records of procedures, financial information,
prescribed medications, and clinical notes on issues such as treatment compliance. Any
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other use of medical data obtained in this manner is termed as the secondary use. This
term reflects the use of any data for non-clinical applications. There is considerable
debate about the extent to which an individual’s medical information can and should be
used for research purposes. In order to ensure that medical data will be used within the
secondary use guidelines of the controlling institution and in a manner that protects
patient information, the majority of data used for medical research is considered
restricted access. Researchers will need to obtain approval for their research plans
through both their institution’s institutional review board (IRB) and receive an additional
IRB approval from the organization that owns the data repository.
Assuming that the researcher chooses to use an existing dataset there are a variety
of different data repositories available through both public and private agencies. Choice
of repository depends on the research question. In comparison to using electronic health
records, the use of data from a study or trial provides concentrated data about a specific
type of patient. Studies allow for the aggregation of interesting cases. Casanova et al.
(2006) chose to use the Jackson Heart Study from the University of Mississippi Medical
Center to uncover potential predictors of T2DM in African Americans. Hertroijos et al.
(2017) elected to use data repositories from two Dutch Diabetes Care networks to
develop glycemic trajectories for patients recently diagnosed with T2DM. The inclusion
of a second, similar repository allowed the team to validate the model developed using
the initial repository. By using data from a specific study, the researchers can focus their
efforts on highlighting unique aspects related to a subpopulation. In some instances,
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studies allow researchers to study the effectiveness of treatment protocol since the
patients included within the study receive standardized care.
In comparison, the electronic health record (EHR) system aggregates individual
patient treatment data for a larger population. The medical repository may be defined by
medical facilities within a geographic location or, more likely, by agreements between
large health providers. The establishment of an EHR system has created a more
standardized, readily accessible repository of medical information on a large sample of
patients. Researchers have recognized that use of data compiled as part of an EHR could
support clinical research by providing longitudinal treatment data for a robust patient
population. These records have the potential to allow researchers to evaluate treatment
outcomes and develop screening criteria for known health risks. The transition from
paper to electronic records made the aggregation of medical data easier. Each EHR is
unique to the controlling medical system and may include important information like a
patient’s medical history, diagnoses, current medications, immunizations, and laboratory
reports. Lack of standardization of what medical data must be included within an EHR
would limit aggregation at the national and international level and causes challenges for
how to externally validate developed models with region EHR data. In addition,
researchers have recognized that use of data compiled as part of an EHR could support
clinical research by providing longitudinal treatment data for a robust patient population.
These records have the potential to allow researchers to evaluate treatment outcomes and
develop screening criteria for known health risks.
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Researchers continue to explore existing medical databases to find new novel
indicators for unique sub-populations and develop greater knowledge of non-invasive
indicators. The growth of electronic data bases, better methods for the measurement of
known characteristics, increased knowledge of genetics, and the increased availability of
data analysis tools capable of handing the scale of medical data have contributed
improvement in this area.
2.3.2.2 Medical Dataset Variable Categories
The availability of the data used in the majority of the research efforts was
dependent on the data collected and stored in an existing data repository. The majority of
the variables within the datasets fell into nine general categories. The following
summarized types provides a general overview of the types of data that may be included
for that category for a given study.
a. Demographic. This type of variable includes information such as a patient’s age,
ethnicity, gender, time to diagnosis, and source of medical insurance. Most of the
variables included within this type are nominal data types such a gender or ethnicity.
b. Clinical laboratory tests. These variables includes outcomes for tests performed on
samples of blood, urine, or other tissues take from the patient. The laboratory tests are
performed with the intent to diagnose a disease or to monitor the patient for changes
in their health conditions.
c. Prescribed medications. Patients under the care of a medical provider for a health
condition may be prescribed drugs to control physical reactions. For example a
patient may be diagnosed medication to control blood pressure. Information
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contained within this section should then include the type, frequency, and quantity of
each prescribed drug.
d. Vital signs. As part of an initial screening when meeting with a medical professional
at a care clinic, a patient’s vital signs are recorded. Variables annotated within
medical repositories may include a patient’s height, weight, blood pressure, or resting
heart rate. These variables provide the medical staff important information about a
patient’s health particularly when observations are conducted over a period of time.
e. Genomic Data. Identifiable variations in an individual’s genes can provide medical
professionals with important information that can impact medical care decisions.
While still not common practice to gather genotype data for all patients, this
collection and analysis of this type of data is growing.
f. Anthropometric measurements. This type of measurement is used to assess the size
and shape of the human body. Common measurements may include waist
circumference, waist-to-hip ratio (WHR), waist-to-height ratio (WHtR), and body
mass index (BMI).
g. Diagnosis codes. The U.S. healthcare system uses the International Classification of
Disease (ICD) codes to annotate a patient’s disease and heath conditions when the
patient is seen by a medical provider (National Center for Health Statistics, 2018).
The ICD system as a whole is a comprehensive tally of health conditions that
standardizes entries in patient records. First adopted in 1893, the ICD allowed
researchers to assess health trends across time and space. The codes are published in
two different manuals for separate purposes. ICD-10-CM is used for outpatient
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coding and contains over 68,000 codes. While ICD-10-PCS contains the procedural
classification system for use in an inpatient setting. Finally ICD-10-PCS contains
over 87,000 codes. T2DM had 86 distinct codes. Table 2.8 contains a sampling of the
codes to illustrate the details regarding a patient that can be gained from the ICD
code.
Table 2.8. Classification Codes for Diabetes Mellitus (National Center for Health
Statistics & Centers for Medicare and Medicaid Services, 2018)
ICD
Code
E11621
E11630
E11641
E11649
E1165
E1169
E118
E119
E1110
E1111
E1122
E1129

Description

Type 2 diabetes mellitus with foot ulcer
Type 2 diabetes mellitus with periodontal disease
Type 2 diabetes mellitus with hypoglycemia with coma
Type 2 diabetes mellitus with hypoglycemia without coma
Type 2 diabetes mellitus with hyperglycemia
Type 2 diabetes mellitus with other specified complication
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with ketoacidosis without coma
Type 2 diabetes mellitus with ketoacidosis with coma
Type 2 diabetes mellitus with diabetic chronic kidney disease
Type 2 diabetes mellitus with other diabetic kidney complication
Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular
E11311
edema
h.

Specialized tests. Depending on the medical issue at hand, medical providers have

additional medical tests which may provide information about a particular aspect of a
patient’s health. Variables pertinent to this category include information obtained from
tests like an echocardiogram, a sonogram of the heart, or electromyography, a test to
analyze nerve and tissue electrical activity.
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i.

Medical Images. Pictures of certain structures within the body may provide additional
information about a disease. Common medical images that are used for diagnosis are xrays, computed tomography scams, magnetic resonance images ultrasounds, and nuclear
medicine imaging. Those images are reviewed by medical specialists trained to look for
abnormalities.
2.3.2.3 Insights on Training and Validation
Prior to using the dataset, the researchers must develop a data plan to describe
how the available data will be used to train, validate, and test the model developed using
machine learning. There are two commonly used methods for how to use available data
to train and validate model performance. Traditionally, the available dataset is separated
into three sections and training dataset is used to develop the model. The data is then
provided to the machine learning algorithm as a set of examples from which parameters
are identified. The validation dataset is used to adjust the parameters used for a classifier.
This dataset can also be used for feature selection. The test set is held in reserve to judge
the performance of the model. However, this method only works when there is a large
volume of data. The second method, the development of model parameters through the
use of cross validation, may allow the researcher meet both the test and validation
requirements without losing modeling or testing capability. In general the data set will be
divided into small, equal sections. The data sections will then be allocated into training
and validation test sets. These tests will be used to develop the model. Once completed,
the sections will be re-allocated to form a new training and validation test sets. The
process will continue until either all possible ways to divide the original sample into
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training and validation sets is complete (exhaustive cross validation) or until a predetermined number of runs is complete (non-exhaustive cross validation).
Within this literature review the preponderance of the researchers chose to use kfold validation by dividing the training dataset into k subsections. The model is then built
using k-1 sections. Once the model is complete the model is then tested using the
remaining section and the researcher annotates the model performance. The process is
then repeated until each section has been held in reserve as the validation set. The overall
model performance is the average of the model performance when tested using the
section held in reserve.
2.3.2.4 Insights on Limitations Due to Dataset/Structure
Within each article, the researchers annotated the limitations of their work due
stemming from the available data. The primarily limitations were due to the size of the
available data set, frequency of missing values, class imbalance, large dimensionality,
and limited variable types. All of the papers selected to be part of this literature review
cited missing entries as a limitation in performing the analysis. Researchers had three
options for how to deal with missing data. First, the researcher could choose to remove
all cases for which there was missing data. Farran et al. (2013) only used patients with
complete data for the variables within the model. From over 270,000 patients, termed
“hospital visitors,” the number considered in the model was 10,632. This option, although
valid, removed a significant portion of the available data from the analysis. Han et al.
(2017) also chose to delete vacant data. As a result, the sample size shrunk from 9,562 to
7,913. Secondly, the researcher could choose to approximate the missing data based on
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other data entries. Lastly, the researcher could choose to impute the data. Before opting
for this method, the researcher must determine why the data is missing. Is the missing
data related to other available information about the subject or is the missing data
dependent on the value? One possible reason for missing data is that the patient chose to
censor particular information such as a family history of a disease. The second most
prevalent issue that researchers needed to address was how to deal with class imbalance.
This particular issue occurs when there is a large difference between the size of groups
with or without a feature. For example, there may be 200 entries of patients that screened
for T2DM, but only 5 percent of the patients showed large glycemic variability. Datasets
that link output variables to input variables are particularly valuable in the development
of risk models.
2.3.3 Recent Machine Learning Algorithms Used for Type 2 Diabetes Mellitus
ML is a method which automates model building based on the idea that systems
can learn from data to identify patters and make informed recommendations. In this
context ML is used to improve performance in T2DM prevention, diagnosis, and
management. Choice of the best type of ML to use was dependent on both the available
data and the research questions. In most cases, the research questions attempted to answer
how best to predict health risk for patients. The dataset chosen to support the analysis
included the known classification of the patient which made the data amenable to use
supervised learning. The research questions that used genetic information as possible
predictor variables applied unsupervised methods to determine which features were most
important.
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The preponderance of the research used supervised ML for the purposes of
classification and prediction. Acciaroli et al. (2018) used supervised ML to build
prediction models with the capability to distinguish between three classes of individuates:
healthy people, patients with impaired glucose tolerance, and patients with T2DM. The
researchers chose to use logistic regression build with 5 fold cross validation since the
size of the dataset was too small for the traditional division of the dataset into a training,
validation, and test set. Contrarily, Allalou et al. (2016) used ML to develop a
metabolomics signature for the prediction of patient progression from gestational diabetes
to T2DM. Using feature selection, their team was selected the top 22 variables out of 182
known variables to develop an accurate prediction model.
Anderson et al. (2015) used unsupervised ML to explore relationships within the
dataset. The end result of their work was the development of a prediction model for the
progression of pre-diabetes into T2DM using variables found within EHRs. Finally,
Argwal et al. (2016) applied a reinforcement ML technique in an effort to examine an
alternative method to manual labeling to create training sets. The research team correctly
surmised that labeling a dataset for use with machine learning was prohibitive due to both
cost and availability of medical specialist to review the requisite number of files.
2.3.2 Software Utilized by Research Teams
Researchers working at the intersection of T2DM most often use open software.
The two packages used the most often are R and the Waikato Environment for
Knowledge Analysis (WEKA). Developed by Bell Laboratories, R is a free software
package that is capable of working on a variety of platforms to include Windows and

56

MacOS. The frequent use of R can be attributed to its ability to handle large datasets, its
graphical capabilities, and the thought that went into the development of its programming
language. Additionally, ready-made functions for ML algorithms to include neural
networks, deep learning, recursive partitioning, random forests, regularized and shrinkage
methods, and support vector machines are available for download. Table 2.9 includes a
small sample of over 150 available R ML packages. Even though the table is not
comprehensive, it hints at the breadth of what exists.
Table 2.9. Examples of existing ML packages for R (Hothorn, 2018)
R Package

Purpose

Authors

randomForest

Classification and regression based on a forest of
trees using random inputs

Leo Breiman, Adele Cutler,
Andy Liaw, Matthew Wiener

rpart

predictive models by indirect classification and
bagging for classification

Andrea Peters, Torseten
Hothorn, Brian D. Ripley,
Terry Therneau, Beth Atkinson

tree
nnet

classification and regression trees
software for feed-forward neural networks with a
single hidden layer and for multinomial log-linear
models

Brian Ripley
Brian Ripley, William
Venables

ROCR

flexible tool for creating cutoff-parameterized 2D
performance curves

Tobias Sing, Oliver Sander,
Niko Beerenwinkel, Thomas
Lengauer

caret

training and plotting classification and regression
models

Max Kuhn

svmpath

computes the regularization path for the two-class
SVM classifier

Trevor Hastie

kernLAB

Kernel-based ML for classification, regression,
clustering, novelty detection, quantile regression,
and dimensionality reduction

Alexandros Karatzoglou, Alex
Smola, Kurt Hornik

glmpath

a path-following algorithm for L1 regularized
generalized linear models and Cox proportional
hazards model

Mee Young Park, Trevor Hasite

CoxBoost

routines for fitting Cox models by likelihood
based boosting for a single endpoint or in the
presence of competing risks

Harold Binder

BayesTree

implementation of the Bayesian Additive
Regression Tree

Hugh Chipman, Rober
McCulloch
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Like R, WEKA is a free licensed software that is used for data analysis. Written in Java,
the program has a variety of tools for data pre-processing, classification, regression,
clustering, association rules, and visualization (WEKA, n.d.).
2.4 Further Research Insights and Common Concerns
At the end of their papers, research teams highlighted their concerns regarding the
findings and the potential applications of the work. One prevalent concern expressed was
the need to limit negative consequences to the patient when employing machine learning
findings. The researchers were particularly concerned when the final result of the analysis
was intended to replace a human within the analysis portion of diagnosis and treatment
decisions. There was a common understanding that the final model needed to perform at
least as well as medical professionals before the model should be used in clinical
practice. Another concern expressed by researchers was whether the work would have
meaningful impact. Some researchers considered whether the available prediction model
would provide meaningful warnings to patients with enough time for the patient to
change their behavior to avoid undesirable consequences.
The results of the research included within this literature review aptly illustrated the
positive impact that the integration of supervised ML into medical research can have on
the identification of important variables for the purposes of classification and prediction
models for T2DM applications. Continued advancements using ML will depend on
fostering a small community of researchers that consistently explore the use of ML for
T2DM application, the development of improved medical datasets to support the
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research, and the cost to assess the predictive value of an indicator against the cost to take
the measurement and store the data.
Of the 266 authors who contributed to the literature included in this study, only a
small subset had published more than one paper involving ML for T2DM applications.
This may indicate that there needs to be greater support, both financially and
intellectually, to encourage more analysts to pursue research in this area. The creation of
a community of practice for the application of ML for DM. The group will be able to
facilitate changes to medical database construction to support future research efforts.
Furthermore, the community of practice will be able to initiate discussions with the
medical community to solicit input from subject matter experts on proposed research
questions and methodologies. The engagement will also provide researchers to share their
findings and potential influence changes to the medical system.
To produce the most benefit, datasets needs to be complete and comparable. A large
number of missing data entries within large data repositories can create variation in the
final predictive models. If cases with missing data are deleted, the available data for
analysis is significantly smaller than the initial data set. Placing values on improving
completeness of electronic health records will improve the resultant models. In addition,
the limited availability of research databases has restricted researchers from verifying
their findings or those researchers within a reasonable timeframe and also limits their
ability to compare the results of single analytic method with more than one dataset. This
could be especially important in the ability to compare the results of research utilizing
electronic health records.
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Analysis conducted in isolation may result in recommendations that cannot be applied
in practice due to practical considerations. Future work that seeks to find best variables to
use for prediction of T2DM should consider selecting multiple sets of variables for
various scenarios. When comparing prediction models that rely on the availability of
select pieces of data to make a prediction, it is imperative that researchers need to
consider the portion of patients which are likely to have the variables in their datasets and
the cost of those tests.
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CHAPTER THREE
DEVELOPMENT OF PERFORMANCE LOSS FUNCTIONS FOR
HEALTHCARE APPLICATIONS
3.1 Introduction
Relatively recent advances in both medical knowledge and increased
technological capability to measure changes within the human body have made the role
of a healthcare provider increasingly difficult. Doctors are expected to digest excessive
amounts of data and, from that data, develop actionable recommendations in a timely
fashion. This global “expectation” of healthcare providers creates a demand for increased
involvement of other specialties within the scientific community in the development of
better methodologies for transforming data into information and then using the resultant
information to develop optimal treatment plans. The Precision Medicine Initiative (PMI)
outlines a goal of tailoring medical care for the individual patient. For this effort to be
successful, it is incumbent upon research teams to think critically about the problem at
hand, determine what aspect of patient treatment their field could provide assistance in
improving, and start an open dialogue with the medical community. This paper seeks to
establish an informative exchange as to how quality engineering methodologies can be
applied to treatment protocol selection by examining how to adapt the quality loss
function for use within the healthcare domain. In support of a larger effort to develop
improved metrics for health assessments and patient’s physical performance this article
develops the concept of reference interval-based performance functions.
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3.1.1 Research Motivation and Scope
The rise of the financial cost of healthcare in the United States has intensified the
desire to find efficiencies within the medical system to lower overall costs and, at the
same time, improve the quality of medical care for patients. The phrase healthcare costs
encompasses all funding related to the management of the complex healthcare system as
well as the costs stemming from the lack of productivity of the ailing portion of the
population. Non-optimal treatment plans, ineffective treatment, or lack of care can lead to
longer patient recovery time, multiple cycles of treatment, loss of life, or the inability of
the patient to recover to their pre-ailment physical condition.
This chapter examines how the adaptation of an existing analytical methodology
within quality engineering could facilitate the establishment of better decision tools for
healthcare providers. Improved decision tools that combine laboratory results, available
treatment options for the ailment, and associated treatment risks would assist medical
professionals in the selection of the best treatment option for the patient.
The advances made during past century in medical knowledge and practice have
made a medical professional’s role increasingly difficult. Doctors are expected to digest
vast amounts of data and, from that data, develop actionable recommendations in a timely
fashion. Based on an assessment of the number of medical articles published in the 20
major clinical journals in 1992, researchers estimated that doctors would need to read 17
articles a day to keep up with advances in medicine (Davidof et. al, 1995). Since the
publication of this research effort, the number of medical articles published per month
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has continued to increase. The continued growth had made staying abreast of the most
recent advancements even more difficult for practitioners. For this reason, it is important
to develop improved decision tools for medical professionals to harness the available
information. The involvement of other disciplines will serve to innovate current processes
and, if successful, improve the quality of patient care through decreased diagnosis time
and improved treatment efficacy. The importance of involving other parts of the scientific
community is best highlighted by the establishment of PMI. The initiative’s research
platform outlines the vision of tailoring medical care to the individual (Ashley, 2015).
The multidisciplinary research effort leverages medical databases to find better
techniques for both diagnosis and treatment informed by individual patient characteristics.
For PMI to be successful multidisciplinary research, teams must think critically about the
problems at hand, determine what aspect of the problem their respective academic fields
can assist in solving, and then start an open and productive dialogue with other teams
working on the same problem and practitioners. This paper seeks to establish a
productive discussion centered the application of quality engineering methodologies to
treatment selection within healthcare. Existing analytical tools refined within the field of
quality engineering for manufacturing applications have potential to improve healthcare
system efficiency. In particular, the adaptation of the quality loss function (QLF) for use
within the medical field would provide a means of mapping a measured physical
characteristic to either physical performance loss or an increased risk of future health
complications. The technique could allow providers to assess the value of a treatment
protocol on a patient’s overall health prior to selecting the best treatment.
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Before applying the manufacturing quality methodologies to the healthcare field,
researchers will need to adjust developed techniques to account for differences in the
initial problem construction between a manufacturing application and a medical
application. This paper provides a brief review of QLFs and their development for use
within the manufacturing sector. After outlining the unique aspects of medical quality
characteristics, the author proposes a new methodology for assessing performance of an
individual based on measurable physical characteristics. Lastly, insights for the potential
use of performance functions for both univariate and bivariate healthcare assessments are
discussed.
3.1.2. Manufacturing Loss Functions
In the manufacturing sector, quality engineers are often tasked to develop and
monitor a process whose output needs to adhere to a pre-identified specification value for
a select measured quality characteristic with minimum variance. The desired value is a
single number commonly referred to as the “target” or “target value.” The examined item
is only usable by the customer if its measured characteristic meets the pre-identified
requirement. If an item’s measurement exceeds the specification limits, the product must
be scrapped or reworked. If the item does not meet the specification requirement, the
manufacturer incurs a financial loss related to that item since the entity is not able to sell
the item. Suppose that a company manufactures nails to be used for wood frame
construction of residential homes. If the nail manufacturing process is flawless, the
measurable characteristics of each nail produced on the assembly line are the predefined
targets. In this case, the manufacturer incurs no financial penalty related to production
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defects. In reality, production lines are not perfect and sources of variance exist within
the process. Few nails produced in the factory are exactly the target length of 1.45 inches
long. The consumer base, however, does not need nails that are exactly 1.45 inches long.
As long as the nails are within 0.05 inches of the target’s desired length, they can still be
used safely for frame construction. Any nails that do not fall within the

0.05 tolerance

window must be scrapped. Quality engineers work diligently to ensure that the
manufacturing process produces nails with the smallest ratio of defective items to usable
items. Their job, in essence, is to reduce the loss to the manufacturer. The quality
engineer mathematically relates the cost of defective items to process performance using
the target value and process variance. This methodology will be described in greater
detail in Section 2. The relationship between the measured characteristic and the cost
enables the manufacturer to identify strategic points within the production process for
investment to reduce process variability and improve desired target achievement.
Like the manufacturing sector, the healthcare industry strives to improve the
effectiveness of treatments through both target acquisition and variability reduction.
Variability in patient response to treatments has the potential to incur additional expense
on the part of the patient, the treating medical organization, society at large, or a
combination thereof. The purpose of this paper is to examine how QLFs could be used
within the healthcare community to relate an analyte’s measurement and associated
healthcare costs. An analyte is a substance that is analyzed by finding the measurements
of its chemical subcomponents (Merriam-Webster, 2017). By relating the measured value
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of physiological characteristics with costs patients and medical professionals will be
better able to assess the value of a treatment protocol.
3.2 Quality Loss Functions
3.2.1 Development and Application in Manufacturing
Loss functions are a mapping of an event to an associated cost. Traditionally loss
has been defined from the viewpoint of a manufacturer and, as such, occurred when the
item produced was unable to provide value to the manufacturer without additional
investment. Using the example discussed in the introduction, let us consider again the
case of a manufacturer who produces nails for wood frame construction. The target value
for the nail’s length is 1.45 inches. Natural variability in the assembly process affects
production and the end result is that no two nails produced are exactly the same length.
As long as the nail’s measured length is within a specified tolerance of the target, in this
case

0.05 inches, the nail can still be used safely for frame assembly by the customer

and the nail maintains value to manufacturer. If a nail exceeds the predetermined
tolerance limit the item would be scrapped and the value of the nail to the manufacturer
would decrease. A nail that measures less than 1.39 inches or more than 1.51 inches
could not be used by a consumer for the intended purpose. A traditional step loss function
relates the nail length to the manufacturer’s cost, L(y). Other practical scenarios for loss
functions may include the additional possibility of reworking an item in addition to that
of scrapping the item when the tolerance is exceeded.
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3.2.2 Traditional Step Loss Functions in Manufacturing
Traditional step loss functions (Taguchi et al., 2004) vary by the type of quality
characteristic chosen: nominal-the-best type (n-type), smaller-the-better type (s-type), and
larger-the-better type (l-type). The three types of characteristics are explained in more
detail below.
3.2.2.1 Step Loss Functions: Nominal-the Best Type Quality Characteristic
For nominal-the-best type (n-type) quality characteristics the manufacturer
accepts all items whose measurement of a chosen characteristic lies within the predetermined upper and lower specification limits. The specification limits are defined by
the allowable tolerance, Δ, from a desired target value, τ. Loss is incurred by the
manufacturer only when a tolerance limit is exceeded. The step loss function for an ntype quality characteristic can be written as:

L(y) is the loss associated with y, the measured value of the desired quality
characteristic. The cost for scrapping or reworking the product is A, a constant cost. The
lower specification limit, LSL, is the lowest value that a characteristic can be without the
item being scrapped or reworked. The upper specification limit, USL, is the largest value
that a quality characteristic can be without the product having to be scrapped or
reworked. Figure 3.1 illustrates a step loss function for an n-type quality characteristic.
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Figure 3.1 Traditional Step Loss Function: Nominal-the-Best Type Quality Characteristic
The light grey area illustrates the additional cost that a manufacturer incurs from
scrapping or reworking a product. As can be seen, the loss value is uniform when the
measurement exceeds the specification limits. As long as the measurement of the
characteristic is within the tolerance window the product’s value to the manufacturer is
not affected by either the absolute distance between the measurement and the desired
target or by the absolute distance between the measurement and the closest specification
limit.
3.2.2.2 Step Loss Function: Smaller-the-Better Quality Characteristic
For smaller-the-better type (s-type) characteristics, the company strives to
manufacture items whose measured characteristic is as small as possible. Traditionally
the target value for an s-type characteristic is set to zero. A practical example of an s-type
characteristic could be the sound created by a lawnmower. In this case, the manufacturer
desires the noise volume for engine to be as small as possible. If the sound emitted by the

68

machine exceeds the hearing safety threshold or, more likely, exceeds the threshold for
which consumers are willing to purchase, the product will need to be scrapped or
reworked before being sold. The traditional step loss function for an s-type quality
characteristic is expressed mathematically as:

The loss to the manufacturer, denoted by A, is incurred by the manufacturer only when
the measurement of the characteristic exceeds the tolerance window. Figure 3.2 illustrates
a traditional step loss function for an s-type quality characteristic.

Figure 3.2 Traditional Step Loss Function: Smaller-the-Better Type Quality
Characteristic.
The light grey area illustrates the additional cost that a manufacturer incurs from
scrapping or reworking a product. As can be seen, the loss value is uniform when the
measurement exceeds the upper specification limit. As long as the measurement is less
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than the USL the product’s value to the manufacturer is not affected by the absolute
distance between the measurement and the desired target or by the absolute distance
between the measurement and the upper specification limit.
3.2.2.3. Step Loss Function: Larger-the-Better Type Quality Characteristic
For the case of a larger-the-better type (l-type) quality characteristic, the
manufacturer desires to produce products with the largest possible measurement for the
chosen quality characteristic. Practical examples of an l-type characteristic could include
a product’s useful lifespan or the amount of resistance an exercise band could endure
before snapping. The traditional loss step function for an l-type quality characteristic may
be expressed mathematically as:

As seen in Figure 3.3, the manufacturer incurs a loss when the measured
characteristic is less than the established specification limit.

Figure 3.3. Traditional Step Loss Function: Larger-the-Better Type Quality Characteristic
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There are two notable shortcomings to the traditional step loss function. First, the
manufacturer cannot use a known value of the loss to determine the measured
characteristic’s value. The uniform formulation results in an uncountable number of
different measurements which could result in the same loss. The manufacturer cannot use
loss to determine how the process should to be tweaked to obtain better results in the
future. Secondly, the value of the loss, L(y), only takes into account manufacturer’s
financial loss. The loss to the customer is ignored by the traditional step function. When a
product fails to match expectation of the customer, the value of the product decreases in
the eyes of the customer. A company advertises a product with specific characteristics
and the customer chooses to purchase the product based on the advertised characteristics.
The difference between reality and expectation could create frustration in the consumer.
While the manufacturer does not incur an immediate loss when the item does not meet
the target but remains within the specification limits, the deviation from the target value
has the potential for future losses due to recalls, returns or warranties.
3.2.3 Development and Description of Quality Loss Functions
Taguchi (Taguchi et al., 2004) believed that any deviation of a measured quality
characteristic from a desired target value results in loss. He articulated a more
comprehensive value of the loss by adding the customer’s perceived loss (the difference
between the expected value and observed value) to the manufacturer’s loss. Deviation
from a characteristic’s target value, even if the measurement remains within the accepted
tolerance window, can result in a loss of goodwill from the customer due to the variance
in quality. Taguichi’s quality loss function (QLF) incorporates both the viewpoint of the
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manufacturer and the customer. The loss function increases in value as the amount of
deviation from the target increases. Inclusion of the customer’s loss provides recognition
that not all products produced within specification limits are equal. In his work, Taguchi
looked at the best way to calculate the value of loss for three different types of quality
characteristics: nominal-the-best (n-type), smaller-the-better (s-type), and larger-thebetter (l-type). This methodology is explained in more detail below.
3.2.3.1 Quality Loss Function: Nominal-the-Best Type Quality Characteristic
For n-type of quality characteristics, the closer the measurement of the quality
characteristic to the desired target the smaller the summative loss to the consumer and
manufacturer. Taguchi opted to use the quadratic function to represent the approximate
loss between the specification limits. A function to estimate the loss is necessary since
true relationship between measured value and the resultant loss is unknown when the
measurement lies within the tolerance window. The mathematical representation of the
loss function for an n-type characteristic can be written as:

The approximate loss is calculated by multiplying the loss coefficient, also known
as the proportionality constant and denoted by k, by the square of the difference between
the measurement of the characteristic and the desired target value. If the value of the
characteristic exceeds either the lower or upper specification limit, the loss occurred is a
constant value of A. As can be seen in Figure 4, the QLF accounts for the loss between
the specification limits (customer’s loss) in addition to the loss that occurs when the
specification limits are exceeded (manufacturer’s loss). Whether the deviation is to the
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left or to the right of the target value does not impact the loss calculation because of
symmetry. The value of k is chosen by the analyst to relate the measured characteristic’s
numerical value to the loss incurred at that measurement by the customer. As such, the
value is unique for each problem. As stated earlier, the true relationship between the
measured value and the customer’s value of loss is unknown. The curve merely estimates
how the loss changes within the tolerance window. For manufacturing applications with
assumed symmetric loss above and below the desired target, the constant k relates the
loss associated with the specification limit with the distance of the limit from the target
value. The mathematical form of a loss coefficient for a symmetric n-type characteristic
can be expressed as:

The constant c is the loss associated at a specification limit and d is the absolute
distance between the specification limit and the desired target value of the characteristic’s
measurement. If the loss incurred is not the same at the upper and lower specification
limits or the target value is not in the center of the tolerance window, there should be
different values of k calculated for the customer’s estimated loss if the measured value is
below the target and if the measured value is above the target.
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Figure 3.4. Quality Loss Function: Nominal-the-Best Type Characteristic
3.2.3.2 Quality Loss Function: Smaller-the-Better Type Characteristic
For the s-type quality characteristic, it is desirable that the measured value of the
characteristic be as small as possible. Traditionally the target value for an s-type
characteristic is set to zero. The quality loss function imposes a penalty for any deviation
of the measured reading above zero (the readings cannot be negative). Once the deviation
surpasses the upper specification limit the loss reaches a maximum value of A, the loss to
the manufacturer. The mathematical formulation for the quality loss function for an stype quality characteristic can be as:

The loss between the target (zero) and the specification limit is calculated by
multiplying the loss coefficient, k, by the square of the measured value of the selected
quality characteristic. As shown in Figure 3.5, the loss increases as the difference
between the measured quality characteristic and the desired target grows.
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Figure 3.5. Quality Loss Function: Smaller-the-Better Type Quality Characteristic.
Practical examples of characteristics which could be considered s-type include
noise levels, the weight of an item, and the breaking distance of a car. Manufactures
desire to produce products in which identified s-type characteristics as small as possible.
The measurement must, however, always be positive.
3.2.3.3 Quality Loss Function: Larger the Better Type Quality Characteristic
For the case of an l-type quality characteristic, the manufacture’s goal is to
maximize the measurement of the quality characteristic, y. Like the traditional step loss
function, the manufacturer’s loss is denoted by the constant A and is incurred by the
manufacturer when the measurement of quality characteristic, y, is less than the
specification limit. The quality loss function takes into account the loss to the consumer
when the quality characteristic deviates from the desired target, but is still within the
acceptable tolerance window. The QLF imposes a penalty for all values of y that are less
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than the target, but more than the specification limit. The quality loss function for an ltype characteristic is defined as:

The loss estimate is calculated by multiplying the loss coefficient, k, by the
reciprocal of the square of the value of the measured characteristic. Practical examples of
l-type quality characteristics in manufacturing include a product’s useful life, reliability
of component parts, or the strength of a component material. As can be seen in Figure
3.6, the customer’s loss grows as the distance between the measured characteristic and
the target grows.

Figure 3.6. Quality Loss Function: Larger-the-Better Type Quality Characteristic
The quality loss function proposed by Taguchi provides two distinct advantages
over the traditional step loss function. First, in using the traditional step function the
analyst is forced to accept the assumption that all products whose measured characteristic
is within the tolerance window have the same value to the customer. Only the loss of the
manufacturer is taken into account and the voice of the customer is lost. The quality loss
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function allows for the inclusion of the voice of the customer. In addition, the traditional
step loss function does not provide gradated differences in loss related to the measured
value. The loss of value to the customer due to the measurement’s deviance from the
target when the measurement with within the tolerance window is not included in the
overall loss estimate. In comparison, Taguchi’s methodology allows for the calculation of
the total loss which incorporates both the loss to the manufacturer and the loss to the
customer.
Figure 3.7 provides a visual means for which to compare the differences of the
two methodologies. The picture shows measurements (a-d) for a single, measured
characteristic of four products (A-D), the target value for the characteristic ( , and the
upper and lower specification limits (

,

). As can be seen in the illustration,

three of the measurements span a large portion of the tolerance window and one
measurements sits to the right of the upper tolerance. If using a traditional step loss
function, the loss values for products A, B, and C would all be zero. Product D would be
the only product with a valued loss of A, the manufacturer’s loss. Only using the quality
loss function can differences between the products be articulated to the manufacturer
using the estimated loss value. Given the differences in measurements, one should expect
that the customer would perceive a difference in product performance when using
product A versus product C. The figure shows that there is relatively the same amount of
distance between the measurements of a and b, and the measurements of c and d.
Common sense would dictate that the loss incurred by product would be closer for two
products whose measurements are relatively close. Using the traditional step function to
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value loss, the loss value for the product C would be closer to loss value for the products
A and B than product D.

Figure 3.7. Illustrative Diagram: Measurements Relative to Specification Limits.
Since the true value of the loss to a customer is not measurable, Taguchi developed
a reasonable methodology to estimate loss utilizing the quadratic function. The quality
loss function, while not perfect, was an improvement upon the traditional step method for
loss valuation.
3.3 Motivation to Alter Manufacturing Loss Functions for Future Healthcare
Application
3.3.1 Uniqueness of Healthcare Characteristics
Like manufacturing, the healthcare industry relies on the use of physical
measurements to assess a product. In order to determine the proper diagnosis and
treatment plan for a patient, medical professionals use qualitative and quantitative data to
form and validate hypotheses about the patient’s health. Qualitative information is
collected as medical professionals observe the patient during the initial screening and
subsequent meetings. Based on the information provided during the screening and
knowing possible ailments which could presumably cause the identified reaction or
ailment, the medical professional may then order select laboratory tests to help confirm
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the suspected cause. Once the sample is analyzed, the laboratory provides the resulting
measurement and the associated tolerance window to the medical professional
responsible for the patient. Almost 80% of medical decisions made by doctors are
influenced by information from laboratory reports (Katayev, 2010). To assess the
measurement’s significance, the measurement the medical professional uses the provided
the reference interval, decision limit, or the reference change value to assess whether the
measured physiological characteristic is considered to be within a normal range. The
differences between these measurements will be discussed more in depth in Section 3.2.
The assessment about the physical characteristic provides information to the doctor to
narrow down possible causes for the ailment.
A key to improving both the speed and quality of diagnosis and effectively
choosing an appropriate treatment protocol is the development of a deeper understanding
of important measurable characteristics in the human body. The knowledge regarding
healthcare quality characteristics has been limited by four distinct challenges. First,
medical knowledge is still a growing field. As an example, deoxyribonucleic acid, DNA,
profiling was not developed until 1984. Today DNA is used to test for an individual’s
susceptibility to known hereditary diseases. Within the span of 30 years, the improved
test expanded the breadth of the medical community’s capability drastically. Medical
professionals are still learning about the building blocks the human body and their
importance to peak functioning. Secondly, researchers continue to develop and refine
techniques to measure specific physical indicators. As the testing process improves the
amount of information that a doctor can glean from a patient’s sample will continue to
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grow. Furthermore, the increased medical data repositories and computational capability
provided by modern systems will allow medical research teams to identify physiological
differences between subpopulations which can either indicate a smaller tolerance window
for a measurable physical characteristic or might indicate the selection of a specific
treatment protocol. Normal ranges for known characteristics potentially may be refined
so that inter-population variability will no longer mask ailments. Some tolerance
windows for specific physical characteristics have been established for each gender.
Continued research focused on the identification of important sub-groups and associated
reference ranges is needed to narrow current reference ranges. Wide tolerance windows
do not help medical professionals efficiently treat patients since they provide little
information. Lastly, medical professionals are forced to primarily rely on univariate
analysis to support multivariate decisions. Many of the references available, to include
reference intervals, are compiled while holding all other factors stable. For example,
doctors are not able to provide a reference interval for characteristic a given that
characteristic b is not within the normal range. Additional research needs to be conducted
so that medical professionals are better able to understand how to treat patients with
multiple ailments using on or more approved drugs. As medical knowledge grows,
technology improves, and subpopulations are identified medical professionals will be
able to better use the results from laboratory measurements to diagnose and treat patients.
Specifically, the ability to understand the significance of a single value in light of a
patient’s personal history will allow doctors to possible diagnose patients sooner or to
treat a patient more efficiently. Over time, continued research on healthcare quality
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characteristics will enhance our understanding of the human body and how it reacts when
stressed.
In comparison to quality characteristics within the manufacturing sector, there are
two distinct facts make healthcare characteristics unique. First, the target for a healthcare
characteristic is defined as a range rather than a point value. The optimal level of glucose
in the blood stream for a specific individual is not empirically known. Diligent medical
research teams have been able to specify a range within which the glucose reading for
95% healthy population would fall. Reference intervals (RIs) for select quality
characteristics are established through well-documented studies and will be explained in
more detail in Section 3.1.2. RIs are currently the most prevalent metric used to assess a
patient’s health. Unlike manufacturing where engineers compare a measurement to a
point target, doctors compare the laboratory result to a target range. The use of an
acceptable range aligns with the concept that each human is unique and the realization
that human understanding of medical science is limited. Secondly, a naturally occurring
inter-variability between the physical qualities of people and possible intra-variability
between successive measurements of a single patient. Differences between successive
measurement can be due to error in measurement technique or biological changes (in a
single patient) or biologic differences (between patients) (Ricos et al., 2004). In
healthcare, the biologic differences have the potential to impact the choice and
effectiveness of treatment plans. The following paragraphs provide a brief summary of
the different comparison metrics that are used by providers to understand laboratory
results.
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3.3.2 Healthcare Measurement References
There are three different numeric values which medical professionals may use to
assess the significance of a patient’s laboratory result. The comparison references are
used to determine if the sample’s measure is atypical. The three numeric values are
discussed in more detail in sections 3.3.2.1 to 3.3.2.3.
3.3.2.1 Reference Intervals
Reference intervals (RI) are the range within which 95% of the values of the
population from which the sample was taken are estimated to fall. In the case of medical
RIs, the reference group from which samples were taken was limited to selection from a
pre-screened healthy sub-population. This type of numeric reference is the most widely
used yardstick used to help determine a patient’s health. When test results for an
individual’s laboratory assessment are sent back each measure will be paired with the
appropriate reference interval.
RIs can be published both by the manufacturer of the equipment used to perform
the test and by independent laboratories that employ the equipment. Before processing
analyte samples, it is recommended that laboratories establish a laboratory specific
reference interval or verify existing reference intervals from another facility are
applicable to the serviced population (Clinical Laboratory Standards Institute, 2008). It is
important to note that the RI for a given characteristic may vary between locations.
Variance between the published reference intervals for similar reference populations at
different laboratories can be attributed to the use of different types of test equipment, the
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types of chemicals used in the analysis, or technician technique (American Association
for Clinical Chemistry, 2017).
Recent advancements in technology and published methodologies for determining
and verifying intervals have improved the quality of the intervals over the past few
decades. Often cited and referenced, EP28-A3c: Defining, Establishing, and Verifying
Reference Intervals in the Clinical Laboratory offers the most comprehensive
examination of laboratory protocols which ensure usefulness and reliability of reference
intervals (Clinical Laboratory Standards Institute, 2008). The focus on standardization
has helped to reduce the variability between RIs from different locations. Differences in
reference intervals between laboratories and medical facilities have the potential to
induce additional confusion into the decision-making process (Plebani, 2016). The
following paragraph will briefly describe the process for establishing an RI. First, the
laboratory must fully document its proposed methodology to include criteria for the
reference sample population. Next, at least 120 reference individuals from a reference
population must be used to form the reference sample group (Clinical Laboratory
Standards Institute, 2008). The reference sample group is screened to ensure that they
meet the minimum health standards outlined by the documented protocol. In a numerical
study using National Health and Nutrition Examination Survey (NHANES) data, Horn et
al. (2013) was able to show that inclusion of unhealthy subjects could increase the width
of the RI by as much as 30 percent. A wider RI can result in an increased number of
individuals who are not appropriately diagnosed. The reference sample group then
provides the necessary samples. The RI is found by including the central 95% of the
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values found within a sample. The lowest and highest 2.5% of samples are excluded.
While separate methodologies for creating reference intervals for parametric and
nonparametric data are included in EP28-A3c, the guide recommends the use of the
nonparametric methodology for simplicity (Clinical Laboratory Standards Institute,
2008).
Accurate reference ranges are needed by the medical community for patient care
and to interpret data from vaccine trials (Kibaya et al., 2008). The accuracy of a reference
interval have the potential to impact treatment decisions for patients. As highlighted by
Brewster et al. (2007), patients can be misdiagnosed when inappropriate reference limits
are used. The team analyzed serum creatine kinase (CK) from ethnically diverse sample
to validate the applicability of the published reference interval. Their findings indicated
that specific ethnic subgroups had naturally higher CK level activity than the general
population. If the RI established for the general population was used for diagnosis, the
patient’s laboratory readings would block the patient from participation in statin therapy.
This study illustrated that RIs had the potential to impact the availability of treatment
options for patients. In order for a RI to be useful, the sample reference population must
be reflective of the population for which the RI will be used. If the patient population is
not adequately represented in the sample used to establish the reference interval, the
resultant limits can lead to a suboptimal decision on whether to start or continue
treatment.
Past studies, like the one by Brewster et al. (2017) bring into question the
applicability of common reference intervals to all patients. While it has been
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acknowledged that the quality of RIs is better than at any point in history there is still
ample room for improvement. Establishing quality RIs is hampered by the availability of
adequate sample reference groups and by a limited understanding of which factors impact
the levels of a substance within the human body. It has been noted that establishment of
RIs for the pediatric population is difficult due to ethical considerations of sampling
healthy patients. In addition healthy reference sample group for the geriatric population is
difficult due to the high percentage of that population who do not meet the minimum
health requirements to provide usable sample (Ceriotti, 2012). A recent National Health
and Nutrition Examination Survey (NHANES) study showed only one out of ten subjects
in the 70-80 age range could meet the requirements to be part of the reference sample
group (Horn & Pesca., 2003). In addition to the complications in gathering data from
subpopulations due to ethical concerns and health issues, the lack of understanding of
what factors can affect measurements hinders the identification of appropriate
subpopulations which could allow for narrowed RIs. As pointed out by Ceriotti only 47
out of the 296 analyte reference intervals provided in the Tietz textbook included a
separate RI for each gender (Ceriotti, 2017). This statement suggests that while gender
does influence the levels of 47 analytes, not all analyte levels are influenced by gender. In
summary, reference intervals provide a range in which a healthy individual could expect
the reading to fall. Wide RIs hinders prompt diagnosis by masking abnormal values. The
identification of subpopulations with potentially narrower RIs in comparison to the
general RI may have a profound impact. Of all the researched limits for medicine, RIs are
the most widely documented and researched.
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3.3.2.2 Decision Limits
Initially termed “discrimination value” by Sunderman, decision limits are used to
mark the difference between the “healthy” and “diseased” population (Sunderman, 1975).
While reference intervals focus on describing a physiological state of a healthy person,
decision limits were created to help medical professionals determine the risk of disease
(Ceriotti, 2008). The two conditions which affect the identification of decision limits are
the clinical question for which the lab was ordered and the patient category (Ceriotti,
2008). There are currently three different methods used to establish decision limits:
Bayesian, epidemiological, and physiopathological. The Bayesian approach uses
knowledge of the diagnostic test, distribution for the analyte in a healthy population,
distribution for the analyte in an unhealthy population, and the cost of misdiagnosis to
determine an appropriate decision limit for the clinical question. The epidemiological
approach is based evidence from population studies. The limits are determined by
consensus. The last approach, physiopathological, is based on clinical experience. To
date, only eight analytes have universally accepted decision limits. Those analytes are
total cholesterol, LDL cholesterol, HDL cholesterol, non-HDL cholesterol, triglycerides,
apolipoprotein A-I, apolipoprotein B, and glycated hemoglobin (Ceriotti, 2017).
Standards continued to be refined and are updated as new information becomes
available. For example, in 1997, an International Expert Committee recommended
changes to criteria used to diagnose diabetes (Kahn, 2003). Specifically, the panel
recommended that the fasting plasma glucose level that distinguished between those with
diabetes and those without be lowered. The recommended change reflected the
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knowledge gained from examination of data that clearly showed diabetic retinopathy, a
diabetes complication that affects the eyes and can result in blindness, occurred
frequently at a lower reading of fasting plasma glucose. The lower threshold for fasting
plasma glucose will directly influence the number of people who are diagnosed with
diabetes. The change could potentially result in less people loosing eyesight since they
are more aware of the importance of proper control of blood sugar.
3.3.2.3 Reference Change Values
Reference change values are the difference in an individual’s analyte
measurement over a period of time. A reference value may be used to monitor individuals
who have been diagnosed with either an acute or a chronic condition. The utilization of
reference change value increases a provider’s sensitivity to an individual’s pathologic
changes in comparison to the use of reference interval. If an individual is taking
medication to alter the level of an analyte within his or her body, comparison of a
laboratory measurement to a target range value may or may not show that the medication
was having the intended affect. Comparison of an individual’s successive lab results has
the potential to illuminate physical change that might not be apparent because the
patient’s natural variability falls within the bounds of the population variability. The use
of the reference change value is limited to instances when successive readings of the
same analyte are taken from one individual.
3.3.3 Need Unmet by the Quality Loss Functions in the field of Healthcare
Quality loss functions are used within the manufacturing application area to
determine where limits should be set in order to minimize the loss to society. In
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transferring the concept of loss functions to a healthcare setting it is important discuss
two important aspects of loss functions: the purpose of the measurement and the meaning
of the measured value. Prior to use, there must be agreement on the purpose of the loss
valuation within healthcare. The purpose of the loss value for manufacturing serves as
motivation to improve the process for long term gains to society as a whole. The quality
loss function maps an event or measurement to a cost. When establishing a summative
loss function for use within healthcare, it is important to keep in mind that the value will
help medical professionals compare the impact of treatment protocol options. The
measurement of a select physical characteristic maps to a valuation of health. Unlike
manufacturing there only two perspectives need to be included, the use of an adaption of
the loss function within healthcare will need to take into account three perspectives: the
provider, the patient, and society at large. Loss functions allow the user to clearly see
what will happen if a quality characteristic does not meet the target. For example, use of a
loss function in healthcare could provide insight into the meaning of a laboratory test
does not fall within the allowable bounds. A loss function would allow for health
providers quantize a patient’s physical performance based on the measured characteristic.
Readings outside a specified tolerance window would indicate health implications, the
possible need for further tests, or the need for immediate treatment. The second
influential decision use of loss functions within healthcare is the meaning of the
measured characteristic. When loss functions used within the manufacturing sector, the
manufacturer specifies both the target value and the limits for the product. The target
value is a point target. The product performs best when the measured characteristic is at
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the target value. The limits delineate the lowest and highest measurement within which
the product can still be used for its intended purpose. In healthcare, the loss function
would need to be adapted for use with a target interval. Medical knowledge has not
advanced to the point where the best value of an analyst for an individual is known. At
this juncture, there is only general consensus that a healthy value of a measured analyte
exists within a specified range. The limits for the loss function could be based either on
decision limits or the reference interval. The following two sections propose univariate
and bivariate loss functions for use within healthcare. The performance function is an
adaptations of the loss functions with a target interval for use within the medical field.
3.4 Proposed Univariate Performance Functions
3.4.1 Applications of Univariate Performance Functions
Performance functions provide a means of mapping a patient’s physical
performance outcome given a measured physical characteristic. A clinician could
reference a performance diagram to make an assessment of how to further investigate,
diagnose, or treat the patient. Readings outside the specified tolerance limits would
indicate possible health risks.
3.4.2 Healthcare: Nominal-the-Best Type Characteristic
As explained earlier, an n-type characteristic for a quality loss function consists of
a target value with established upper and lower specification limit. An n-type
characteristic for a performance function would consist of a target range and with upper
and lower specification limits. If the patient’s measurement falls within the target range,
the patient’s measurement would be considered optimal. A patient’s value for the
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measured characteristic may however fall above or below the specified target range and
indicate possible associated health risks. If performance functions are adapted by the
medical community, the following three physical characteristics would be designated as
n-type measurements.
a. Heart Rate: Heart rates typically are between the ranges of 60 to 100 beats per
minute(bpm) (American Heart Association, 2018). The rate measurement for an
individual may vary based on a large number of factors to include gender, fitness,
current emotional state, and the individual’s position while the reading was being
taken (sitting, standing, or lying down). Some issues that can be indicated by heart
rate are rhythm disorders include tachycardia (heart rate exceeding 100 bpm),
bradycardia (too low heart rate), pre-mature contraction, and Adam-Stokes
disease (very fast and steady).
b. Ferritin: A protein found in in reticuloendothelial cells, ferritin stores iron and
releases it to the rest of the body in a controlled fashion. The amount of iron can
be measured by radioimmunoassay. Typical values for adults by gender are 20 to
200 nanograms per milliliter (ng/mL) for men and 20 to 120 ng/mL for women
(US National Library of Medicine, 2018). A test result that is less than the
established normal range could indicate chronic iron deficiency. A slight increase
above the normal level could indicate renal disease. Levels above the normal
range could be an indication that the patient has acute or chronic hepatic disease,
iron overload, leukemia, or an acute or chronic infection.
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c. Vitamin D: This substance plays a role in the control of calcium and phosphate
levels within the human body. The amount of Vitamin D is measured through a
blood test. The normal range of range is between 20 and 40 ng/mL (Mayo Clinic,
2018). A lower than normal level can be due to the lack of exposure to sunlight,
insufficient diet, or liver or kidney diseases. Low levels of Vitamin D have also
been linked to greater risk for cardio vascular disease. The use of certain
medications such a phenytoin, an anti-epileptic drug, can also result in a lower
reading of Vitamin D. If Vitamin D is too high, a patient could experience adverse
symptoms which could include nausea or kidney stones.
d. Thyroid Simulating Hormone (TSH): Produced by the pituitary gland, this hormone
signals the thyroid to generate and release triiodothyronine (T3) and thyroxine
(T4) in to the blood steam. T3 and T4 help to control the body’s metabolism. To
test for the substance, the patient provides a blood sample. The normal range for
TSH in an adult is from .4 to 4.0 milli-international units per liter (Mayo Clinic,
2018). If TSH is below this range, the measurement could mean that the thyroid is
not producing enough thyroid hormone and possible hypothyroidism. If the TSH
is too high, the measurement could indicate that the thyroid is too active and
possible hyperthyroidism.
3.4.2.1 Healthcare: Step Function for Nominal-the-Best Type Characteristic
For an application in healthcare, the traditional step loss function is renamed as a
“performance” function. The function provides a numeric estimate of how well the body
is performing based on the measured physical characteristic. Performance values close to
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zero are considered optimal. A higher performance value indicates decreased
performance of the body and associated increased risk of future health complications.
Figure 8 graphically illustrates the proposed performance function for an n-type
characteristic. The horizontal axis is broken down into three distinct zones. Each zone is
indicative of the performance that may be achieved with the given characteristic
measurement. Zone 1 coincides with the specified target interval and should align with
the established reference interval for measured substance. As can be seen, the
performance loss within zone 1 is zero. As the measured value deviates outside zone 1,
the recommended target interval, the individual experienced decreased performance or
increased future health complications.

Figure 3.8. Performance Step Function for Nominal-the-Best Type Characteristic.
The performance loss function would be unique to each physical attribute measured.
Some health characteristics are known to have a greater impact on an individual’s
physical performance or are associated with higher risk for long term health
complications. The mapping of values outside of the established tolerance window would
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result in a larger value of performance loss. Variations of the performance function could
include more zones to communicate known risks with set measurements outside the
tolerance window. Other physical characteristics might exhibit asymmetric performance
degradation. Careful analysis will need to be conducted for each health characteristic to
determine the most appropriate number of zones, to verify symmetry of performance, and
determine the “magnitude” of the estimated performance loss and increased risk. The
mathematical form of the performance step function for an n-type characteristic would
be:

0

Performance( y )   L1
L
 2

LSL1  y  USL1
LSL2  y  LSL1 ,USL1  y  USL2
y  LSL2 ,USL2  y

Like the traditional step loss function, the performance function does not offer a
good estimate of performance degradation in the middle of a zone. The advantage of this
method is that it is easy to calculate performance loss and increased risk with a
quantitative measurement.
3.4.2.2 Healthcare: Performance Function for Nominal-the-Best Type Characteristic
In order to make the performance function more sensitive to changes in the
measured physical characteristic, the step function is replaced with a smooth continuous
function. Figure 3.9 provides an illustrative example of a loss function for an n-type
characteristic with symmetric loss outside of zone 1. Like the step function shown in
Figure 3.8, zone 1 is the accepted tolerance window for a normal measurement. As the
measurement increases or decreases from the boundary of zone 1, the performance loss
grows.
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Figure 3.9. Performance Function for a Nominal-the-Best Type Characteristic.
The mathematical form of the performance function for an n-type characteristic
would be as follows:
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By using the quadratic function to model the decreased performance, the loss
would be increased by an amount proportionate to the absolute value of the deviation of
the measurement from the specified target. Since performance loss would most likely be
different if the patient’s test result is less than or more than the target, asymmetric
performance loss modeling is a future research area.

94

3.4.3 Healthcare: Smaller-the-Better Type Quality Characteristic
Next let us consider a performance function for an s-type characteristic. S-type
quality characteristics have an upper specification limit with an ideal target at zero.
Below are three examples of in which s-type quality characteristics can be found in the
health domain.
a. Blood Glucose Levels: Doctors monitor the average level of blood glucose over a
window of two to three months utilizing a glycohemoglobin test. The test has a
variety of names to include A1c, glycated hemoglobin, glycosylated hemoglobin,
hemoglobin, and HbA1C. The test examines the average sugar levels over time
within the blood stream. The results are given as a single value (percentage form),
and are interpreted along a range. The higher the number, the higher the average
blood glucose level over the time window. A normal test result is considered any
value below 5.7 percent (Mayo Clinic, 2018). Prediabetes is present with an A1c
result between 5.7 and 6.4 percent. A patient is considered diabetic with an A1c
greater than 6.4 percent.
b. Cancer Antigen 125 (CA 125): CA 125 is a membrane-bound protein on the surface
of cells and is released into blood. The test is used to monitor the status of cancer
before, during, and after treatment. High levels of the protein have been linked
with ovarian cancer, pelvic inflammatory disease, pancreatitis, and the first
trimester of pregnancy. Sample measurements reading below 46 units per
milliliter (U/ml) are considered normal (Mayo Clinic, 2018)
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c. Antimitochondria Antibodies (AMA): In an autoimmune response, the body’s
immune system will attack healthy cells, tissues, and organs. An AMA test
measures the amount of antibodies in the blood stream. The normal range for
AMA is less than 1.0 units.
In healthcare s-type characteristics, it is desirable that the measurement reading
from a laboratory test be as small as possible.
3.4.3.1 Healthcare: Step Function for Smaller-the-Better Type Characteristic
A performance function for an s-type characteristic estimates the growing
performance loss as the measured characteristic deviates from the desired target range.
The target range and boundaries for the zones are based on established reference intervals
and decision limits. Like the performance function proposed for the n-type characteristic,
the performance loss is due to mounting medical complications associated with the
measured characteristic and increased risk for future health complications. Once the
deviation surpasses an upper specification limit the loss value is set at a constant L.
Figure 3.10 illustrates an s-type medical characteristic which spans three zones of health
risk.
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Figure 3.10. Performance Step Function for a Smaller-the-Better Type Characteristic.
The mathematical form the performance step function for the s-type characteristic
would be as follows:

0  y  USL1
0

Performance( y )   L1 USL1  y  USL2
L
USL2  y
 2
The performance step function maps the value of a physical measurement to
performance loss. The drawback of using a step function is that it is not sensitive to
changes in a patient’s measurement when the measurement remains within the same
zone. As long as the measurement of the characteristic does not leave a zone, the
performance loss will be the same for all measurements within the zone. The next section
will propose an alternative to the s-type performance step function that allows for more
sensitive means of articulating the performance degradation (health risk) of the patient.
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3.4.3.2 Healthcare: Performance Function for Smaller-the-Better Type
Characteristic
In this section, we will look at altering the s-type performance function to be more
sensitive to changes in the health measurement. Figure 11 illustrates the s-type
characteristic with three levels of risk. Zone 1 represents the low risk area and is defined
as the normal range for the measured characteristic. Within this range, a patient’s
measurement falls within the published reference interval. As the patient’s reading
increases above the published range, the patient’s risk for additional health complications
increases. In zone 2, the increasing loss line is illustrative of the physical performance
loss experienced by the patient. Once a patient’s reading reaches zone 3, the patient is at
high risk for additional health complications.

Figure 3.11. Performance Function for a Smaller-the-Better Type Characteristic
The mathematical form of the performance function for an s-type medical
characteristic would be as follows:
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3.4.4 Healthcare: Larger-the-Better Type Characteristic
The last type of health characteristic to be defined is the l-type medical
characteristic. In this case, the patient’s performance peaks when the measured value is as
large as possible. L-type characteristics have a lower specification limit with an ideal
target at infinity. Below are three examples of l-type characteristics found in the medical
domain.
a. High-density lipoproteins (HDL): Lipoproteins help move lipids, fat molecules,
around the body. HDL, one of the five major types of lipoproteins, helps to
remove fat molecules from cells to the liver. A lipid panel is used to determine the
amount of HDL in the body. A healthy amount of HDL is determined to be
greater than 60 mg/dL. Patients with less than 40 mg/dL are considered to be at
high risk for heart disease(Mayo Clinic, 2018). Patients with at least 60 mg/dL are
not considered to be at risk for heart disease.
b. Vo2 Max: A practical example of a larger the better type quality characteristic in
the healthcare field is the lung capacity of a patient measured as Vo2 max. The
test determines cardiovascular and respiratory fitness. The greater the test score
achieved by the patient indicates a greater level of fitness.
c. Strength: Another quality characteristic of the larger-the-better type could include
muscular strength. There is no limit on the amount of strength that a person
should have. A lower bound exists so that a person can perform “daily” tasks.
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3.4.4.1 Healthcare: Step Function for Larger-the-Better Type Characteristic
A performance function for an l-type characteristic needs to be able to estimate
the growing performance loss and increased health risk as the measurement deviates to
the left of the target range. The target range and boundaries for the zones would be based
off the reference intervals and established decision limits. Like the performance function
proposed for the n-type characteristic, the zones reflect a varying level of performance
loss due to mounting medical complications associated with the measured characteristic.
Once the deviation surpasses a lower specification limit, the loss value is set at a constant
L. Figure 3.12 shows an example of a step performance chart for an l-type medical
characteristic. The example shows an increased risk to the patient’s health and a loss of
physical performance with a lower reading of the medical characteristic.

Figure 3.12. Performance Step Function: Larger-the-Better Characteristic.
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The mathematical form of the performance step function for an l-type
characteristic would be as follows:
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As stated earlier, the performance step function is a good starting point for
articulating physical performance of a patient based on a measurement. Like step
functions used within manufacturing, the step loss function is not sensitive to changes in
a characteristics measurement if the measurement remains within a defined window. For
example at the low end of zone 2, the patient’s situation is more precarious than at the
high end of zone 2 because of the greater probability of moving into zone 3. Using the
step function, the loss value does not adequately convey that risk to the medical
professional. The next section will propose an alternative that allows for more sensitive
means of articulating the performance degradation (health risk) of the patient.
3.4.4.2 Healthcare: Performance Function for Larger-the-Better Type
Characteristic
The step function discussed earlier is not sensitive changes in the measured
physical characteristic within a zone’s boundaries. By altering the form of the
performance function from a step function to a continuous function, the provider may
better associate relationship between the measured characteristic and the increased health
risk to the patient. Figure 3.13 illustrates the performance loss of an l-type medical
characteristic across three levels of risk. Zone 1 is the low risk area and encompasses the
characteristic’s published reference interval. Within this range a patient’s measurement
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falls within the published “normal” ranges. As the patient’s reading decreases below the
published “normal” range, the patient has an increased risk for additional health
complications. In zone 2, the line is illustrative of the physical loss experienced by the
patient. Once a patient’s measurement crosses into zone 3, the patient is considered high
risk for a decreased physical performance.

Figure 3.13. Performance Function for Larger-the-Better Type Characteristic.
The mathematical form of the performance function for an l-type medical
characteristic would be as follows:
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The above illustrations are merely starting points for further research in this area.
The most important aspect of this conceptual work is the mapping of a physical
measurement to associated health risk and the consideration for how the loss
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measurement could be used by medical professionals. The potential value in this work is
that it provides a way to articulate the trade space of risk within the medical field.
3.5 Proposed Bivariate Performance Functions
3.5.1 Applications of Bivariate Performance Functions
Both the traditional step loss function and the quality loss function described in
Section 4 examine performance loss for a single quality characteristic. Given that there
are possible trade-offs between the different types of characteristics, better insights might
be obtained from looking at the region of interest for two loss characteristics and the
resultant mapping of the measurements to a performance valuation. Since the body is a
complex system, it would be more appropriate to assess treatment options based on sets
of analyte values instead of in isolation. The use of bivariate performance functions might
aid medical professionals in evaluating treatment options for multiple symptoms.
Bivariate performance loss functions potentially may provide an avenue for treating
medical conditions affecting one physical measurement characteristic using treatments
whose side effects are known to affect another measurable physical characteristic. With
the performance loss function, it would be possible to estimate the total performance loss
before the medication is prescribed. For example, select medicines used to relieve high
blood pressure can affect the glucose level in the blood stream. In the case of individuals
with borderline A1c readings, it would be prudent to assess whether using the blood
pressure medication would push the patient’s A1c past a decision limit. However, use of
the medication might be useful if it did not push the total performance loss to an
unacceptably high level. This research is particularly important given the rise of patients
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diagnosed with multiple ailments and prescribed multiple drugs. The following sections
lead the reader through investigations of three bivariate cases. These conceptual
illustrations allow the reader to ponder the possibility of the impact of bivariate
performance functions.
3.5.2 Investigation of Two Nominal Type Characteristics
The use of bivariate performance functions would help medical professionals
effectively assess the impact of a treatment on more than one physical characteristics.
Figure 3.14 illustrates the region of interest for two n-type characteristics, A and B.
Ideally, the patient’s lab results would fall within the recommended reference intervals,
the area between the LSL1 and USL1. The area in which both characteristics’
measurements are within the “normal” reference interval is named the ideal conformance
region. This region is illustrated by the light grey square in the center of Figure 3.14. If
either of the patient’s lab result measurements for characteristic A or B exceeds the
associated LSL1 and USL1 the patient’s performance moves from the ideal conformance
region into the acceptable conformance region. The acceptable conformance region is
denoted by a darker shade of grey than the ideal conformance region. Within this area,
the patient is at an increased risk for medical complications. Decision limits are
illustrated in this instance as LSL2 and USL2. As stated earlier a decision limit is a
universally accepted boundary for a specific analyte between “diseased” and “not
diseased.” While only a few decision limits currently exist, it is expected that more
decision limits will be defined in the coming years. As either of the patient’s lab result
measurements for characteristic A or B exceeds the associated LSL2 and USL2 the patient
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moves into the non-acceptable conformance region. Within this region, the patient will
experience health complications. The diagram provides a method of visualizing increased
risk to the patient or decreased performance for multiple characteristics. Treating the
medical issue as a multivariate problem is both more realistic and safer for the patient.

Figure 3.14. Conformance Region for Two Nominal Type Medical Characteristics.
Figure 3.14 illustrates a bivariate performance step function for two n-type
characteristics. For this example, both n-type characteristics are symmetric. Like the
performance step function described for the univariate case, loss is only incurred after the
characteristic’s measurement exceeds the first set of specification limits. For this
example, the first set of specification limits is the upper and lower founds for the
reference interval. The number of specification limits will depend on the number decision
limits associated with the analyte.
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Figure 3.15. Bivariate Step Function for Two Nominal-the-Best Type Characteristics.
Figure 3.15 illustrates a performance function for two, symmetric n-type
characteristics. Like the performance step function, the value of the performance function
is zero if the reference intervals are not exceeded for either of the measured
characteristics. Once either characteristic exceeds the upper or lower bound of the
reference interval, the performance function takes on a value. The value of the
performance loss is the distance from the plane connecting the axis for the values of
characteristic B and characteristic A to the surface curve.
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Figure 3.16. Bivariate Performance Function for Two Nominal-the-Best Type
Characteristics.
3.5.3 Investigation of a Nominal-the-Best Type & a Smaller-the-Better Type
Characteristic
Figure 3.16 illustrates the region of interest of an n-type characteristic, A, and an
s-type characteristic, B. Ideally, the patient’s lab results would fall within the
recommended reference intervals which are bounded in the illustration by LSL1 and USL1.
This region is illustrated by the light grey rectangle in the center of the diagram. As the
patient’s measured characteristics exceed the reference interval limits, the patient moves
into the acceptable conformance region, the next darker area. If the patient’s values
exceed the next set of limits, LSL2 or USL2, for either characteristic, the patient moves
into the “non-acceptable” conformance region. Within this area, the patient has a
diagnosed health complication.
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Figure 3.17. Conformance Region for a Nominal-the-Best Type & a Smaller-the-Better
Type Characteristic.
Figure 3.17 below illustrates the performance function created by an n-type
characteristic, A, and an s-type characteristic, B. Ideally, the patient’s lab results would
fall within the recommended reference intervals, the ideal conformance region bounded
by LSL1 and USL1 for each characteristic. Within the ideal conformance region, the
performance loss is zero. As the measurement for the n-type deviates above or below the
target interval and as the measurement of the s-type characteristic gets larger, the value of
the performance function increases. While the patient’s values remain between the
reference interval and the decision limit values, the patient is considered to be within the
acceptable conformance region. Once the one of the patient’s lab results indicate that a
decision limit has been passed the patient moves into the non-acceptable conformance
region. The figure illustrates that the value of the performance increases between the
established limits. The goal of medical professionals is to treat a patient so that the
overall performance function is minimized.
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Figure 3.18. Bivariate Performance Function for a Nominal-the-Best Type & a Smallerthe-Better Characteristic.
3.5.4 Investigation of a Nominal-the-Best Type & a Larger-the-Better Type
Characteristic
Figure 3.18 illustrates the region of interest for the interaction of an n-type
characteristic, A, and an l-type characteristic, B. In the ideal conformance region, both
measured characteristics are within the established “normal” region. This region is
illustrated by the light grey rectangle in the center of the diagram. As either of values for
characteristic A or B passes the first set of specification limits, the interaction between the
characteristics enters the acceptable conformance region. The next set of specification
limits, as shown on the diagram with a subscript 2, is associated decision limits with the
measured characteristic. As either of values for characteristic A or B passes the second set
of specification limits, the interaction between the characteristics enters the nonacceptable conformance region
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Figure 3.19. Conformance Region for a Smaller-the-Better Type & a Larger-the-Better
Type Characteristic.
Figure 3.20 below illustrates the performance function created by an l-type
characteristic, A, and an s-type characteristic, B. Ideally, the patient’s lab results would
fall within the recommended reference intervals, the ideal conformance region bounded
by LSL1 for characteristic A and USL1 for characteristic B. Within the ideal conformance
region, the performance loss is zero. As the measurement for the l-type characteristic gets
smaller than LSL1 or the measurement for the s-type characteristic increased above USL1,
the value of the performance function increases and the patient enters the acceptable
conformance region. While the patient’s values remain between the reference interval and
the decision limit values, the patient is considered to be within the acceptable
conformance region. Once one of the patient’s lab results indicate that a decision limit
has been passed the patient moves into the non-acceptable conformance region. The goal
of medical professionals is to treat a patient so that the overall performance function is
minimized.
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Figure 3.20. Bivariate Performance Function Conformance Region for a Smaller-theBetter Type & a Larger the Better Type Characteristic.
3.6 Conclusion
With the involvement of a diverse and innovative team that spans the entire
scientific community, the promise of precision medicine has the best chance of becoming
a reality. The purpose of this initiative is to assist medical professionals to more
accurately predict the best prevention measures and treatment strategies for a specific
disease for an identified group of people. While traditionally involved in solving
manufacturing problems, quality engineers have a critical role to play in the development
of precision medicine. The purpose of this paper was to initiate a dialogue about how to
apply existing quality engineering methodologies to healthcare. Specifically, this paper
looked at how to adapt the concept of quality loss functions first developed by Taguchi
for use in valuing performance loss and increased risk for future medical complications
given biometric measurements. The proposed performance function provides medical
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professionals with a quantitative means of relating changes to physical measurements to
an individual’s overall health. As stated earlier, the most important step in adapting
traditional quality engineering methodologies for use within healthcare is in identifying
the defining the differences in the problem construction between manufacturing and
healthcare. Each identified difference presents an opportunity for the quality engineer to
either validate the universality of the methodology or to suggest an alternate methodology.
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CHAPTER FOUR
DECISION MAKING IN HEALTHCARE USING ROBUST DESIGN WITH
CONDITIONS-BASED SELECTION OF REGRESSION ESTIMATORS
This chapter has been published in Quality and Reliability Engineering International and
should be cited as:
Pegues, K. K., Boylan, G. L., & Cho, B. R. (2017). Decision making in health care using
robust parameter design with conditions‐based selection of regression estimators.
Quality and Reliability Engineering International, 33(8), 2151-2169.
The foundation for the aforementioned publication was the joint work with Boylan, G.
(2013).
Boylan, G. (2013). Robust Parameter Design in Complex Engineering Systems. (Doctoral
dissertation). Retrieved from Tiger Prints, Clemson University.
4.1 Introduction
4.1.1 Research Motivation and Scope
Robust Parameter Design (RPD) is an engineering philosophy and statistical
method used to determine the optimum conditions that bring the mean process
performance towards the desired outcome target with minimum process variability.
While the RPD methodology has been applied mainly in the manufacturing sector, we
believe that this methodology has the potential for greater impact within the healthcare
domain. Since tackling RPD problems for healthcare sector is a multistage effort, the
purpose of this paper is to provide clarification on estimator selection when high
variability and asymmetry dominate healthcare process outputs. In particular, a variety of
alternative regression approaches are examined via experimental analysis and simulation
to determine which methods produce the best solutions.
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This chapter provides readers a clear, conditions-based approach for the
application of RPD when the conditions of either asymmetry or a high degree of process
variability cannot be ruled out. This work is an extension of previous efforts to examine
situations in which the parameters needed for ordinary least regression (OLS) fail to hold.
Data analysis can illuminate intrinsic process conditions that should inform selection of
the regression estimation method. In a parallel paper Boylan and Cho (2012) examined
distributional characteristics in the context of the four sample moments and investigated
how variations in those moments affect the normal probability plot, focusing on the
presence of skewness and kurtosis in the data under study. In that instance, residual-based
assumptions supporting the use of OLS regression were assumed to hold to facilitate
comparisons between the estimators considered. The paper also examined how the
validity of assumptions associated with underlying populations impacts the resultant
statistical analysis of the data. Many of the statistical procedures commonly utilized
within quality engineering literature are based upon the assumption of normality. The
assumption of normality, although helpful for tractability, may not reflect reality for
healthcare applications. As the research community develops a deeper knowledge of
medical conditions and underlying causes, a parallel effort within the engineering
community should focus on developing better methodologies for dealing with nonnormal distributions and asymmetry. The ramifications of utilizing faulty analysis can
include increased cost to the organization, physical harm to the patient, or a combination
thereof. Given that asymmetry naturally exists in situations involving smaller-the-better
(s-type) and larger-the-better (l-type) healthcare quality characteristics, the use of a
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normal distribution for modeling healthcare outcomes may not be appropriate when
asymmetrical effects become amplified and are coupled with elevated degrees of process
variability. A variety of alternative approaches to regression estimation exists and is
documented in both statistics and regression-based literature. This chapter explores the
performance of existing regression estimation techniques under varying process
conditions with the aims of creating renewed interest in alternative approaches. To
simulate asymmetric conditions, a skew normal distribution is integrated into the
research. This distribution, also known as an asymmetric Gaussian curve, generalizes the
normal distribution to allow for non-zero skewness.
The combination of experimental investigations and simulation allow us to
evaluate which regression approach performs best in terms of producing the best results
under examined conditions. A sequence for implementing this approach is portrayed in
Figure 4.1. Monte Carlo simulation and numerical case studies are used in Section 4.3 to
provide clarification as to which estimators should be considered in Phase Ib. In Section
4.2, a proposed healthcare specific methodology is developed using the skew normal
distribution as the basis for modeling system attributes. In Section 4.3, the numerical
demonstration provided is composed a case study with Monte Carlo simulation. Finally,
in Section 4.4, the results are analyzed.
4.1.2 Robust Parameter Design: Development and Application
Although many researchers endorse the philosophical arguments behind
Taguchi’s (1986, 1987) original version of RPD methods his mathematical approaches
have generated criticism. The differing viewpoints of the research community regarding
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the validity of Taguchi’s assumptions, the varying assessments as to the effectiveness of
the approach, and the associated analytical methods are thoroughly documented by many
researchers, including include Box (1988) and Tsui (1992). A review of the RPD
literature since 1980 reveals that a majority of the work focused on alternative
optimization techniques. The degree to which a response surface yields a “good fit” is
contingent the correct identification of the prevailing conditions of the sampled data and
the appropriateness of the method used to develop the fitted model. Researchers, by
proceeding forward into the optimization phase of research, are endorsing that that the
parameter estimates are sufficient for use, that estimates are obtained using appropriate
estimators, and that prevalent conditions within the data support the chosen parameter
estimator technique.

Figure 4.1. Methodology process map for healthcare applications.
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A review of statistics-based literature highlights the variety of existing regression
estimation methods. The volume of literature focused on alternative estimation
approaches quantitatively demonstrates the need for better results than those found with
OLS. Many of these alternatives were developed to overcome issues associated with
outliers, contaminated data, non-normality in the responses and/or residuals, and
heteroscedasticity. The spectrum of estimation methodologies includes data
transformations, generalized linear models (GLM), the weighted least squares (WLS), and
an assortment of various resistant and robust regression techniques to include least
trimmed squares (TLS), least absolute deviation (LAD), M-estimation, M-M estimation,
and S-estimation. A selection of these methods will be discussed in greater detail in
Section 4.3.3.
To overcome non-normality of a data sample, researchers applied transformations
on the response (Y) or utilized GLMs. As Ryan (2009) observed, the drawback is that the
use of transformations can induce change in both the distribution of data about the
regression line and the vertical spacing of the observed values. Since the need to
transform data may stem from a few influential observations, researchers are urged to use
caution as they proceed. GLMs, another approach for dealing with non-normality, have
received considerable attention as a practical alternative to transformations (Myers et al.,
2002, Myers et al., 1997). The critical aspect of GLMs is the use of a smooth monotonic
link function
sense,

from any distribution within the exponential family. In a

acts like a transformation and link functions transform
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rather than

itself. Therefore,

transforms the systematic part of a model without altering the

distribution of the associated random variation.
Published papers have aimed to determine the limitations of estimation
approaches and performed limited comparisons between alternatives. Several research
efforts examined the performance differences between select estimation approaches
(Koutrouvelis et al., 2000; Bera et al, 2002). Other research efforts investigated robust
estimators (Muhlbauer et al., 2009; Hamada et al., 1997). These works focused primarily
on statistical measures (relative efficiencies, breakdowns, and robustness) to establish the
superiority of one method relative to other methods. Interestingly, whereas GLMs have
seen attention in the RPD literature, comparatively few RPD-specific efforts have
explored the various resistant regression methods as viable alternatives for determining
optimal solutions. Among those that have, the process conditions examined focus
predominantly on outliers, non-normal (but symmetric) response distributions, and
unbalanced data sets. Table 4.1 summarizes several of the more contemporary research
efforts found in the RPD literature, which are addressed in some detail in the following
paragraphs.
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Table 4.1. Summary of works examining estimator selection in RPD problems.
Researchers

Year

Conditions Examined

Simpson &
Montgomery34

1998

Outliers under normality

Lee & Nelder35

2003

Cho & Park36

2005

Ch’ng et al.37

2005

Robinson et al.38

2006

Lee et al.39

2007

Goethals & Cho40

2011

Non-constant variance and nonidentity (Gaussian) link
functions
Unbalanced datasets
Non-normal responses and
outliers
non-normal (gamma) and
batch-to-batch variation
(random block design)
Outliers, non-normal symmetric
distributions
Heteroscedastic conditions and
unbalanced data

Regression Estimators
Compared
OLS, M, most-B robust, LTS, S,
M-M, various versions of
Generalized M
GLM
OLS vs. WLS
OLS vs. M-M
GLMM
(gamma with log link)
OLS vs. M-M
OLS vs. WLS

Regarding GLMs, Lee and Nelder (2003) examined their use as a generalization
of data transformation and RSM approaches that allowed for “arbitrary variance and link
functions.” In a more recent effort, Robinson et al. (2006) examined generalized linear
mixed models (GLMM) in an RPD context to address the non-normality encountered with
a resistivity quality characteristic by using the known distribution for the response
(Gamma) combined with a log link. While the results in each of these works clearly
demonstrated the potential benefits of utilizing GLMs, they were not necessarily
comparative studies.
The remaining works shown in Table 2.1 pertain to more direct comparisons
between traditional and robust regression approaches. Simpson and Montgomery (1998)
examined alternative regression techniques when dealing with outliers within normally-
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distributed data. However, this study focused more on statistical estimator performance
measures such as efficiency, consistency, and breakdown points rather than optimal RPD
solutions obtained through application. Cho and Park (2005) considered RPD solutions in
the case of unbalanced data and proposed the integration of a WLS approach. The
proposed weighting scheme was based upon the quantity of observations at each design
point and value at the design point is inversely proportional to the variance associated
with the response surface functions obtained for the process parameters. In the interest of
finding better optimal settings in dual-response surface optimization problems when nonnormal conditions and/or outliers exist, Ch’ng et al. (2005) compared OLS to the M-M
robust estimation technique developed by Yohai (1987). In the examination of estimators
in RPD involving contaminated data, Lee et al. (2007) also included a comparison of the
OLS method to the M-M regression technique. It is worth noting that the non-normal
conditions examined in both of these cases focused on symmetric distributions. Goethals
and Cho (2011) extended the work of Cho and Park (2005) to the optimal process target
problem. Their work considered heteroscedastic conditions in addition to the unbalanced
data case.

4.2 Potential Applications of RPD in Healthcare Environments
In an ideal world, medical treatment for a particular issue will have a beneficial
impact on patients. For each instance, a patient would discover a problem, would then be
diagnosed, a treatment plan outlined, and the patient is cured of the initial recognized
ailment. This simplified scenario is not today’s reality. Healthcare is a complicated,
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complex system in which a large number of factors to include a patient’s health, current
intuitional knowledge regarding complaints, resource allocation, provider skill, the
limitation of known developed protocols as well as other factors which play a role in final
outcomes. The combination of compelling emotional medical narratives and the
increasing costs of healthcare has spurred governmental agencies, public and private
business ventures, and research and development teams for both industry and academia to
focus on decreasing the cost (emotional and financial) of healthcare to society at large.
As written, the “cost of healthcare” denotes the sum total cost of healthcare for both
treated and untreated diseases and preventive measures for all aspects of health.
With a common goal of improving healthcare, powerful stakeholders for the US
healthcare system are seeking efficiencies that will improve care and reduce overall costs.
Another change to the United States’ medical system has been brought about by
technological advances of the computer age. Medical records are in the process of being
digitized and the large swaths of data for medical procedures and vital statistics are
available for research. The large data repositories by controlled agencies such as the
National Institute of Health have enabled research teams to start dissecting complicated
issues such as cancer treatment and diabetes management. Research teams are also
working to improve other aspects of healthcare from operating room efficiency to
prosthetic development. At regional and local levels, management teams are working to
make hospital systems operate more efficiently. These parallel, and for most cases,
unlinked efforts improve healthcare in small ways on a daily basis. Small changes

121

improve lives, but the question of how healthcare policies, both nationally and locally,
should be established so that each patient has the optimum chance of recovery remains.
To the best of our knowledge, it is believed that one of existing methodologies
that could significantly impact patient recovery is design of experiments (DOE). The
application of DOE is not new in the healthcare industry and its professional workforce
has long understood important roles of carefully-designed experiments. The most widelyused DOE tools are perhaps full factorial designs and fractional factorial designs with
several factors, each at two discrete levels, in order to study the effects of main factors
and interactions between those factors on the response variable of interest. When the
number of levels becomes more than two, the number of experimental runs required
considerable increases; thus, it becomes less feasible from the perspective of costs
incurred and resources available to complete the whole experiment. In addition, when
those two-level factorial designs are used, one of the fundamental assumptions is that the
effects between the two levels are linear. The advancement of precision medicine relies
on the adoption of evidence-based practices and process validation. Both linear and
quadratic effects of factors and interactions are often inherent within healthcare data.
Capturing those effects can be effectively done by the central composite design and
obtaining optimum conditions through the RPD process.
The methodology for RPD is broken down into two phases. The first phase
includes the identification of the primary quality characteristic, influential control factors,
possibly noise factors, and the experimental region of interest. Control factors are those
that affect outcomes. In the case of a healthcare system, they include the amount of drug
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that a patient is provided or the existence of known, and genetic traits of a patient. Noise
factors are those factors that may not be controllable or very costly, if they can be
controlled, from the point of view of the system. For a healthcare example, those could be
a patient’s diagnosis, the patient’s satisfaction with the benefits provided by his or her
insurance company, or the length of the patient’s trip to the hospital. The idea is to find
optimum conditions for the control factors for which changes along the range of noise
factor values affect healthcare outcomes as little as possible. While in this phase,
observations are collected in a replicated design framework and data analysis is
performed. The outcome of this phase is an approved model for the quality characteristics
of interest. These models are then used to determine optimum conditions which allow the
system to reach close to a specified target with minimum variance.
A comprehensive literature review shows that the RPD concept has not been
applied rigorously in healthcare environments. Some potential applications of RPD for
healthcare decision making are outlined below.
Patient Adherence to Treatment Plans: It has been estimated that less than 60% of
prescribed treatment plans are followed by patients. Why, if the patient has sought out
medical advice, is the final treatment plan not being followed? Possible factors could
include the treatment costs, insurance benefits, medical severity, social factors, and risk
of being admitted. RPD could help doctors determine optimal conditions, or
hospital/insurance policies, which would achieve a target adherence rate with minimum
variability.
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a. Incentive for Preventative Treatments. RPD could potentially provide insights on
how to increase the use of preventive care services made available through
insurance programs, community wellness programs, or direct government
funding. What services or incentives need to be offered to reduce the impact of
uncontrollable factors on the use of preventive care?
b. Gauging Risk. RPD could provide an avenue to make assessments on the amount of
risk (variance) that stakeholders are willing to take on. If the quality characteristic
being studied is the effectiveness of a treatment, then being on target means that
the patient is being effectively treated. As it is further away from the target,
greater costs will be incurred by the healthcare system. Also, a smaller variability
implies a less risk that the health industry is willing to take on.
c. Improved Resource Allocation. During the first phase of RPD, stakeholders gain a
better understanding of specific control factors that influence the quality
characteristic of interest. By exploring the interactions, stakeholders will have a
better idea of how to allocate scare resources to improve the overall quality of
healthcare.
4.3 Proposed RPD Modeling and Optimization Procedures
4.3.1 Experimentation and Analysis
Consider a situation in which we need to obtain the optimal conditions for which a
patient can safely undergo surgery without further compromising health. A clinician
might be interested in determining the range for a patient’s body composition, resting
heart rate, and possible other mitigating factors that must be met prior to commencing the
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procedure. To that end, consider a replication-based experiment conducted with the intent
to find optimal factor settings, x=(

that achieve the desired target outcome,

with the least variability. In this case, the quality characteristic of interest, Y, is suspected
to be influenced by a set of control factors or x. The research team will define an
experiment region which is bounded by the minimum and maximum values for each of
the control factors. The experiment consists of m x n trails where m is the number of
replications for each specified design point, n. For each design point, the values of the
denote the jth response at the qth

control variables are set to predetermined levels. Let

design point, where q = 1, …, n and j = 1, …, m. The tabular layout of a replication-based
design of experiment is depicted in Table 2.2.

Table 4.0.1 Design of Experiment
y
Replications

Design
Point
1
q
n

Control
factor
settings

s



y11………y1j…….y1m

y1

s1

1

yq1………yqj......... yqm

yq

sq

q

yn1………ynj………ynm

yn

sn

n

Parameter estimates for the data are found through analysis of the data collected
at each design point. The estimates include both sample mean, , and standard deviation,
s. If the distribution is suspected to be non-normal, the sample skewness, γ, can also be
calculated to account for the asymmetry in the responses. Parameter estimates at each
design point for a sample are found using the following equations:
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yq




m
j 1

m

yqj

,

s



m
j 1

( yqj  yq )2
m 1

, and



1
m



 m11 

n
j 1

( yqj  yq )3

n

( yqj  yq )2
j 1



3

2

(1)

The next step is to develop response surface functions for the select parameters of
interest that are valid throughout the experimental region. To start, a comprehensive data
analysis of the sample responses and the residuals, the difference between the model and
the sampled responses, is conducted to verify assumptions regarding the underlying
distribution. The analysis of the responses should include an investigation of normality
and variability. The analysis of the residuals should include verification of the
assumptions of normality, homoscedasticity, and independence. Investigators have the
option to use graphical methods, numerical methods, and formal normality tests. Two
approaches are briefly explained in parts (i) and (ii) below:
(i) Assessment of Normality and Variability. To assess normality in a set of
responses, the three most common tests are the Kolmogorov-Smirnov test, the
Anderson-Darling test, and the Shapiro-Wilk test. Generally, due to a variety of
reasons including experimental costs, the sample sizes obtained in RPD
experimentation typically small. Thus, for the Shapiro-Wilk test using the W
statistic given by

where

be a reasonable choice for testing

may
and

. The

term p is defined as the number of observations sorted in ascending order,  is the
largest integer that is less than or equal to p/2, and s denotes the sample standard
deviation. For a given significance level , tables are then used to reference the
coefficients a, and the critical values W. If W* > W, then insufficient evidence
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exists to reject the assumption of normality. One drawback to objective tests is that
if the normal assumption is rejected, the test provides no additional information
regarding the underlying distribution of the data. As discussed by Boylan and Cho
(2012), graphical measures, such as normal probability plots, may be useful tools
to overcome this shortfall and to provide more salient information about the data.
For example, normal probability plots often illustrate whether the distribution is
symmetric or asymmetric, the degree of positive or negative skewness, the degree
of variability, and the degree of kurtosis.
Determining whether a process is highly variable is a more subjective assessment.
According to Willinger et al.(2004), high variability may be loosely defined as a
phenomenon by which a set of observations assumes values that vary over orders of
magnitude, with most taking closely grouped values, a few assuming extreme values that
deviate considerably from the first group with non-negligible probabilities, and
intermediate observations occurring with appreciable frequencies. In general, a trademark
of highly variable data is that the sample standard deviation is quite large. This result
implies a “largely uninformative” sample mean that does not adequately describe the
location of the bulk of the observed values. Using this concept, we classify a highly
variable process as one in which the range of variability in the responses is noticeably
large and where one or more of the responses lies more than three standard deviations
(+/– 3) from the mean response.
(ii) Residual analysis. As with the responses, normality in the residuals may also
be examined using graphical measures such as the normal probability plot. Additional
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complementary, objective methods are provided by the Kolmogorov-Smirnov or the
Shapiro-Wilk tests. To investigate independence, the Durbin-Watson test is usually
sufficient to detect a lack of randomness in the residuals. Should remediation be
necessary, two possible options are the addition of predictor variables or use
transformations in the variables to eliminate interdependencies. Finally,
heteroscedasticity, or non-constant variance, is often investigated graphically using a plot
of the residuals against the fitted values, as well as objectively using either the BrownForsythe test, which is more robust to departures from normality in the data, or the
Breusch-Pagan (B-P) test. The B-P test assumes independence and normality among the
residuals. The test also assumes a relationship for the error variance

among the k

regression coefficients and k-1 predictor variables that in the form
. As can be seen, the error variance fluctuates up
or down with x, based on the sign of the associated coefficients. Constant error variance
corresponds to the instance where constrained coefficients in response function equal 0,
the alternative hypotheses

versus

: not all

are tested

using the statistic,

, in which Nm denotes the total

number of experimental observations, SSR* is the regression sum of squares obtained by
regressing the squared residuals, and SSE is the error sum of squares obtained for the full
regression model. If

then we reject H0 and conclude that sufficient

evidence exists to support non-constant variance. In processes with high variability or
asymmetry in the responses, the assumption of constant variance in the residuals would
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most likely not hold. This situation would necessitate the use of remedial measures, as
outlined in Section 4.3.3.
4.3.2 Modeling Symmetry and Asymmetry
In traditional RPD applications, asymmetric conditions typically observed in the
univariate s- and l-type problems are often modeled via a normal distribution. Ideally, it
would be preferable to use a distributional model capable of supporting both the
symmetry usually assumed in the n-type model, as well as the asymmetry of the s-, l-, and
certain n-type models. This would become particularly important if extending the
problem to the multi-response case. Although some common distributions, such as the
gamma, Weibull, and unbounded Johnson distributions, can effectively portray processes
with innate skewness, these distributions present challenges in modeling normality when
small skewness exists.
Due to an inherent relationship to the normal distribution, the skew normal (SN)
distribution provides a suitable alternative for modeling both symmetric and asymmetric
situations. First introduced by O’Hagan and Leonhard (1976) and addressed more
recently by Azzalini (1985), Azzalini and Dalla-Valle (1996), and Arellano-Valle et al.
(2004), the skew normal distribution extends the normal distribution by incorporating a
third parameter, , as a shape parameter to account for non-zero skewness. The
probability density function for the skew normal relative to the normal distribution is
given by:
f  x |    2  x    x  , x 
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,

where ϕ(x) and Φ(αx) correspond to the probability density and cumulative distribution
functions of the normal distribution, respectively. Recall that the normal probability
density function for some random variable Z with parameters  and 2 can be rewritten in
terms of the standard normal density function
f z ( z) 

 ( z   )2 
1  z 
exp 
 

2 
2

  
2
 2 
1

(2)

We can easily extend this by adding location () and scale () parameters to the density
function, using the transformation x→(x-ξ)/ω. This yields:
f x ( x) 

 ( x   ) 2 
2   x     ( x   ) 
2 1

 
exp 

  


      
  2
2 2  




 ( x   )2 
exp 

2 2 
 2

1

1
 ( x   ) /  

1  erf 
2
2


1
 ( x   ) 

1  erf 
2
  2 

(3)
When  = 0, the skew normal distribution reduces to the normal, making normality a
special case of the SNdistribution. From Azzalini (1985), the mean and standard
deviation of a SN() distribution are given by:

Where δ =

E  y   ˆ =    2 

(4)

s   2 1  2 2  

(5)

. The SN distribution is a relatively new distribution compared

to the more commonly observed family of continuous distributions. Since it derives from
the normal distribution which remains widely used for n-type characteristics, its extension
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to s- and l-type characteristics, as well as certain instances of n-type characteristics, may
help to overcome many modeling complexities encountered in asymmetric situations.
As Goethals and Cho (2012) showed, modeling system properties with the skew
normal distribution can be achieved by initially calculating estimates for the first three
sample moments (mean, standard deviation, and skewness) for the qth design point. In
Table 2, the sample mean

and standard deviation sq then correspond to the location

(q) and scale (q) parameters at the qth design point. Thereafter,

and sq estimates are

used to derive estimates for the skew normal process mean and standard deviation by
applying them to Equations (4) and (5) as follows:
ˆq( SN ) = yq  sq q 2 

(6)

sq ( SN )  sq 2 1  2 q2  

(7)

Here, the parameter q is estimated using the sample skew. In short, using an alternative
formulation for sample skew provided by Azzalini (1985), an estimate for q can be
derived as follows:





3

 2
4 
ˆq 
2 1  2  2  3/ 2

where the sign of


ˆq 

2 ˆ
3q



ˆ3q
2/3

2/3

 ((4   ) / 2) 2/3

determines the sign of q. For the purposes of simulation, the

estimate for q may then be used to estimate the shape parameter directly by rearranging
the previously stated relationship in the following way:
 
q

q
1   q2
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ˆ q 

ˆq
1  ˆq2

This step is necessary within the R environment as the shape parameter and sample skew
are scaled differently in the context of the skew normal distribution. As Equations (6) and
(7) suggest, the estimates for the process mean and standard deviation are influenced by
the inclusion of the sample skew. By using this methodology, we ensure that inherent
process skewness is accounted for in the final response surface estimates, and that actual
process characteristics are more accurately represented.
4.3.3 Selecting an Appropriate Regression Estimator
Prior to completing a comprehensive analysis, a research team needs to evaluate
regression estimation methods and decide on which one to implement. For many groups,
OLS is chosen due to familiarly as well its ubiquity in past research efforts. To obtain an
optimal RPD solution, we advocate that teams instead match the regression estimation
method with the inherent underlying conditions of the dataset. Table 2.3 below lists the
ten methods selected for analysis. In the subsequent paragraphs, a brief synopsis of each
alternative method is provided.
Table 4.0.2. Regression Estimators examined as potential RPD alternatives.
Methods for Determining Regression
Estimator
Base Case

Alternatives
for
Comparison

OLS
1)
2)
3)
4)
5)
6)
7)
8)
9)

GLM (gamma or inverse Gaussian model)
OLS (SN)
WLS ( y and s)
WLS (median and MAD)
Least trimmed squares (LTS)
S-estimation
Least absolute deviation (LAD)
M-M estimation
M-estimation (Huber Proposal 2)
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In early research, Kutner et al. (2003) stated that asymmetry and high variability
would likely bring about non-constant variance. If this is the case, then OLS standard
errors are potentially inaccurate and statistical inferences based on the results could be
potentially misleading. Thus, an alternative method may provide a better estimate for the
regression coefficient.
The first alternative approach considered is that of the generalized linear model
(GLM). The GLM is the conventional regression approach for data sets exhibiting nonnormality. When applying the GLM method, a practitioner needs to specify the linear
predictors’ distribution and select an appropriate link function, g(∙). For the purposes of
this research effort, the GLM method utilizes a gamma or an inverse Gaussian. These
distributions are suitable for modeling varying degrees of asymmetry. Link functions
transform the expected value of the response to the linear predictor and assume the form
. By using GLMs, the selection of the link
function is distinct from the distributional assumption. Although a wide variety of link
functions exist, this research is limited to those listed in Table 2.4.
Table 4.3. Applicable link functions for the gamma and inverse Gaussian distributions.
Link Function
Identity
Log
Inverse
Inverse-square

i = g(i)
i

logei

i-1
i-2

Gamma
X
X
X*

Inverse
Gaussian
X
X
X
X*

* denotes the default link used by the glm()function in R.
Process conditions influence the selection of both the distribution and link
functions. Individual distributions have recommended link functions that typically
produce preferable mathematical and numerical properties. Given a suspected
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distribution, practitioners should be cautioned to take the underlying process conditions
for a particular set of data into consideration prior to using the traditionally associated
link functions. For example, in many applications, the gamma distribution is paired with
the inverse link. Consider a case in which the response y increases somewhat linearly
with control factor

. If the variance appears to increase with the square of the mean,

then the gamma distribution could be paired with the identity link. When choosing the
appropriate link response, researchers should select the GLM model that results in the
lowest Akaike information criterion value, or in other words, the smallest residual
deviance. This recommendation is based on the fact that the response deviance is
similarly scaled for models created with the GLM method.
When dealing with asymmetric conditions, two factors bear considerable
importance. First, depending on the degree of variability and skew, the mean will shift
away from the central tendency of the distribution. Secondly, the standard deviation may
not accurately describe the dispersion in the distribution as it tends to be significantly
affected by the “play” in the skewed or long tail of the distribution. When the data
contains outliers, the effects would worsen. For these reasons, an alternative method of
weighted least squares (WLS) is also examined in this paper. The WLS method was
among the first to tackle how to perform analysis taking residuals into account. The
method of WLS, developed by Aitken in 1935, alters the value placed on data dependent
on the deviance of the residual. If the residual of the qth point is relatively small, then it is
assigned a relatively large weight. On the other hand, if the qth residual is large, the
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impact of the outlier will be reduced utilizing a smaller associated weight. The WLS is
described with the following equation:
n

Minimize
 wq q 2
ˆ


where

(8)

q 1

denotes the residual associated with the qth design point given by

.

The term yq refers to the sample mean if there are multiple replications per design point.
For cases in which the data is assumed symmetric, the mean is typically the “starting
point” or the value what has the greatest probability of occurring. However, in cases
where asymmetry is suspected, the two options for alternate “starting points” are median
and median absolute deviation (MAD). To illustrate this point, consider the comparison of
probability densities for samples drawn from a skew normal distribution and a normal
distribution with the same mean shown in Figure 2.2. For the sample with a normal
distribution, the mean value corresponds to the peak in the density function. For the
sample with this particular skew normal distribution, however, the mean lies to the right
of the preponderance of probabilities. Therefore, in this case, the mean does not have the
greatest likelihood of occurrence. However, an alternate measure, the median, occurs
close to the peak of the distribution. This example illustrates that while the mean
certainly defines the population’s central tendency for any distribution, the mean does not
necessarily correspond to greatest likelihood if asymmetry is present.
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Figure 4.1. Comparison of normal and skew normal densities with the same sample
mean.
N = 61 Bandwidth = 0.07646

Based on the conditions of asymmetry and variance examined in this paper, the
weights for the WLS method are determined in a manner similar to that used by Goethals
and Cho (2011). That is, observations possessing less variance receive greater weight.
Denoting  as the vector of residuals,
standard regression model

in the general form of the
in which Y is the vector of responses, X is the

design matrix, and β is the vector of estimated regression coefficients, in the case of nonconstant error variances, we may rewrite the
0
Var (1 )
 0
Var ( 2 )
Var (ε)  


0
 0

Since

covariance matrix as:

0 


Var ( n ) 
0

for each of n components of  the variance of the qth component

is equal to the expected value of the squared error of the qth component, or
. In practice, a vector of squared residuals is used to estimate the error
variance. By regressing the squared residuals against the predictors in X, the fitted values
of the resultant variance vector, φ, establish the n design point weights, wq. As the
weights as inversely proportional to the error variance with the value of the weight, the
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relationship is defined as

. Articulating the weights in this manner reduces the

effects of high variability exerted by large residuals. If the error variance is large, then the
associated weight would be comparatively small. Utilizing this method, the WLS
estimator can be written as

. To ensure minimal model error, the

procedure introduced by Goethals and Cho (2011) uses an iterative approach to reweight
the model parameters using subsequent estimation of the error variance. For this method,
the algorithm either stops once either convergence is achieved or when the difference
between the standard error for each of the estimated coefficients in

is quite small

relative to the standard errors obtained in the previous iteration.
The remaining regression alternatives listed in Table 2.3, alternatives 5-9, consist
of variants of robust regression methods. These methods were developed to address the
disproportional influence of outliers on the response surface functions. The term “robust”
describes an estimator’s ability to overcome an outlier’s leverage on the generated
estimate. Often, outlying responses are classified as anomalies or annotated as potentially
contaminated. In the healthcare field, it is often hard to conclusively classify an outlier as
an exception or an indicator of great importance. Robust estimators are particularly
intriguing because they mitigate the leverage of extreme observations without
discounting them altogether. The underlying methods for robust regression approaches
are designed so that violations of supporting assumptions have little impact on the
regression results. The four robust regression approaches analyzed for this study are S,
LAD, M-M, and M estimations.
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It could be argued that the simplest alternative for estimating robust regression
coefficients the LAD. The introduction of the OLS method supplanted its use and interest
in the method waned. A resurgence of in the use of LAD started when Karst (1958)
suggested its suitability for use with data sets containing outliers in comparison to OLS.
The LAD method minimizes the sum of the absolute values of the residuals, or errors
between points generated by the regression function and corresponding data points:
n

Minimize
 q
ˆ


(9)

q 1

Although the LAD method proved more robust than OLS, significant outliers can
still influence the resultant model. This particular shortcoming has motivated increased
research in the search for more robust approaches.
One of the earlier efforts was made by Huber (1973) who introduced the Mestimation for regression. Mathematically, the method focuses on the residuals and takes
the following form:
n

Minimize
ˆ

 q 

   s   n log s
q 1





(10)

where  = some symmetric function with a unique minimum at 0. If we presume s is
known and set

then the maximum likelihood estimator of the regression

coefficients β solves the non-linear system of equations

, where 

represents Huber’s bounded monotone  function. After some modification, this
becomes

, where  is selected for consistency at normality

and the embedded tier-one estimates for location and scale are obtained using Huber’s
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Proposal 2 estimators, which result from solving the following equations simultaneously
for  and 50
n

 yq   
0
  

n

 
q 1

and


q 1

2

 yq   

 
  

This method has proven to be a viable and efficient estimator that is robust to outliers in
the response variable. However, it was also found to lack resistivity to outliers.
Rousseeuw (1984) proposed the least trimmed squares (LTS) method to overcome
efficiency shortcomings with a previous method (least median of squares (LMS)). The
objective in this approach involves minimizing the sum of squared residuals over a
subset, q, of the complete set of n points:
q

Minimize
ˆ



q 1

q

2
q :n

(11)

In short, the residuals are squared and then sorted in ascending order. Of the n residuals
in the full set, the (n – q) largest are “trimmed” so that only the residuals from the
remaining q points are included in the regression. Thus, the (n – q) largest points which
are not used do not influence the fit. The result is a fit that retains the resistivity
properties of the LMS method, and it is known to be more efficient.
Both the LMS and LTS methods involve the minimization of a robust measure of
the scatter of the residuals. Introduced by Rousseeuw and Yohai (1984) as a means for
performing robust regression in time series analysis, these methods find a plane or
hyperplane that minimizes the scale s by obtaining the solution to:
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n

 yq  x q βˆ 
  ( n  p )

 c0 s 

  
q 1

(12)

In this context, p corresponds to the k-1 predictors and  is typically denoted by the
integral of Tukey’s bisquare function given by
 u 6  3u 4  3u 2

 (u)  

1

|u| 1
|u| 1

,

and c0=1.548 and  = 0.5 are selected for consistency at the normal distribution. This
method is highly resistant to leverage points, robust to outliers in the response, and is
often more efficient than the LTS method.
Yohai (1987) proposed the M-M estimator as an improved alternative that
essentially blended earlier methods in order to retain the robustness, while gaining the
efficiency of M-estimation. The M-M method proceeds in three stages. The first involves
an initial estimation of regression coefficients. In the second, a highly robust and resistant
S-estimate is computed that minimizes an M-estimate of the scale of the residuals. In the
final stage, the estimated scale is then held constant, while a nearby M-estimate of the
regression coefficients is determined.
4.4 Integrating the Estimators into the RPD Framework
Pursuant to the selection of a regression estimation approach based upon inherent
process conditions, fitted response surface functions are then developed for the process
location and scale. For the purposes of comparison, this is done for each of the alternative
regression methods outlined in Section 2.3.3, using full second-order polynomial model.
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Thus, the general form of the estimated response functions with k –1 predictor variables
is expressed as:
Location:

(13)

Scale:

(14)

where XT =  X 1 X 2
1×k

where

(and

),

(and

X k 1 

), and

 1 
 11 12 / 2
 

 22
, bˆ   2  , and Bˆ  
k
×k
k ×1
 

 


 k
 sym.

(and

1k / 2 
 2 k / 2 



 kk 
,

), reflect the estimates of the

intercept, first-order, and second-order coefficients of the response surface functions for
the location and scale, respectively. In addition, the terms and  correspond to the
residual error for the location and scale deviation, respectively. In order to investigate the
performance of the fitted functions at estimating a response, a mean squared error (MSE)based optimization scheme is used on either a spherical region of interest such that
, where  is the radius of the sphere, or a cubic region bounded by (-1, 1). Using
this approach as a framework, each of the models delineated in Table 2.3 are evaluated
on the RPD solution they produce.
4.4 Numerical Demonstration via Simulation
In this section, we examine a case using commonly-applied experimental data sets
as bases for Monte Carlo simulation. The overarching purpose of the simulation is to
determine the degree to which underlying process asymmetry and variability (and,
consequently, non-constant variance) affect estimator performance in the context of RPD
solutions, which should ultimately serve as a guideline for engineers and healthcare
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professionals as to which estimators tend to perform best under a particular set of
conditions.
This numerical study involves approximately normally-distributed data with
moderately low variability in which all of the base assumptions concerning the data hold.
An initial examination is intended to verify expectations regarding conventional
approaches when assumed conditions hold. Subsequently, through experimentation, the
impacts of increasing variability on estimator performance are examined. We examine
four scenarios derived from combinations of high/low asymmetry with high/low
variability to determine the effects on estimator selection. Within each case study, initial
results are obtained from the base data and observations are then drawn to assess
estimator performance. Thereafter, 1,000 iterations of each simulation scenario are
conducted to facilitate performance trend analysis and assessments regarding estimator
performance under the evaluated conditions. Simulations were developed in the statistical
computing environment R version 2.14.1 (2012) which is open source software. For the
purpose of estimator comparison, each simulation involves several key settings that are
applied to each estimation model:
1) Using the actual experimental data, simulated data are derived using the
skew normal approach.
2) Full second-order response surface functions are developed for the location
(mean or median) and scale (standard deviation or MAD) response surface
functions.
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3) Optimization results are obtained for each estimation model using the MSEbased optimization scheme developed by Cho (1994) and Lin and Tu (1995).
Pursuant to (3) above, estimation approaches are then evaluated based on the optimal
solutions they generate in terms of deviation from the established process target and
variability in the result.
4.4.1 Case Study: Investigating the Effects of Variability on Estimator Performance
In this experiment, adapted from Phillips et al. (1995) and Shin et al.(2011),
normally-distributed n-type quality characteristic is of interest. The control factors, X1,
X2, and X3 are known to influence the outcome Y with the desired target value  = 57.5.
Using the original data obtained from Shin et al.(2011) and the procedure delineated in
Section 2.3.2, five replicates were generated at each design point. The experimental
framework displayed in Table 2.5 is a central composite design (CCD) comprised of
eight factorial points, six axial points, and six center points, with the calculations for the
mean, standard deviation, and skewness at each design point.
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Table 4.4. Experimental framework for Case Study A
Run
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Coded Units
Cut Speed Cut Feed Cut Depth
X1
X2
X3
-1
-1
-1
1
-1
-1
-1
1
-1
1
1
-1
-1
-1
1
1
-1
1
-1
1
1
1
1
1
-1.682
0
0
1.682
0
0
0
-1.682
0
0
1.682
0
0
0
-1.682
0
0
1.682
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Y1
44.6
63.9
45.6
67.1
59.4
67.6
65.5
67.4
58.2
69.5
63.2
59.5
51.7
65.3
60.3
59.2
58.5
62.4
64.8
53.4

Observed Responses (simulated)
Y2
Y3
Y4
Y5
52.5
57.4
52.4
57.8
60.3
64.7
65.8
67.5
51.5
45.4
62.0
52.8
64.5
61.6
58.6
55.5
55.6
51.4
57.7
59.5
64.6
64.3
71.8
67.4
60.8
60.5
57.2
55.6
66.5
71.8
68.2
72.0
56.1
61.3
65.0
47.3
63.2
59.3
73.0
61.0
60.4
59.0
61.0
65.8
62.6
61.7
57.3
59.9
66.3
57.2
61.9
64.4
66.1
61.4
72.5
64.2
56.5
64.1
61.1
60.5
66.9
56.7
62.7
57.8
59.0
61.2
56.4
57.2
53.0
59.6
64.0
56.6
63.3
60.9
54.9
66.3
60.5
60.9
64.7
59.9

Metal Removal Rate
(mm3/min)

s
Y
53.2
3.82
0.19
62.9
3.51 -0.77
53.4
3.67 -0.24
62.6
3.24 -0.32
57.3
3.10 -0.11
67.9
4.31 -0.21
59.8
4.47
0.46
67.8
3.21 -0.85
59.1
4.73 -1.13
65.9
4.46
0.73
60
3.55 -0.16
60.7
3.10 -0.17
57.4
4.29 -1.13
63.2
5.04
1.32
59.2
3.87 -0.03
60.4
3.74 -1.18
59.1
3.95 -0.08
60.6
3.71
0.22
60.8
4.00
0.64
58.9
3.92 -0.51

4.4.1.1 Preliminary Data Analysis
The initial graphical analysis of the responses suggests approximate symmetry and
moderately low variability exist. Applying the Shapiro-Wilk test yields
0.951, and since

=0.958 vs.

, insufficient evidence exists to reject normality.

Notwithstanding, the non-zero values in the γ column of Table 2.5 coupled with the few
responses in Figure 2.3(a) that deviate from the reference line suggest that some
asymmetry is, in fact, present. In terms of process variability, Figure 4.3(b) shows the
deviations between the observations and the mean response to be quite small, and well
within the 3 threshold defined in Section 4.3.1.
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Investigating Variability in Responses
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Figure 4.2. Assessing a) normality and b) variability in the responses.
After performing a preliminary regression for a full second-order model for the mean
response

using the OLS approach, a graphical analysis of the residuals (Figure 2.4)

suggests that the assumptions of normality and independence hold, but that non-constant
variance may exist. Yet, application of the Breusch-Pagan (B-P) hypothesis test yields
=16.1 <

(.95,9)=16.9 which suggests constant variance and thus disputes the

deduction suggested by the plot in Figure 4(c). It is often the case with smaller sample
sizes that the objective test results fail to capture the presence of non-constant variance.
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Figure 4.3. Investigation of a) normality, b) independence, and c) variance in the
residuals.
After performing a second-order regression for all 100 experimental observations,
reiterating the Breusch-Pagan test yields

, which is clearly less than

(.95,9)=.1691 and reinforces the initial test results. The revised residual plots shown in
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Figure 5 are based on the full complement of 100 observations and illustrate the validity
of the basic residual assumptions in this case.
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Figure 4.4. Residual analysis based on all 100 observations in the metal cutting study.
Taken together, the results of the data analysis suggest that the experimental data
meet all requisite provisions for the application of OLS regression. This implies that OLS
would be the best approach given that this method is known to produce the best linear
unbiased estimates for the process location and scale, or dispersion, when these
conditions hold.
4.4.1.2 Results Based on Original Experimental Data
We first performed a single run of the experiment to motivate the discussion on
conditions-based estimator selection. Additionally, the run demonstrates the benefits of
using the skew normal distribution to model system properties. The OLS method using
traditional tier-one estimators under the assumption of zero skewness is also applied. The
results in Figure 2.6 show the optimal operating conditions

obtained

under each regression model using the MSE-based optimization scheme, the associated
optimal process mean and standard deviation, and the resulting target bias and MSE. For
the GLM approach, the Gaussian-identity (default) distribution-link combination was
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used, which essentially mirrors the OLS counterpart and is appropriate when traditional
assumptions hold. From the results in Table 4.6, a single run of the experiment suggests
two things: first, accounting for even low degrees of asymmetry can produce better RPD
solutions than the traditional approach to OLS estimation; and second, OLS regression
(under the SN approach) is still suitable, although the use of the median-based WLS
method can achieve superior results. However, recognizing that these solutions are
estimates, it is therefore quite likely that subsequent implementations of the experiment
could yield different sets of optimal coordinates.
Table 4.5. Regression and optimization results of a single run with five simulated
observations.
x1
x2
x3
ˆ ( x*)

bias

ˆ ( x*)

MSE

OLS
(Traditional)
-0.380
-1.682
-0.170
57.172
0.328
2.649
7.127

OLS
(SN)
-1.682
-1.682
1.014
57.615
0.115
2.086
4.365

WLS
Mean/s
-0.071
1.682
-1.682
58.825
1.325
2.733
9.225

WLS
Median/MAD
-0.515
-1.682
1.682
57.540
0.040
0.449
0.203

LTS
0.056
-1.682
-1.682
57.466
0.034
2.369
5.612

S
0.023
-1.682
-1.682
57.490
0.010
2.169
4.703

LAD
-0.215
1.682
-1.682
58.430
0.930
2.563
7.431

MM
0.101
-1.682
-1.682
57.459
0.041
2.928
8.575

Huber
Prop 2
-1.682
-1.682
1.155
57.586
0.086
2.064
4.266

GLM
-1.682
-1.682
1.014
57.615
0.115
2.086
4.365

Moreover, the objective is to examine trends to develop a better sense of how the
estimators perform on average, which cannot be achieved via a single run. Accordingly,
we conducted 1,000 iterations of the simulation, generating fresh random data based on
the original experiment at each iterate. At the end of each simulation run, the MSE and
target bias were recorded for the optimal RPD solutions and then averaged across all
iterations to observe trends. Table 4.7 contains the simulation results, along with the
proportion of iterations in which a particular estimation approach yielded the smallest
MSE and bias.
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Table 4.6. Simulation results under low variability conditions.

Avg MSE
% Best
MSE
Avg Bias
% Best
Bias

OLS
(Traditiona
l)
4.029
4.90%
0.300
7.20%

OLS
(SN)
3.250
3.50
%
0.266
4.80
%

WLS
Mean/
s
3.349

WLS
Median/MA
D
2.379

5.10%
0.260

30.30%
0.243

6.70%

19.50%

LTS
2.636
20.70
%
0.205
23.10
%

S
2.593
20.50
%
0.200
19.90
%

LAD
3.359
9.20
%
0.220
9.70
%

MM
3.205
5.50
%
0.220
7.70
%

Hube
r
Prop
2
3.292
1.90
%
0.259
3.90
%

GLM
3.250
3.50
%
0.266
4.80
%

Noting that all nine of the alternative estimation approaches outperformed the
traditional OLS approach in Table 4.7, it is clear that despite approximate
symmetry/normality in the process data, there is enough inherent skewness to affect the
optimization results. In the most basic sense, this is illustrated by comparing the first two
columns in Table 4.7 (OLS-Traditional vs. OLS-SN), which suggests that by accounting
for even slight levels of non-zero skewness, better RPD results can be obtained. Beyond
this, the fact that median-based approaches (WLS, MAD, LTS, and S estimations) yielded
better results in terms of both average performance and consistency suggests that these
methods are preferable when any degree of asymmetry exists. The main reason that the
WLS procedure produced better results on average is most likely from the result of downweighting those observations with higher variability, thus demonstrating the viability of
using that method to exert greater control over sources of process variation.
4.4.1.3 Investigating the Effects of High Variability Conditions
To examine the effects of variability, we incorporated a simple modification to
the simulation that would induce a greater degree of variability in the process. Whereas
before we used the sample standard deviation(s) in Table 4.5 to generate normal random
variates in the base scenario, in this instance we randomly sampled an integer from a
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range of 2 to 5 at each design point to serve as a factor that would then be multiplied by
the original values for s. Hence, the variability at each design point would be increased
by a factor of anywhere from 2 to 5 times.
The idea here is that simply multiplying the s vector by a single common factor
would not have any impact on the results other than to scale them by that factor. That is,
there would certainly be more variability in the responses, but the proportional change in
each design point would be the same and would negate any real effects on the results as
the underlying conditions regarding base assumptions would still hold. Thus, our
objective is to inject variability not only horizontally within each design point, but also
vertically across the vector of sample standard deviations. This would challenge system
performance and very likely upend the underlying assumptions of response variability
and heteroscedasticity. As the plots in Figure 4.6 show, this is precisely what occurs, as
several observations exceed the 3threshold (Figure 4.6a), and the variability trends
coupled with the Breusch-Pagan results in Figure 4.6b clearly suggest non-constant
variance in the residuals. As noted previously, the presence of such conditions inhibits
the use of OLS and suggests the need for either remedial measures or alternative
estimation approaches.

Investigation of Variability Trends in the Residuals
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Figure 4.5. Analysis of responses (a) and residuals (b) under high-variability conditions.
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To establish performance trends among the estimators, we performed 1,000
iterations of the high-variability scenario. In this instance, the GLM approach is modified
to account for differences in the data. Specifically, further analysis of the residual data for
response surface functions for both the mean and variation suggested the need to consider
either a gamma or inverse Gaussian distribution to correct for non-constant variance.
After preliminary modeling using the various distribution- link function combinations in
the GLM approach, it is determined that the gamma-identity and inverse Gaussian-log
combinations would produce the best fit for the mean and standard deviation response
surface functions, respectively. Results for the MSE and bias were then averaged across
all 1,000 iterations, and performance proportions were calculated to produce the results
shown in Table 4.7.
Table 4.7. Simulation results under high variability conditions.
OLS
(Traditiona
l)
Avg MSE
% Best
MSE
Avg Bias
% Best
Bias

35.604
4.90%
2.225
5.20%

OLS
(SN)
30.39
8
3.70
%
2.079
2.80
%

WLS
Mean/
s
28.26
1

WLS
Median/MA
D

7.30%
2.087

18.30%
1.790

6.40%

15.10%

20.194

LTS

S

19.714
17.40
%
1.579
15.90
%

20.277
16.10
%
1.694
14.40
%

LAD
32.28
4
8.60
%
2.089
8.10
%

MM
28.51
4
5.60
%
2.037
4.90
%

Hube
r
Prop
2
31.25
3
3.40
%
2.112
3.50
%

GLM
3.643
16.00
%
0.166
24.80
%

The results in Table 4.7 draw several insights. First, all nine of the alternatives
once again produced a better result than the traditional OLS method, reinforcing the
benefit of using the skew normal approach for modeling process asymmetry. Second, it is
clear that the increased variation induces a change in estimator performance such that the
GLM method using the gamma-identity and inverse Gaussian-log combinations
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outperforms all others on average, both in terms of the resulting MSE and target bias.
While the next-best performers (LTS, WLS (median/MAD), and S-estimation methods)
performed relatively well, they all achieved an average MSE nearly six times larger than
the GLM method.
Although differences in the generated data can be a contributing factor, the
reasons behind these results can also be attributed to the increased likelihood of extreme
observations in either tail. And if an extreme observation from one tail is not counterbalanced by an extreme point from the other, then the resulting sample could very well
appear skewed, despite being generated from a normal distribution. Obviously, when the
data are approximately normal, the mean and the median will have nearly the same value.
However, as the data become skewed due to the occasion of one or more extreme
observations, mean-based estimators deteriorate in their ability to provide the best
estimate of central tendency due to the influenced of outlying data points. Similarly, the
standard deviation no longer provides the best measure of the true dispersion in the
distribution. The median and the MAD, on the other hand, retain their properties and are
resistant to extreme observations, thereby making them preferable when such conditions
exist. In addition to this, high variability typically will also induce non-constant variance,
which invariably results in suboptimal solutions if OLS regression is applied. As the plots
in Table 2.8 show, this is precisely what is occurring in this scenario, and serves to
explain why the robust and GLM approaches perform well.
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4.5 Summary of Findings
The numerical results in several key insights for solving the RPD problem in
asymmetric and highly variable conditions, which are summarized in (i)-(iii) below:
(i) Most importantly, the simulation results across all scenarios clearly demonstrate
that as process variability increases, alternative approaches to the traditional OLS method
are not only necessary, but preferable. When coupled with asymmetric conditions, the
effects become even more pronounced, particularly when the levels of both conditions
are high. The key question is why. As previously discussed, once elevated degrees of
variability and inherent asymmetry shift the data from assumed normality, the
performance of traditional approaches to estimation suffers as a result of the influence
exerted by extreme observations from the long tail of the skewed distribution. The
alternative methods examined (namely the GLM, S-, LTS, and WLS (median/MAD)) tend
to overcome those influences most effectively. As the results have shown, the GLM
approach tended to perform very well, if not best, in all of the examined scenarios. But it
is important to recognize that this is predicated on the identification of the right
distribution-link combination, which is data-dependent and so constitutes another
required step in the application of that particular method. However, viable alternatives to
this are the WLS (median/MAD), LTS, and S-estimation methods, which also performed
markedly better than traditional OLS and WLS approaches in high variability and high
asymmetry-high variability situations. Thus, in view of the aims of this paper, the
pressing question for healthcare professionals is which approach to use and when. Based
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on the analysis of the presented results, the answer is depicted in Figure 4.7, which shows
the modification to Phase 1b of the original process map from Figure 4.1.
Two additional points should be made. First, some might suggest that high
variability should not pose an issue, as it could be overcome by simply increasing the
sample size required for estimation. Added replication at each experimental design point
could ameliorate potential issues and would be preferred. However, this is often not
feasible due to time and cost constraints, as well as other limitations on resources
required for experimentation. Second, the results obtained in the numerical example show
performance trends rather than definitive conclusions as to the certainty of one
estimator’s performance versus another’s. What they demonstrate is that when elevated
degrees of process variability and asymmetry exist, estimator selection matters in terms
of achieving the best RPD solutions. This echoes the importance of a detailed analysis in
the early stages of experimentation to ascertain the degree to which such underlying
conditions exist in the data, which in turn will influence the selection of the most
appropriate estimation approach to use for response surface modeling and optimization.
(ii) The use of the skew normal distribution facilitates more accurate modeling of the
inherent distributional properties associated with a particular set of data and, based on the
results of the numerical example, can produce better RPD results in terms of minimal
bias and variability. Most notably, because normality is a special case, the skew normal
can very easily capture both symmetric and asymmetric properties, thereby accounting
for the presence of either in process outputs. Thus, by using the first three moments to
replicate experimental observations in the numerical example, we were able to more
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accurately portray process characteristics. This is important, as elevated variability and
asymmetry are, in reality, quite probable in many healthcare and medical processes.
Hence, the use of the skew normal distribution provides the capability to model either
situation simultaneously, thereby allowing for a more accurate accounting of innate
system properties.
(iii) The ease and explicitness associated with the OLS approach has helped to
solidify its position as the basis for regression estimation for more than two hundred
years; and it continues to see the preponderance of use throughout the literature and in
applied statistics texts. Moreover, what tend to steer engineers away from considering
realistic process conditions (i.e., asymmetry) and many alternative estimation methods
are the computational complexities associated with them. But with today’s high-speed
computing power and myriad readily-available software platforms such as R, the
computational complexity of alternative estimation methods should no longer be avoided.
As our results show, these methods can make a significant difference in the quality of the
results achieved when certain conditions exist. But the reality is that these conditions
actually exist more in practice than otherwise; and when they do, the necessary
assumptions that underpin OLS regression no longer hold. If used in spite of this reality,
the OLS method may likely yield suboptimal solutions.
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i. Data Analysis using graphical inference supported by statistical hypothesis testing
Analysis of Responses:
- Process highly variable?
- Inherent asymmetry exist?

Development/analysis of
preliminary estimators
and 2nd order models

Residual Analysis:
- i.i.d. N(0,2)?
- Constant variance?

ii. Conditions-based selection of regression estimation approach
OLS is suitable

No

Can also use Huber Proposal 2 or GLM
(with Gaussian-Identity link function) to good effect

Yes

If more direct control over variability sources is
required/desired: use WLS (median/MAD)

Alternative Approach Required
per following guidelines

Yes

No

Suggested Regression Approach
under Stated Conditions

Ancillary Notes

Low – Low

GLM with distribution-link combos
Mean: Inv. Gaussian – Inv. Square
Variation: Gamma – Inverse

1) Distrib.-link combos may be data-dependent
2) OLS and Huber methods achieve same MSE
result on average, but with far less consistency

Low – High

S-estimation

High – Low

S-estimation

Method achieves best results on average for MSE
and Bias, and does so with greatest consistency.

High – High

GLM with distribution-link combos
Mean: Gamma – Inverse
Variation: Gamma - Identity

Conditions
(Asymmetry – Variability)

1) Distrib.-link combos may be data-dependent
2) S-estimation can be a suitable alternative, as it
achieves the lowest MSE and Bias most often

iii. Development of Response Surface Designs for Process Location and Scale

ˆ(x)  Xˆ (where ˆ  (X T X)1 X T y)
ˆ(x)  Xˆ (where ˆ  (X T X)1 X T s)
Approved Models for Quality Characteristics

Figure 4.6. Conditions-based selection guidelines for regression estimation in asymmetric
and/or high-variability process conditions.
4.6 Conclusion
High variability and asymmetry are conditions that occur quite often across a
broad range of healthcare applications and it is believed that it should be given special
consideration in the experimental process regarding the selection of appropriate
approaches to response surface estimation. To that end, the focus of this paper has been
to examine various alternatives to OLS regression in the RPD framework when such
conditions prevail. The results and analysis demonstrate that, as process conditions
evolve (i.e., variability and/or asymmetry increase), the estimator selection process
should evolve, as well, to achieve the best solutions possible. In particular, the results
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have shown that the GLM, S-, LTS, and median-based WLS methods tend to yield better
RPD solutions. While such methods are fairly well-known in statistical circles, their use
by healthcare professionals in robust parameter design applications is comparatively rare,
as noted by Haenkamp et. al (2009):
“The majority of past [robust parameter design] research has traditionally
been carried out by statisticians targeting an audience with good insights on
statistics. When, instead, targeting engineers with less statistical knowledge
as the major audience, clearly other demands are put on guidelines and
tools.”
One such demand is a clearer understanding of which tools to use and when. The
methodology and analysis offered in this paper should help to answer this need by
providing healthcare professionals with some clarification as to which estimation
approaches will tend to provide the best RPD solution when certain conditions exist. The
analysis in this paper is based upon controlled experimentation, the replication of
observations made on a specified quality characteristic of interest under highly variable
and asymmetric conditions, and the implementation of the skew normal distribution to
effectively model both symmetric and asymmetric instances. Future research may expand
the investigation to include additional conditions, as well as processes that involve
multiple quality characteristics of interest. Furthermore, the development of skew
normal-based link functions for use with GLM approaches would also add benefit. In the
end, proper accounting for the inherent conditions in the data will allow healthcare
professionals to more accurately model the processes they endeavor to optimize, which
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will invariably translate to better RPD solutions and more reliable recommendations to
decision makers.
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APPENDICES

A. Summary Table of Stated Healthcare Concerns and Associated Research
Focus
APA Reference

Healthcare Concern

Research Focus

Acciaroli et al.,
2018

How to use glycemic variability indices
to classify subjects remains
controversial

Agarwal et al.,
2016

[1] ML approaches to electronic
phenotyping are limited by the scarcity
of training datasets
[2] Manual creation of training sets for
ML approaches is time intensive

[1] Assess feasibility of using a
glycemic variability index to
distinguish between healthy individuals
and those with impaired glucose
tolerance (IGT) or T2DM
[2]Assess feasibility of using a
glycemic variability index to
distinguish between individuals with
IGT versus T2DM
Investigate an alternative method to
manual labeling to create training sets
for statistical models of phenotypes

Allalou et al., 2016

[1] Gestational diabetes (GDM) affects
3-14% of pregnancies
[2] 20-50% of women with GDM will
develop T2DM within 5 years
[3] Prediction of progression from
GDM to T2DM critical for individual
risk stratification

Develop a metabolomics signature to
predict patient progression from
gestational diabetes mellitus to T2DM

Anderson et al.,
2016

25% of T2DM are undiagnosed due to
inadequate screening

Assess whether electronic health record
phenotyping could improve T2DM
screening compared to conventional
models

Anderson et al.,
2016

Providing more detailed insights on
factors that drive progression to DM
would be valuable in characterizing and
intervening on at-risk patients

Develop a prediction model ensemble
for progress to prediabetes or T2DM
using variables found within electronic
health records

Basu et al., 2017

It is unclear how to best individualize
glycemic targets

Identify characteristics of patients at
high cardiovascular risk with decreased
or increased mortality risk from
glycemic therapy

Basu et al., 2017

There exists substantial mis-estimation
of risks of diabetes complications using
existing equations (RECODe)

Develop updated risk equations for
complications of T2DM (RECODe)
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APA Reference

Healthcare Concern

Research Focus

Cao et al., 2017

Molecular basis for the comorbidity of
schizophrenia and T2DM is not
completely understood

Determine molecular commonality
between schizophrenia and glycemic
markets of T2DM (identify a polygenic
schizophrenia signature and explore its
impact on T2DM

Casanova et al.,
2016

Prediction for incident diabetes is based
on limited variables

[1] Investigate relative performance of
machine learning method such as RF
for detecting diabetes in a high
dimensional setting
[2] Uncover potential predictors of
diabetes

Chen et al., 2015

Performance of the recommended
glomerular filtration rate (GFR)estimating equations in T2DM
population is inferior to the nondiabetic
population; important for drug dosing

Develop new GFR-predicting models
for use in Chinese patients with T2DM

Dagliati et al., 2017

ML algorithms can be embedded into
data mining pipelines to extract
knowledge from data

Predict the onset of retinopathy,
neuropathy, or nephropathy at different
time scenarios

Dong et al., 2017

Missing heritability is still a big
problem for Genome-wide association
studies ; susceptibility loci identified by
GWAS only account for a limited
proportion of the observed heritability
of diseases

Development of more powerful
methods to predict novel risk SNPs
from the large amount of SNP data and
regulatory features

EITanboly et al.,
2017

Detecting early retinal changes in
T2DM to give patients a chance to
delay further complications is absent so
far

Diagnosis of diabetic retinopathy (DR)
using optical coherence tomography
(OCT) images for T2DM patients

Farran et al., 2013

Efficient preventative strategies are
needed to control risk factors for
T2DM; use knowledge to on
individual population or at population
level to identify groups of high-risk
patients

Build classification models and risk
assessment tools for diabetes,
hypertension and comorbidity using
ML algorithms on data from Kuwait

Han et al., 2017

Need a system or process to stratify
individuals according to disease risk for
clinical disease prevention

Develop a risk stratification model of
clinical disease to be used for
interventions
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APA Reference

Healthcare Concern

Research Focus

Hertroijs et al.,
2017

Iplementation of precision medicine
based solely on genomics has proven to
be difficult for certain diseases;
phenotyping approach to precision
medicine is only sparsely adopted in
evidence-based guidelines for diabetes
treatment

[1] Identify subgroups of people with
newly diagnosed T2DM with distinct
glycemic trajectories
[2] Predict trajectory membership using
patient characteristics
[3] Validate findings in different cohort
of patients with T2DM

Kagawa et al.,
2017

Existing phenotyping algorithms are
not sufficiently accurate for screening
and identifying clinical research
subjects

Distinguish T2DM patients based on
electronic health records; propose new
metric to evaluate practicality of
algorithms

Kim et al., 2017

Need to find markers for end-stage
renal disease; because diabetic patients
are likely to develop ESRD it is
imperative to discover which elements
of diabetic patient's medical problems
lead to ESRD

Discover frequently appearing medical
complications at various levels of
kidney functions for two different
subpopulations defined by ethnicity

Lee et al., 2016

No study has assessed the predictive
power of phenotypes based on
individual anthropometric
measurements

Assess the association between the HW
phenotype and T2DM in Korean adults

Lee et al., 2014

Prediction of type 2 diabetes using a
combination of anthropometric
measures remains a controversial issue

Predict the fasting plasma glucose
status that is used in the diagnosis of
type 2 diabetes by a combination of
various measures of Korean adults

Leung et al., 2013

Diabetic kidney disease is rising in
parallel to the growing epidemic of
T2DM / rapid advancement of
molecular tech, large datasets
containing many genotypes and
phenotypes; challenge is in
synthesizing discoveries and translating
them to clinical practice

Explore computation tools with a
comprehensive data base on T2DM

Li et al., 2016

Growing risk to patient population with
the use of Electronic health records;
need to reconcile the preservation of
patient privacy and the need to have
sufficient data for modeling and
decision making

Develop two adaptive distributed
privacy preserving algorithms based on
a distributed ensemble strategy
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APA Reference

Healthcare Concern

Research Focus

Lo-Ciganic et al.,
2015

Little empirical evidence to support
medication adherence threshold levels
as a predictor of health outcomes

Apply ML to examine how adherence
to oral hypoglycemic medications is
associated by avoidance of
hospitalization; identify adherence
thresholds for optimal discrimination of
hospitalization risk

Lopez et al., 2017

Need to definitively link single
nucleotide polymorphisms to disease
development

Identify relevant SNPs to T2DM and
build a decision support-tool for risk
prediction

McCoy et al., 2017

Individualized diabetes management
would benefit from prospectively
identifying well-controlled patients at
risk of losing glycemic control

Identify patters of H1bA1c change
among patients with stable controlled
diabetes

Moreno et al., 2017

Develop noninvasive method to test for
T2DM

Screen for the presence of T2DM by
means of the signal obtained by a pulse
oximeter

Neugebauer et al,
2013

Clinical trials are unlikely to be
launched for many comparative
effectiveness research questions

Adaptation of a data adaptive
estimation approach called Super
Learning avoids reliance on arbitrary
parametric assumptions in CER

Neugebauer et al.,
2016

Contribute to the understanding of
potential consequences of the choice of
estimation for propensity scores in real
world comparative effectiveness
analysis
T2DM is a chronic disease associated
with a wide range of serious health
complications

Use EHR data to evaluate the effects of
four adaptive treatment intensification
strategies (bias from incorrect
parametric model specification)

Ozery-Flato et al.,
2016

Development of a tool that could
automatically evaluate a patient's
response to treatment, identify patients
who are most likely experiencing
problems, and focus physicians'
attention on those patients who require
it most would be extremely valuable

New approach for detection and
analyzing patients with expected
responses to antidiabetic drugs

Ozery-Flato et al.,
2013

Only limited information is available
on the predictors ofT2DM in the group
of patients already diagnosed with
metabolic syndrome

Investigate the predictive value of
different biomarkers for the incidence
of T2DM in patients with metabolic
syndrome

Olivera et al., 2017
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Develop and validate predicative
models for detecting undiagnosed
diabetes

APA Reference

Healthcare Concern

Research Focus

Peddinti et al.,
2017

Predictive biomarkers are needed to
allow physicians to identify and
monitor individuals at high risk for
T2DM

Systematically evaluate the predictive
power of comprehensive metabolomics
profiles to predict T2DM

Pedersen et al.,
2016

Not all patients undergoing weightloss surgery experience diabetic
remission, but the mechanistic insights
that cause the heterogeneous therapy
results are not understood.

Combine clinical and genomic factors
using heuristic methods to identify
patients who may have a low likelihood
in responding to bariatric surgery for
improved glycemic control

Pimentel et al.,
2016

Current methods of treating T2DM are
inadequate therefore it is important to
focus on prevention of the disease

Propose a new approach for T2DM
based on EHR without using invasive
techniques

Pazavian et al.,
2015

Interventions can only be cost effective
when the target population has a high
likelihood of developing diabetes at the
baseline

Develop a population-level risk
prediction model for type 2 diabetes
that can be used with health insurance
claims or other readily available data

Pamezankhani et
al., 2016

Most ML classified work well when the
class distribution is evenly distributed,
but class imbalance is prevalent in
medical datasets

Evaluate the impact of synthetic
minority oversampling technique
(SMOTE) on the performance of
probabilistic neutral network, naïve
Bayes (NB), and decision tree (DT)
classifiers for predicting diabetes

Sudharsan et al.,
2015

Minimizing the occurrence of
hypoglycemia is a challenging task
since T2DM patients typically check on
1-2 self-monitored blood glucose levels
per day

Develop a probabilistic model to
predict an hypoglycemic event within
the next 24 hours

Vyas et al., 2016

The number of revealed protein-protein
interactions is limited compared to the
available protein sequences of different
organisms

Develop a model for discriminating
disease proteins from non-disease
proteins for T2DM

Zheng et al., 2017

Existing expert based identification
algorithms often have a low recall rate
and could miss valuable samples

Propose a data informed framework for
identifying subjects with and without
T2DM from EHR via feature
engineering and machine learning
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B. Summary Table of Machine Learning Techniques and Selected Dataset
Machine
Learning
Algorithms
logistic
regression

Model
Performance
Metrics
accuracy, F1
score,
precision,
recall

Agarwal et
al., 2016

L1 penalized
logistic
regression

accuracy,
against rulebased
definitions,
positive
predictive
value

XPRESS

United
States

Standford
Children's
Health and
Stanford
Healthcare

January
1994 June 2013

Allalou et
al., 2016

decision
tree, J48
decision
tree, Naïve
Bayes,
logistic
regression

accuracy, area
under the
curve, F-score
precision ,
specificity,
sensitivity

R-studio,
Waikato
Environmen
t for
Knowledge
Analysis
workbench

United
States

Study of
Women, Infant
Feeding, and
Type 2
Diabetes
Mellitus After
GDM
Pregnancy
(SWIFT)

20082014

Anderson et
al., 2016

logistic
regression,
random
forest

accuracy, area
under the
curve, positive
predictive
value, negative
predictive
values,
sensitivity,
specificity

R

United
States

Practice
Fusion
Diabetes
Classification

20092012

Anderson et
al., 2016

Bayesian
posterior

area under the
curve

Reverse
Engineering
and Forward
Simulation
(REFS)

United
States

Humedica
Electronic
Health
Records

20072012

APA
Reference
Acciaroli et
al., 2018

Machine
Learning
Software

Dataset
Origin
Finland
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Dataset
Name or
Source
Botnia Study
Group

Dataset
Time
Frame

APA
Reference
Basu et al.,
2017

Basu et al.,
2017

Cao et al.,
2017

Machine
Learning
Algorithms
gradient
forest,
decision tree

Model
Performance
Metrics

elastic net
regularizatio
n to inform
the Cox
Hazards
Model

Machine
Learning
Software
R

R

accuracy,
Nagelkreke’s
R2

R

164

Dataset
Origin
United
States
and
Canada

United
States
and
Canada

Dataset
Name or
Source
Action to
Control
Cardiovascular
Risk in
Diabetes
(ACCORD)

Dataset
Time
Frame
20012009

[1] Action to
Control
Cardiovascular
Risk in
Diabetes
(ACCORD)
[2]Diabetes
Prevention
Program
Outcomes
Study [3]
Action for
Health in
Diabetes

[1] 20012009 [2]
19962001 [3]
20012012

[1] GEO
database:
GSE53987,
GSE21138,
GSE35977,
GSE12679,
GSE38642,
GSE3489,
GSE36980 [2]
GWAS Data:
GO, KEGG,
Panther,
Reactome,
Target Scan
[3] Expression
Atlas: GTEx

APA
Reference
Casanova et
al., 2016

Machine
Learning
Algorithms
random
forest,
logistic
regression

Chen et al.,
2015

artificial
neural
networks
(back
propagation)

Dagliati et
al., 2017

logistic
regression,
naïve Bayes,
support
vector
machines,
random
forest

Model
Performance
Metrics
area under the
curve, standard
panel accuracy,
sensitivity,
specificity

Machine
Learning
Software

Dataset
Origin
United
States

MATLAB
2011A

accuracy, area
under the
curve,
matthew’s
correlation
coefficient,
negative
predictive
value, positive
predictive
value,
sensitivity,
specificity,
area under the
curve

Dataset
Name or
Source
Jackson Heart
Study,
University of
Mississippi
Medical
Center

China

Third
Affiliated
Hospital of
Sun Yatsen
University

Italy

[1] Istituto di
Ricovero e
Cura a
Carattere
Scientifico Research
hospital
[2] Istituto
Clinico
Scientifico
Maugeri
(ICSM)
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Dataset
Time
Frame

Machine
Learning
Algorithms
decision
tree, class
analogy,
random
forest,
support
vector
machines

Model
Performance
Metrics
F1 score,
number of
features,
sensitivity,
specificity,
accuracy

Machine
Learning
Software
R

EITanboly
et al., 2017

deep
learning
(compared
with K-Star,
K-Nearest,
Random
Tree,
Random
Forest)

Accuracy, area
under the
curve,
sensitivity,
specificity

Waikato
Environment for
Knowledge
Analysis
workbench

Farran et al.,
2013

logistic
regression,
k-nearest
neighbors,
support
vector
machines

classification
accuracy

MATLAB MATrix
LABoratory

Han et al.,
2017

k means
variants
(base, PSC,
Seeded,
COP, PCK,
MPCK,
Supervised,
Constrained,
FSCL),
random
forest

ratio of
minimum to
expected,
sensitivity,
specificity,
standard
deviation in
cluster sizes,
Youden index,
standard
deviation in
cluster sizes

R

APA
Reference
Dong et al.,
2017
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Dataset
Name or
Source
[1] 1000
Genome
Project
[2] ENCODE;
Roadmap
Epigenomics
Project,
expression
quantitative
trait loci data
in T2DC
relevant issues
from the GTEx
database
[3] genomic
regions from
the GERP++

Dataset
Time
Frame

Kuwait

Kuwait Health
Network
(KHN)

(12 years)

China

Chinese
Hospital Data

(7 years)

Dataset
Origin

Machine
Learning
Algorithm
k-nearest
neighbor,
Fisher,
Parzen,
quadratic
discriminant
classifier,
linear
discriminant
classifier,
support
vector
machine,
logistic
regression,
stacked
support
vector
machine

Model
Performance
Metric
Akaike
Information
Criterion,
Bayesian
Information
Criterion, LoMendelRubinlikelihood
ratio test,
predicted and
observed
trajectory,
calibration
slopes,
sensitivity,
specificity,
positive
predictive
values,
negative
predictive
values

Machine
Learning
Software

Kagawa et
al., 2017

Support
vector
machine,
PheKB

sensitivity,
area under the
curve,
specificity,
sensitivity

R (kernlab,
ROCR,
caret)

Kim et al.,
2017

apriori

Lee et al.,
2016

naïve Bayes,
logistic
regression

area under the
curve

Lee et al.,
2014

naïve Bayes,
logistic
regression

area under the
curve,
sensitivity,
specificity

APA
Reference
Hertroijs et
al., 2017

Dataset
Origin
Netherlands

Dataset
Name or
Source
[1] Zwolle
Outpatient
Diabetes
Project
Integrating
Available Care
(ZODIAC)

Dataset
Time
Frame
[1] 20062013
[2] 20092013

[2] ZIO, a
regional care
group

Japan

University of
Tokyo
Hospital

20092014

2012 Cerner
database
SPSS 19,
Waikato
Environmen
t for
Knowledge
Analysis
data mining
tool
SPSS 19,
Waikato
Environmen
t for
Knowledge
Analysis
data mining
tool
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Korea

Korea

Korean
Health and
Genome
Epidemiolog
y Study
Database

Nov 2006
- August
2013

APA
Reference
Leung et al.,
2013

Li et al.,
2016

Machine
Learning
Algorithms

Model
Performance
Metrics

Machine
Learning
Software

decision
tree, random
forest, naïve
Bayes,
neural
networks,
partial least
squares
regression,
support
vector
machine
AdaBoost
(local
learner)

ROC,
sensitivity,
specificity

R for ML,
but SPSS for
statistical
analysis

random
survival
forest

Lopez et al.,
2017

classify:
random
forest,
support
vector
machine,
logistic;
predict:
regression,
k-nearest
neighbor
random
forest

area under the
curve,
prediction
accuracy

random
forest,
gradient
boosting,
linear
discriminant
analysis
super
learning

area under the
curve,
sensitivity,
septicity

Moreno et
al., 2017

Neugebauer
et al., 2013

Dataset Name
or Source

Dataset
Time
Frame

China

Hong Kong
Diabetes
Registry

1 July
1994 - 30
June 1998

area under the
curve, F
measure,
sensitivity,
precision

Lo-Ciganic
et al., 2015

McCoy et
al., 2017

Dataset
Origin

SAS 9.3 and
R

United
States

Practice
Fusion
Diabetes
Classification
Challenge
(2002)
Pennsylvania
Medicaid
program

20072011

Biomedical
Research of
Girona

R

MATLAB
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Spain

OptumLabs
Data
Warehouse

20012013

6 Clinics
around
Barcelona

2013

EHR from
patients of four
sites of the
HMO research
network
consortium

January
2006 June 2008

APA
Reference

Machine
Learning
Algorithms

Model
Performance
Metrics

Machine
Learning
Software

Dataset
Origin

Dataset Name
or Source

Neugebauer
et al, 2016

super
learning

Olivera et
al., 2017

logistic
regression,
artificial
neural
network,
naïve Bayes,
k-nearest
neighbor,
and random
forest
k-nearest
neighbor,
support
vector
machine
logistic
regression

accuracy, area
under the
curve,
balanced
accuracy,
sensitivity,
specificity,

R

Brazil

area under the
curve

MATLAB

Lithuani
-a

Lithuanian
High
Cardiovascul
ar Risk
primary
prevention
program

artificial
neural
network

Area under
the curve,
accuracy,
integrated
discrimination
improvement

R, Plink

United
States

CardioMetabo
chip,
eMERGE,
GIANT,
DIAGRAM,
MAGIC

Pimentel et
al., 2016

regularized
least squares

area under the
curve

R

Finland

Botnia
Prospective
Study (BPS)

19902000

Pazavian et
al., 2015

logistic
regression

area under the
curve,
sensitivity,
specificity,
positive
predictive
value

United
States

cohort study of
beneficiaries
of
Independence
Blue Cross

20052013

Ozery-Flato
et al., 2016

Ozery-Flato
et al., 2013

Peddinti et
al., 2017
Pedersen et
al., 2016
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real-world
comparative
effectiveness
research
Longitudinal
Study of Adult
Health (ELSABrazil)

Dataset
Time
Frame

20082010

20072011

Machine
Learning
Algorithms

Model
Performance
Metrics

Pamezankha
ni et al.,
2016

probabilistic
neural
networks,
decision
trees, naïve
Bayes

Konstanz
Information
Miner
(KNIME)

Sudharsan et
al., 2015

random
forest,
support
vector
machine, knearest
neighbor,
naïve Bayes
support
vector
machine

accuracy, Fmeasure,
precision,
sensitivity,
specificity,
precision,
Youden's
index
accuracy,
sensitivity,
specificity

accuracy, area
under the
curve,
precision,
accuracy,
recall

LibSVM

United
States

accuracy,
precision, area
under the
curve,
sensitivity,
specificity

Weka

China

APA
Reference

Vyas et al.,
2016

Zheng et al.,
2017

k-nearest
neighbor,
naïve Bayes,
decision
tree, random
forest,
support
vector
machine,
logistic
regression

Machine
Learning
Software
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Dataset
Time
Frame

Dataset
Origin

Dataset Name
or Source

Iran

Tehran Lipid
and Glucose
Study (TLGS)

(12 years)

De-identified
patient data
from a clinical
trial of patients
with T2DM

(1 year)

Regional
distributed
EHR in
Shanghai
China

20122014
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